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Jamaican males are a high-risk population for aggressive prostate cancer (PrCa) due to 
genetic influences, and identifying empirical data on treatments, which provide survival 
benefits is a prime challenge for clinicians who manage Jamaican PrCa patients. Thus, 
the purpose of this investigation was to elucidate treatment effects of brachytherapy and 
ERBT in the survival of a Jamaican PrCa cohort. Differences in survival outcomes of 
brachytherapy and ERBT treated Jamaican, and White U.S.-born PrCa patients with 
localized PrCa were compared. The mechanism of radiation programmed cell death in 
PrCa carcinogenesis explained in the oxidative stress theory, was the theoretical base for 
interpreting the research questions. A retrospective cohort design was used, and included 
survival analysis of secondary data from the Surveillance Epidemiology and End Results 
database. The sample size was 10,752 Jamaican and White U.S.-born prostate cancer 
patients diagnosed between 1992 and 2011. Kaplan-Meier and Cox proportional hazard 
regression models confirmed that brachytherapy resulted in enhanced survival benefits to 
the Jamaicans, HR 0.63, 95% CI [0.55, 0.73], p < .001, but ERBT did not, HR 1.6, 95% 
CI [1.38, 1.84] p < .001. Hence, brachytherapy may be an appropriate treatment option 
for Jamaican PrCa patients. Clinicians and health care planners can utilize the results for 
policy decisions aimed at increasing access to brachytherapy treatments to Jamaicans. 
Improving access to efficient PrCa treatments could reduce the morbidity and mortality 
rates of PrCa among Jamaicans, decrease years of potential life lost from PrCa, and 
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Chapter 1: Introduction to the Study  
The survival outcome of brachytherapy and external beam radiation treatment 
(ERBT) for the management of localized PrCa, is understudied among Jamaicans in their 
native country (Morrison, Aiken, & Mayhew, 2014). The effects of brachytherapy and 
ERBT are well documented among Europeans (Goldner et al., 2012; Zuber et al., 2015), 
Canadians (Smith et al., 2015), and in U.S. populations (Alumini et al., 2015; Cendales et 
al., 2015). However, the findings of current studies may not apply to Jamaican PrCa 
patients. Jamaican PrCa patients are typically diagnosed with higher prostate-specific 
antigen (PSA) levels, Gleason scores, and tumor stages when compared with the White 
and African American PrCa patients (Fedewa & Jemal, 2013; Rich et al., 2013). 
Jamaicans also have the recessive and dominant genes, which increase their risk for PrCa 
(Kidd et al., 2012). Kidd et al. (2012) compared the influence of Chemokine-associated 
single nucleotide polymorphisms (SNPs) in PrCa susceptibility of African Americans and 
Jamaicans. The findings of Kidd et al. demonstrated that the Jamaican cohort had 1.52 to 
1.73 increased for PrCa (p < .001), due to the genes CCR5 rs1799987 AA, CCR5 
rs1799988 GG, and CCR7 rs 3136685 AG+GG. Hence, conclusions of current literature 
suggested that Jamaican PrCa patients may have other biological factors which, could 
support the type of PrCa noted in this cohort. Consequently, ERBT and brachytherapy 
treatment outcomes of PrCa patients of other populations may not generalize to 
Jamaicans. 
Recent studies have also indicated that higher numbers of Jamaican PrCa patients 
residing in the United States and Jamaica are diagnosed with Gleason scores 6 and 7 
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PrCa; when compared with men who are diagnosed with Gleason scores 8 to 10 PrCa 
(Anderson-Jackson, McGrowder, & Alexander-Lindo, 2012; Kampel, Tse, & Joseph, 
2011). In a cohort of 127 Jamaican PrCa patients who were treated at the Memorial 
Sloan-Kettering Cancer Center in New York, Kampel et al. (2011) recognized that 51 
(40%) were diagnosed with Gleason score 6 PrCa, while 57 (45%) had Gleason score 7 
PrCa. Fewer PrCa patients (15%) were diagnosed with Gleason scores 8 to 10 (Kampel et 
al., 2011). In Jamaica West Indies, Anderson et al. (2012), documented similar patterns 
of PrCa diagnosis among 191 PrCa patients treated at a private diagnostic center in the 
country. Anderson et al. reported that the highest proportion of PrCa patients (69.7%) 
who were treated at a radiology center in Jamaica had Gleason scores 6 and 7 PrCa. The 
findings of Anderson et al. and Kampel et al. suggested that currently Jamaican males are 
detected at the earlier stages of PrCa. Therefore, it was important to determine the 
treatment methods, which are most appropriate for Jamaicans with the earlier stages of 
the disease.  
Currently, urologists in Jamaica are challenged with identifying publications, 
which support evidenced-based decisions for treating Jamaican PrCa patients with 
localized PrCa (Morrison et al., 2014). Besides, advocates for PrCa treatment in Jamaica 
are promoting greater use of brachytherapy, ERBT, and active surveillance for managing 
localized PrCa (Morrison et al., 2014). At present, brachytherapy, ERBT, and active 
surveillance are underutilized in Jamaica owing to infrastructural and economic 
constraints (Morrison et al., 2014). Due to the factors which limit the uptake of PrCa 
treatments among Jamaicans in their homeland, data are needed to base decisions on the 
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most clinically efficient and cost-effective treatment methods for these PrCa patients with 
localized disease (Morrison et al., 2014). 
It was necessary to determine the efficacy of brachytherapy and ERBT treatment 
for the management of early stage PrCa among Jamaicans males. Researchers reported 
increase utilization of brachytherapy treatment in the United States since the 1990s 
(Alumini et al., 2015; Cendales et al., 2015; Goldner et al., 2012; Marshall et al. 2014; 
Nepple et al., 2013). Investigators have also described the survival benefits and 
limitations of brachytherapy and ERBT for patients with localized PrCa. Schreiber et al. 
(2013), cited that brachytherapy provided improved survival outcomes and fewer side 
effects when compared with other PrCa treatments. On the other hand, Schreiber et al. 
reported that brachytherapy is associated with socioeconomic constraints resulting in 
disparities in its use among African American and White PrCa patients. Williams et al. 
(2011) noted that younger PrCa patients were also more likely to access brachytherapy. 
Furthermore, when compared with the traditional ERBT, brachytherapy treatment did not 
demonstrate superior survival benefits for men with the earlier stages of PrCa (Goldner et 
al., 2012; Nepple et al., 2013; Smith et al., 2015). However, the reports of recent 
investigations demonstrated no treatment effects of brachytherapy and ERBT in a 
Jamaican cohort. Hence, additional studies are necessary to elucidate the survival benefits 
of brachytherapy and ERBT in the management of localized PrCa among Jamaicans. 
In existing publications, investigators documented mixed results for PrCa patients 
who did not receive directive treatment for the disease (Bul et al., 2013; Odom et al., 
2014; Selvadurai et al., 2013; Wilt et al., 2012). Current studies showed disparities in 
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survival outcomes of White and African American PrCa patients who were managed with 
active surveillance (Bul et al., 2013; Odom et al., 2014; Selvadurai et al., 2013; Wilt et 
al., 2012). Researchers also indicated that African American PrCa patients who were 
managed without directive PrCa treatment were more likely to progress to the advanced 
forms of the disease (Odom et al., 2014). Nevertheless, the survival outcomes of active 
surveillance as a treatment protocol in White and African American cohorts documented 
in other studies may not apply to Jamaicans. Investigators documented that small samples 
of the Black populations in studies on PrCa survival limit extrapolation of the findings to 
similar groups (Bul et al., 2013; Odom et al., 2014; Selvadurai et al., 2013; Wilt et al., 
2012).  
Additionally, investigators alluded to the impact of the sociodemographic 
characteristics of the PrCa patient and smoking in their survival (Crawford, 2013; Fufaa, 
2011; Huncharek et al., 2010; Lin, Porter, & Montgomery., 2009; Parris, 2013). Data on 
the influence of the sociodemographic characteristics in the treatment outcomes of 
Jamaican PrCa patients were not reported in current publications.  
Jamaicans in the 18 participating Surveillance Epidemiology and End Results 
(SEER) database were chosen for this study to infer findings to their populations. 
Jamaicans in the SEER database were selected for data analysis because they comprised 
the largest subgroups of non-U.S.-born Black males of the SEER cancer registries 
(Fedewa & Jemal, 2013). Besides, Fedewa and Jemal (2013) documented that Jamaicans 
in the SEER database had Gleason scores, which were comparable with Jamaicans 
residing in their native country. Moreover, I identified a higher proportion of Jamaican-
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born PrCa patients (87.64%) in the SEER database with localized PrCa when compared 
with PrCa patients who were diagnosed with the distant stage of the disease 21 (7.87 %). 
Thus, the findings of the SEER database suggested that the cohort of Jamaican-born PrCa 
patients in that dataset was appropriate for this research.  
This study was necessary because current findings on PrCa treatment effects may 
not generalize to the Jamaican communities owing to differences in the disease 
characteristic of Jamaicans and other groups of PrCa patients (Fedewa & Jemal, 2013; 
Kid et al., 2012; Rich et al., 2013). Jamaicans are usually diagnosed with higher stages 
and grades of PrCa when compared with other populations (Fedewa & Jemal, 2013; Rich 
et al., 2013), and researchers recommended other studies on the treatment of localized 
disease among men with this type of PrCa (Klotz et al., 2010). Researchers also endorsed 
future studies on the relationship between disparities of brachytherapy treatment, race, 
socioeconomic status and PrCa survival (Schreiber et al., 2013). Furthermore, it was 
important to understand the role of socioeconomic status in treatment outcomes among 
the Jamaican cohort because, brachytherapy treatment is not adequately utilized among 
native Jamaicans without health insurance (Morrison et al., 2014). The reason for this 
disparity among Jamaicans is not well documented in the literature. Consequently, this 
dissertation which investigated the effectiveness of treatments for localized PrCa among 
Jamaicans was relevant. 
I anticipate that this dissertation will contribute to public health practice and 
policies aimed at improving the years of potential life lost (YPLL) of a Jamaican PrCa 
patient. I also project that this research may provide information to the medical fraternity 
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of urologists in Jamaica who currently seek data on appropriate treatment choices for 
Jamaicans with localized PrCa. Additionally, I assume that this study will offer evidence 
to influence the decision-making of PrCa patients with localized disease about 
appropriate treatment choices and assist health care planners in increasing access to these 
PrCa treatments. The efficacy of brachytherapy and ERBT in the management of early 
and intermediate stages PrCa among Jamaicans, may improve the survival rates of 
affected males and enhance their survival outcomes (Fufaa, 2011).  
In Chapter 1, I presented the background of this dissertation; the research problem 
statement, questions, and purpose; as well as the theoretical framework, nature of the 
study, and the definitions of the primary variables. The background summarizes the 
current literature on the survival outcomes of PrCa patients who were treated with 
brachytherapy and ERBT. The problem statement discusses the focus of the investigation 
and the need for new data to guide treatment decisions for the management of low and 
intermediate stages PrCa among Jamaicans. In Chapter 1, 1 also included the five 
research questions and hypotheses, which were intended to measure the relationship 
between brachytherapy treatment and ERBT with PrCa survival. The research questions 
and hypotheses allowed me to compare differences in PrCa survival with Jamaicans and 
the White U.S.-born cohort of the SEER 18 research databases. The research questions 





Since the 1990s, brachytherapy, and active surveillance are accepted treatment 
choices among men with low-grade PrCa (Cooperberg & Carroll, 2015; Mahmood et al., 
2014; Safdieh, Wong, Weiner, Schwartz, & Schreiber, 2016; Valdivieso et al., 2015; 
Weiner, Patel, Etzioni, & Eggener, 2015). However, in studies on the management of 
localized PrCa with brachytherapy, ERBT, and active surveillance, researchers provided 
mixed results on treatment efficacy (Alumini et al., 2015; Cendales et al., 2015; Marshall 
et al. 2014; Nepple et al., 2013; Rodrigues et al., 2014; Smith et al., 2015; Zuber et al., 
2015).  
Investigators have also documented underutilization of brachytherapy in specific 
populations (Schreiber et al., 2013; Smith et al., 2015; Williams et al., 2011; Zuber et al., 
2015). Schreiber et al. (2013) confirmed that brachytherapy is more widely utilized 
among White males when compared with males of African American descent. Williams 
et al. (2011) revealed that brachytherapy is better accepted among young PrCa patients 
Alumini et al. (2015), Williams et al., and Zuber et al. (2015) reported that brachytherapy 
is a safe and efficient treatment for PrCa patients with Gleason scores 6 and 7. On the 
other hand, Williams et al. indicated that brachytherapy is an expensive treatment option. 
Moreover, Rodrigues et al. (2014) noted that brachytherapy enhances biochemical free 
survival for PrCa patients with low and intermediate stage disease, but it does not 
improve overall survival of PrCa. Additionally, Goldner et al. (2012), Nepple et al. 
(2013), and Smith et al. (2015) reported similarities in the effectiveness of brachytherapy 
treatment and ERBT for the management of localized PrCa. Thus, the results of current 
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studies on the survival advantage of brachytherapy and ERBT provided wide-ranging 
outcomes in the populations studied (Goldner et al., 2012; Nepple et al., 2013; Smith et 
al., 2015).  
There is a dearth of current publications on the effects of brachytherapy and 
ERBT in the survival of Jamaican PrCa patients, and current data on treatment effects 
among Jamaicans are needed (Morrison et al., 2014). In addition, investigators 
recommended additional research on the effects of ERBT and brachytherapy treatment on 
PrCa survival (Bannuru et al., 2011; Klotz et al., 2010; Nepple et al., 2013; Schreiber et 
al., 2013). Klotz et al. (2010) also suggested that further studies on the effects of ERBT 
and brachytherapy treatment on PrCa survival should include men who are diagnosed 
with the aggressive forms of PrCa. Besides, Nepple et al. (2013) recommended that 
further observations on treatment effects should include active surveillance and African-
American men with low-risk disease. Moreover, Rand et al. (2014), and Schreiber et al. 
(2013) endorsed additional inquiries in the disparities of race and socioeconomic status in 
the relationship between brachytherapy and PrCa survival. Hence, this dissertation was 
designed to explore the effectiveness of brachytherapy and ERBT PrCa treatments and 
determine the influence of socioeconomic indicators in treatment effects. 
This study is relevant to provide new insights on the effectiveness of PrCa 
treatments among Jamaicans with localized disease. Jamaicans are diagnosed with 
localized PrCa, and empirical data on the most effective treatment options for that cohort 
are lacking. An understanding of the roles of brachytherapy and ERBT, in the prognosis 
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of Jamaican PrCa patients, could support appropriate treatment decisions, aimed at 
improving their overall survival.  
Problem Statement 
Recent publications established that higher numbers of Jamaican males are 
currently diagnosed with Gleason scores 6, and 7 PrCa, when compared with Gleason 
scores 8 to 10 PrCa (Anderson-Jackson et al., 2012; Kampel et al., 2011). However, 
identifying empirical data on appropriate treatments, which will provide greater survival 
benefits for PrCa patients with early and intermediate stage disease, is a prime challenge 
for the management of PrCa in Jamaica (Morrison et al., 2014). There is also a need for 
data on the outcomes of brachytherapy treatment in the Jamaican population (Morrison et 
al., 2014). 
The effect of PrCa treatment on early and intermediate stage disease in the 
survival of affected males is well studied in many populations (Alumini et al., 2015; 
Cendales et al., 2015; Goldner et al., 2012; Marshall et al. 2014; Nepple et al., 2013; 
Rodrigues et al., 2014; Smith et al., 2015; Williams et al., 2011; Zuber et al., 2015). 
However, findings on the treatment methods which offer the best survival benefits for 
PrCa patients with localized disease require further examination (Alumini et al., 2015; 
Cendales et al., 2015; Goldner et al., 2012; Marshall et al. 2014; Nepple et al., 2013; 
Rodrigues et al., 2014; Schreiber et al., 2013; Smith et al., 2015; Williams et al., 2011; 
Zuber et al., 2015). Several researchers reported favorable treatment outcomes for 
brachytherapy (Alumini et al., 2015; Cendales et al., 2015; Williams et al., 2011; Zuber et 
al., 2015). Other investigators suggested that the traditional ERBT may be a better option 
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for the overall survival of PrCa patients (Goldner et al., 2012; Nepple et al., 2013; Smith 
et al., 2015). None of the studies which explained the effects of brachytherapy and ERBT 
was conducted in the Jamaican population.  
Recent publications cited the survival benefits of brachytherapy in White 
populations (Alumini et al., 2015; Cendales et al., 2015; Marshall et al. 2014; Nepple et 
al., 2013; Rodrigues et al., 2014; Williams et al., 2011). Results on the survival effects of 
brachytherapy and ERBT in PrCa survival were identified among German (Zuber et al., 
2015), Dutch (Goldner et al., 2012), Canadian (Smith et al., 2015), and the U.S. White 
populations (Alumini et al., 2015; Cendales et al., 2015; Marshall et al. 2014; Nepple et 
al., 2013; Rodrigues et al., 2014; Williams et al., 2011). The conclusions of studies in 
other populations may not be relevant to the Jamaican cohort. Jamaicans PrCa patients 
are diagnosed with higher PSA levels, Gleason scores, and tumor stages when compared 
with the White and African American PrCa patients (Fedewa & Jemal, 2013; Rich et al., 
2013). Jamaican PrCa patients also have the recessive and dominant genes which are 
associated with a two-fold increased risk of PrCa in that cohort (Kidd et al., 2012). 
Therefore, it was important to elucidate the effects of treatments for early and 
intermediate stages of PrCa in the Jamaican communities with a similar cohort.  
Purpose of the Study 
In this quantitative dissertation, I utilized a retrospective cohort study design, and 
analyses of secondary data with survival models, to examine the survival patterns of 
Jamaican PrCa patients who were treated with brachytherapy and ERBT for the period 
1992 to 2011. The purpose of this dissertation was to determine the survival outcomes of 
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Jamaican PrCa patients who were diagnosed with early and intermediate stage disease, 
and ascertain whether there were survival differences among Jamaican PrCa patients and 
White U.S.-born PrCa patients who were treated with brachytherapy and ERBT. In this 
investigation, I also aimed to examine the influences of sociodemographic indicators of 
age, marital status, and health insurance status in the survival outcomes of the PrCa 
patients. The key independent variables of this research were a history of brachytherapy 
treatment, history of ERBT, and the stage and grade of PrCa. The dependent variable was 
the length of time a prostate cancer patient lived with the disease after treatment. The 
covariates for this study were the sociodemographic indicators of age, marital status, and 
health insurance status of the PrCa patients. 
Research Questions and Hypotheses 
In this study, I utilized five research questions with their related hypotheses to 
compare the treatments effects in the survival of the Jamaican and White U.S.-born 
cohorts. The smoking variable was not examined because data were not available. The 
hypothesis of this study speculated a difference in the survival time of the Jamaicans 
versus the White U.S.-born PrCa patients. The five research questions and hypotheses 
follow.  
  Research Question 1. Are there differences in the length of time Jamaican-born 
PrCa patients compared with U.S.-born White PrCa patients who were treated with 
brachytherapy for low and intermediate stages PrCa, live with the disease? 
12 
 
  H01: There are no differences in the length of time Jamaican-born and U.S.-born 
White PrCa patients treated with brachytherapy for low and intermediate stages PrCa; 
live with the disease. 
  Ha1: There are differences in the length of time Jamaican-born PrCa patients 
versus U.S.-born White PrCa patients who were treated with brachytherapy for low and 
intermediate stages PrCa, live with the disease. 
  Research Question 2. Are there differences in the length of time Jamaican-born 
PrCa patients compared with U.S.-born White PrCa patients who were treated with 
ERBT for low and intermediate stages PrCa, live with the disease? 
  H02: There are no differences in the length of time Jamaican-born PrCa patients 
and U.S.-born White PrCa patients treated with ERBT for low and intermediate stages 
PrCa, live with the disease. 
  Ha2: There are differences in the length of time Jamaican-born PrCa patients 
compared with U.S.-born White PrCa patients who were treated with ERBT for low and 
intermediate stages PrCa, live with the disease. 
  Research Question 3. Are there differences in 5-year survival intervals of 
Jamaican-born PrCa patients compared with U.S.-born White PrCa patients, according to 
treatment received for the period 1992 to 2011? 
  H03: There are no differences in 5-year survival intervals of Jamaican-born and 




  Ha3: There are differences in 5-year survival intervals of Jamaican-born PrCa 
patients compared with U.S.-born White PrCa patients according to treatment received 
for the period 1992 to 2011.  
  Research Question 4. Are there differences in the length of time brachytherapy 
treated Jamaican-born PrCa patients, and U.S.-born White PrCa patients with low and 
intermediate stages PrCa live with the disease, after controlling for sociodemographic 
characteristics?  
  H04: There are no differences in the length of time brachytherapy treated 
Jamaican PrCa patients and U.S.-born White PrCa patients with low and intermediate 
stages PrCa, live with the disease, after controlling for sociodemographic characteristics. 
  Ha4: There are differences in the length of time brachytherapy treated Jamaican 
PrCa patients, and U.S.-born White PrCa patients with low and intermediate stages PrCa 
live with the disease, after controlling for sociodemographic characteristics. 
  Research Question 5. Are there differences in the length of time ERBT treated 
Jamaican-born PrCa patients and U.S.-born White PrCa patients with low and 
intermediate stages PrCa live with the disease, after controlling for sociodemographic 
characteristics?   
  H05: There are no differences in the length of time ERBT treated Jamaican PrCa 
patients and U.S.-born White PrCa patients with low and intermediate stages PrCa live 
with the disease, after controlling for sociodemographic characteristics. 
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  Ha5: There are differences in the length of time ERBT treated Jamaican PrCa 
patients and U.S.-born White PrCa patients with low and intermediate stages PrCa live 
with the disease, after controlling for sociodemographic characteristics. 
Introduction of the Theory 
The oxidative stress theory was utilized to explain the relationship between the 
variables of this dissertation. Denham Harman conceptualized the oxidative stress theory 
in 1956 as the free radical theory of aging (Preedy, 2014; Sowell, Aluise, & Butterfield, 
2010). The oxidative stress theory postulates that accumulation of the production of free 
radicals and or reactive oxygen species (ROS) affects cellular functioning by impairing 
the deoxyribonucleic acid (DNA), lipid, and protein biomolecules of the cells of the body 
(Preedy, 2014; Sowell et al., 2010). Khandrika, Kumar, Koul, and. Maroni. (2009) linked 
the oxidative stress theory with programmed cell death which occurs because of 
intracellular and extracellular environmental conditions of the prostate gland. According 
to Khandrika et al. (2009), radiation is one of the environmental conditions which 
induces oxidative stress in the prostate gland, increases ROS production and 
consequently inhibits carcinogenesis. I anticipated that the oxidative stress theory would 
support the mechanism of radiation in the cellular transformations of the prostate gland in 
reducing carcinogenesis and consequently influencing the survival of PrCa patients. The 
major premise of the oxidative stress theory was confirmed where the research 
hypotheses were accepted. The mechanism of oxidative stress in PrCa survival is further 
explained in Chapter 2. 
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Kumar, Koul, Khandrika, and Meacham (2008) established that the cancerous 
cells of the prostate gland produced high levels oxidative stress which are toxic to these 
cells. Fang, DeMarco, and Nicholl (2012), and You et al. (2015) also supported the roles 
of the oxidative stress pathway in inhibiting PrCa carcinogenesis through radiation. 
Based on the mechanism of oxidative stress and its link with radiation-induced cell death 
in the prostate gland, this theory was considered appropriate to create the framework for 
providing a better understanding of the relationship between brachytherapy, ERBT, and 
survival of the PrCa patients in this study.  
Nature of the Study 
I utilized a retrospective cohort study design, survival analyses, and secondary 
data sources to answer the research questions. I selected a retrospective study design for 
this study to examine survival patterns of PrCa patients that occurred at different intervals 
between 1992 and 2011. The retrospective design was appropriate to examine both 
exposures and outcomes historically (Aschengrau & Seage 111, 2008, p. 207) and 
promote analyses of time to event data because of its historical nature (Frankfort-
Nachmias & Nachmias, 2008, p. 277).  
The independent variables were PrCa patients diagnosed with localized disease, 
and PrCa treatments which, included brachytherapy treatment, ERBT, and other radiation 
treatment (radiation sequenced with surgery). The dependent variable was the length of 
time that a prostate cancer patient lived with the disease after treatment. The covariates 




The source of secondary data for analysis was the 18 participating Surveillance 
Epidemiology and End Results (SEER) registries of the United States, November 2013 
submission. I chose this database because the SEER program of the National Cancer 
Institute (NCI) is a reputable source of data on the incidence and survival of cancer in the 
United States (NCI, 2017c). The SEER program gathers and publishes cancer rates and 
survival information from 18 participating population-based registries and covers 
approximately 28% of the U.S. population (NCI, 2017c). The SEER program is 
recognized as the only comprehensive population-based registry in the United States, 
which provides data on the tumor stage at the time of diagnosis as well as survival 
information (NCI, 2017c). The SEER registries data include the demographics of the 
PrCa patients and morphology and stage of the tumor at diagnosis (NCI, 2017c). The 
SEER program information also includes the cancer patients’ first course of treatment 
and the follow-up for their vital status (NCI, 2017c). The National Center for Health 
Statistics provide the mortality data to the SEER program, and the U.S. Census Bureau 
the population data. Thus, the SEER database was appropriate for this dissertation. 
The analysis of data for this dissertation included preliminary descriptive 
estimates for each of the variables of the study (Mills, 2011a). In addition, Kaplan-Meier 
analyses were used to estimate the survival distributions and hazard rates of the PrCa 
patients for varying intervals during the observation period. Furthermore, the Cox-
proportional hazards regression model was utilized to measure differences in the 
relationship between the independent and dependent variables and to evaluate 
confounding effects of the covariates in the outcomes of the study. I interpreted the 
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results of these statistical analyses with alpha level (p < .05), and 95% confidence 
intervals (Rich, 2010). I analyzed the data with the International Business Machines 
(IBM) Statistical Package for the Social Sciences (SPSS) software version 23. 
Definitions of Research Variables Relating to the Research Questions 
Dependent Variable 
The dependent variable of this dissertation is PrCa survival. PrCa survival was 
defined as the duration that an affected person lived with PrCa from the date of initial 
diagnosis to the time of the first outcome (death or censoring) (Hu et al., 2014; Lin et al., 
2009; Redaniel et al., 2013; Thompson et al., 2013). The time of diagnosis was the month 
and year of diagnosis which were documented in the SEER registry database (SEER, 
2013). The time of death was the period the death of a case was recorded in the registry 
database (SEER, 2013). The vital status included the SEER cause-specific mortality 
definition and confirmation of death using death certificate or autopsy information 
(SEER, 2013). Censored cases were PrCa patients who died of causes other than PrCa 
(NCI, 2017a). The definition of PrCa survival also included active follow-up of each 
PrCa patient (SEER, 2013). 
Independent Variables 
In this study, I classified a prostate cancer patient according to the International 
Classification of Diseases for Oncology version 10 (ICD-O) code C60, and used the 
SEER cause-specific death (sequence numbers 01) definition of the 1973 to 2011 
submission (National Institutes of Health [NIH], 2017). Additionally, a prostate cancer 
patient in this research was a confirmed case by histology, or cytology according to the 
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SEER Research Data Record Description 1973 to 2011 (SEER, 2013). Jamaican PrCa 
patients were males with Jamaican birthplace who were recorded in 15 of the 18 SEER 
registries, November 2013 submission (SEER, 2014). The 15 participating SEER cancer 
registries included in the study were Connecticut, Detroit Metropolitan, San Francisco-
Oakland, Seattle (Puget Sound), Atlanta Metropolitan, Los Angeles, New Jersey, Greater 
California, Rural and Greater Georgia, Kentucky, Louisiana, New Mexico, San Jose-
Monterey, and Utah (SEER, 2014). A White PrCa patient was defined as a U.S.-born 
White PrCa patient of the 15 SEER participating cancer registries which, had Jamaican 
PrCa patients (SEER, 2014).  
The definition for the localized stage PrCa included the tumors which, were 
confined to the prostate (Young et al., 2000). PrCa patients with localized disease were 
classified according to Gleason grades G1, G2, and G3 (SEER, 2015, p. 96; Young et al., 
2000, p. 224). PrCa patients were also classified according to the TNM stages T1 and T2 
of the AJCC 6th Edition tumor node metastases (TNM classification), and the SEER 
Historic Stage A classification (SEER, 2013; SEER, 2014). According to the AJCC 6th 
Edition TNM classification, the localized stages T1a, T1b, and T1c, are clinically in-
apparent tumors (SEER, 2013; Young et al., 2000). PrCa was defined as stage T2a with 
the involvement of one lobe; and T2b for involvement of more than one lobe (Young et 
al., 2000). Stage T2NOS was assigned to each PrCa patient who had no specified TNM 
stage (SEER, 2013).  
Prostate cancer treatments were ERBT, brachytherapy, and other radiation 
treatments. Brachytherapy was defined as PrCa patients who received radioactive 
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implants, radioisotopes, and a combination of radioactive implants and radioisotopes 
(SEER, 2013). ERBT was PrCa patients who received beam radiation as monotherapy 
(SEER, 2013). Other radiation treatment was PrCa patients who received radiation 
sequenced with surgery (SEER, 2013). The radiation sequenced with surgery variable 
included other types of radiation treatments, which were not accounted for in the 
brachytherapy and ERBT definitions.  
Covariates 
Covariates for this study were the sociodemographic characteristics of the patient. 
The sociodemographic characteristics included the marital status, age, and health 
insurance status of the PrCa patient as recorded in the SEER registries data and reported 
at diagnosis (SEER, 2013). Marital status was the marital union reported by the patient 
at the time of PrCa diagnosis (SEER, 2013). Health insurance status was the PrCa 
patient’s primary means of payment for health care, and the health insurance coverage 
plan at the time of diagnosis as recorded in the SEER data (SEER, 2013). Age was the 
actual age in years at diagnosis as recorded in the SEER registry database (SEER, 2013). 
Age also included all PrCa patients who were older than 35 years for the 1973 to 2011 
SEER reporting period (SEER, 2013).  
Assumptions 
One of the assumptions that guided the execution of this dissertation was the 
secondary data of the SEER registries were appropriate for the exploratory design of this 
study. The SEER registry data on PrCa patients were collected by federal agencies, which 
employed trained personnel for data collection processes, and applied quality assurance 
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measures (Boslaugh, 2010). In addition, the data were deidentified and recoded where 
appropriate to protect the research participants (SEER, 2013). I also assumed that the 
SEER registry dataset would provide the cancer-specific information, which was related 
to the independent and dependent variables of this dissertation because the SEER registry 
database is a national database (Su & Jang, 2011). Multicenter and national databases are 
better suited to capture data on specific details about the characteristics of the tumor for 
comparisons of the outcomes of different treatments a PrCa patient receives (Su & Jang, 
2011). Hence, I presumed that the SEER registry database was an appropriate data source 
for this study.  
My supposition that the choice of secondary data for this investigation was 
appropriate was grounded in the likelihood that it could determine the probable 
relationships between the dependent and independent variables. The assumption was also 
based on the concept that secondary data sources are advantageous to examine the 
variables of an investigation in a socioeconomic, geographic, and historical context 
(Flowerdew, & Martin, 2013, p. 59). Besides, secondary data are helpful for comparison 
of a specified cohort with the larger population from which it was taken and facilitate the 
evaluation of differences and trends (Flowerdew, & Martin, 2013, p. 59). 
Additionally, I assumed that the theoretical framework was ideal to explain the 
relationships between the independent and dependent variables. The oxidative stress 
theory, which hypothesized that oxidative stress is linked to age-related cancers including 
PrCa, and radiation-induced programmed cell death in the prostate gland is a biological 
concept. A biological conceptual framework generates data for defining, evaluating, and 
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managing clinical problems (Wenzel, 2017, p. 492). Hence, I presumed that the oxidative 
stress theory was suitable to determine the role of radiation in the oxidative stress 
pathway and PrCa carcinogenesis. 
Scope and Delimitations 
The primary focus of this dissertation was to determine survival outcomes of 
brachytherapy and ERBT treated Jamaican PrCa patients who were diagnosed with 
localized disease and resided in the United States. The study was important because there 
were limited publications on PrCa treatment outcomes among Jamaicans and studies on 
PrCa treatments were primarily conducted in the White populations and with small 
samples of African Americans. Hence, results of current publications were not applicable 
to Jamaicans. Subsequently, an enquiry using a Jamaican cohort was necessary to 
extrapolate the findings to that cohort. 
In this study, I included all Jamaicans from the SEER database who met the 
selection criteria. The Jamaicans in the SEER registries database were the largest non-
U.S.-born Black population (87.6%) (Fedewa & Jemal, 2013) and had the similar stage 
and grade PrCa as the patients residing in Jamaica West Indies (Anderson et al., 2012; 
Kampel et al., 2011). I balanced the selection of a White U.S.-born comparison group 
with the Jamaican cohort by excluding three of 18 SEER reporting sites (Hawaii, Iowa 
and Alaska Native) which had no Jamaican PrCa patients.  
The study included all the PrCa patients who satisfied the selection criteria in the 
SEER registry data set to maximize group differences on the dependent and independent 
variables and improve generalization of the research findings (Polit & Beck, 2013, p. 
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246). The inclusion of a White U.S.-born referent group improved the sensitivity of the 
study to detect the effects observed (Polit & Beck, 2013, p. 246) among the Jamaican and 
White U.S.-born cohorts. I included the variable, radiation sequenced with surgery, to 
determine whether the treatment outcomes would differ significantly from brachytherapy 
and ERBT. The radiation sequenced with surgery variable included other types of 
radiation treatments that were not accounted for in the brachytherapy and ERBT 
definitions, hence it was important to determine whether it contributed significantly to the 
outcomes of the study. Additionally, I chose a biological theoretical framework to 
conceptualize the findings of the study because the research problem and questions were 
focused on PrCa treatment effects. 
Limitations 
One of the primary limitations anticipated in this study was the inability to make 
causal inferences about the variables from secondary data sources (Smith et al., 2011). 
Secondary data limits the options to choose appropriate populations for the study and 
influences the generalizability of the research results (Smith et al., 2011). Nonetheless, 
the questions of this research were developed to address the limitations on the study’s 
findings (Smith et al., 2011). The research questions were structured based on logical 
reasoning from the conclusions of the literature reviewed and the recommendations of 
other researchers. The questions were developed on the premise that although they may 
not facilitate causal inferences from the data, they can generate findings on the clinical 
significance of the research (Smith et al., 2011). The SEER registry (a national database) 
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which collects data from 18 participating cancer registries in the USA was used for the 
data analysis to enhance generalizations of the research findings.  
I utilized survival models for data analysis, and there are limitations of these 
statistical techniques. The Kaplan-Meier survival method is not effective to quantify the 
actual effect size of the study and is limited in addressing confounding effects (Flynn, 
2012). However, in this study the Cox-proportional hazards model complemented the 
Kaplan-Meier survival model. The Cox-proportional hazards regression model is robust, 
flexible, and uses data efficiently (Harrell, 2015). The Cox-proportional hazards 
regression model also replaced the proposed Ederer 11 and Pohar Perme methods, which 
were limited in analyzing PrCa patients in the older age group (Lambert, Dickman, & 
Rutherford, 2015; Roche et al., 2013; SEER*Stat, 2015; Seppa, Hakulinen, & Pokhrel, 
2015).  
Possible Biases 
A potential bias in this study was the threat of maturation of the research 
participants (Polit & Beck, 2013, p. 247). Some PrCa patients may change their vital 
status with time, irrespective of the treatment they receive, because of other conditions 
such as comorbidities, which could not be measured in this study owing to the limitations 
of the dataset.  
Another possible source of bias for this dissertation was sampling bias (Leighton, 
2010a, p. 83). In addressing the likelihood of possible selection bias in this dissertation, I 
used an evidenced based approach to create the selection criteria. I developed the 
selection criteria for the research participants using their characteristics in the SEER 
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Research Data Description for PrCa cases who were diagnosed between 1973 to 2011 
(SEER, 2013). I also utilized a random selection method to choose the comparison group 
for the study. 
Significance 
This dissertation may add new epidemiological data to the current body of 
knowledge on PrCa in the Jamaican community. While PrCa is a public health problem 
among Jamaicans, there is limited information on the treatment of localized PrCa in the 
Jamaican communities (Aiken & Eldemire-Shearer, 2012; Fedewa & Jemal, 2013; 
Gibson, Hanchard, Waugh, & McNaughton, 2013; Morrison et al., 2014; Rich et al., 
2012).  
I also expect that this dissertation will contribute to public health practice and 
policies aimed at improving the years of potential life lost (YPLL) of a Jamaican PrCa 
patient, by informing clinical interventions and policies that address access to treatments 
for localized PrCa. If these interventions are effective in managing the early and 
intermediate stages of this disease, the survival rates of affected males may be improved 
because earlier stages of PrCa demonstrate better survival outcomes (Fufaa, 2011).  
This study has important social change implications for the Jamaican population. 
The Jamaican population has a high rate of PrCa, and affected males experience 
disparities in access to PrCa treatment (Aiken & Eldemire-Shearer, 2012; Gibson et al., 
2013; Rich et al., 2012). This inequality is primarily due to a combination of social 
factors such as lack of health insurance and affordable preventive care (Aiken & Shearer, 
2012; Morrison et al., 2014). Therefore, this research may provide data, which can be 
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used to make appropriate decisions for improving the clinical management of PrCa 
patients, enhance access to health care, improve the health outcomes of PrCa patients, 
and subsequently reduce the disparities in PrCa survival. Currently, the Jamaican 
government is seeking to advance the services offered to cancer patients in Jamaica by 
utilizing assistance from the international organization International Atomic Energy 
Agency (IAEA) to address the existing epidemiological status of cancers in the country 
(Ministry of Health Jamaica, 2013). The Jamaican urological society is also seeking 
information on PrCa treatment effectiveness among Jamaicans, which will support 
appropriate treatment choices for localized PrCa (Morrison et al., 2014). This research 
would improve access to empirical data that focused on addressing the PrCa cancer 
epidemiology among Jamaicans.  
Summary and Transition 
The treatment of PrCa patients with low and intermediate stage disease using 
Brachytherapy and ERBT are well documented among the White population of the 
United States as well as other European cohorts. However, findings of recent publications 
may not generalize to Jamaicans because of small samples of African Americans, which 
were included in those investigations. There is also a dearth of information on the 
relationship between brachytherapy treatment, ERBT, and PrCa survival among 
Jamaicans. Besides, it was important to study the effects of brachytherapy and ERBT in 
localized PrCa among Jamaicans because of currently reported trends in the detection of 
the disease. Additionally, it was relevant to examine for intervening effects of the 
sociodemographic characteristics in the survival of PrCa patients because of their 
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relationship with the key variables of the study. Hence, the sociodemographic indicators 
of the research subjects were studied for their covariate effects in the results of the 
research. The research utilized a retrospective design and survival models to examine the 
effects of brachytherapy and ERBT on the survival of Jamaican PrCa patients with low 
and intermediate stage PrCa. These survival models included the Kaplan-Meier and Cox-
proportional hazard models. The oxidative stress theory was chosen to explain the 
relationship between the main variables of the study. In Chapter 2, I provided a deeper 
analysis of the literature that clarifies the theoretical framework of the study. Chapter 2 
also has the literature synthesis which describes the variables of the study, their roles in 
the study; and the gaps in the literature.   
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Chapter 2: Literature Review  
Introduction 
The outcomes of brachytherapy and ERBT in treating low and intermediate stage 
PrCa are well reported in retrospective, prospective, and observational studies (Alumini 
et al., 2015; Cendales et al., 2015; Goldner et al., 2012; Marshall et al. 2014;  
Nepple et al., 2013; Rodrigues et al., 2014; Smith et al., 2015; Williams et al., 2011; 
Zuber et al., 2015). However, researchers documented diverse conclusions on the 
effectiveness of brachytherapy, ERBT, and active surveillance for treating localized PrCa 
(Alumini et al., 2015; Cendales et al., 2015; Goldner et al., 2012; Marshall et al. 2014; 
Nepple et al., 2013; Rodrigues et al., 2014; Smith et al., 2015; Williams et al., 2011; 
Zuber et al., 2015). Findings of current publications were noted primarily in the White 
populations (Alumini et al., 2015; Cendales et al., 2015; Marshall et al. 2014; Nepple et 
al., 2013; Rodrigues et al., 2014; Williams et al., 2011). Additionally, investigators who 
examined treatment effects of brachytherapy and ERBT in PrCa survival, documented 
limitations of small sample sizes of the Black population (Cendales et al., 2015; Goldner 
et al., 2012; Nepple et al., 2013; Smith et al., 2015; Zuber et al., 2015). Hence, data from 
current literature may not extrapolate to the Jamaican cohort. Consequently, the intent of 
this dissertation was to explore the effects of ERBT, and brachytherapy treatment on the 
survival of Jamaican PrCa with low and intermediate stage disease. This dissertation was 
also designed to examine the covariate effects of the sociodemographic indicators of age, 
marital status, and health insurance status in the survival rates of Jamaican and White 
U.S. PrCa patients. This research investigated the association of PrCa treatment for low 
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and intermediate stage disease with the survival rates of Jamaican and U.S.-born White 
PrCa patients, using a retrospective cohort study design, secondary data, and survival 
models.  
A vast number of current retrospective and prospective studies documented 
disparities in PrCa survival in the African American, and Caribbean Black populations 
(Antwi, Tucker, Coker, & Fleming, 2013; Mutetwa et al., 2012; Ragin, Mutetwa, Attong-
Rogers, Roach, & Taioli, 2011; Tyson & Castle, 2014). Meliker, Goovaerts, Jacquez, 
AvRuskin, and Copeland (2009), and Tyson and Castle (2014) reported that the White 
PrCa patients in the United States experienced better survival overall when compared 
with Black males. Mutetwa et al. (2012) and Ragin et al. (2011) established that men who 
were born in the Caribbean and lived in the United States had similar five-year survival 
patterns from PrCa as other African Americans. However, the reasons for the survival 
disparities in PrCa among racial groups were not well explained in current literature.  
Recently, researchers also documented that brachytherapy (with or without 
ERBT), and active surveillance, were popular treatment choices among PrCa patients 
who are living in the United States (Hamilton et al., 2010; Weiner, 2015). However, 
retrospective, prospective and observational studies on brachytherapy treatment and PrCa 
survival demonstrated mixed results (Alumini et al., 2015; Cendales et al., 2015; 
Marshall et al. 2014; Rodrigues et al., 2014; Williams et al., 2011; Zuber et al., 2015). 
Alumini et al. (2015), Cendales et al. (2015), Smith et al. (2015), Rodrigues et al. (2014), 
Skowronek (2013), and Zuber et al. (2015) reported survival benefits among 
brachytherapy treated PrCa patients. On the other hand, Goldner et al. (2012), Nepple et 
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al. (2013), and Smith et al. (2015) cited no statistically significant differences among 
PrCa patients who were treated with ERBT as a monotherapy, versus PrCa patients who 
received brachytherapy with and without ERBT. Moreover, Schreiber et al. (2013) 
documented disparities in brachytherapy treatment among Whites and African 
Americans. Furthermore, Williams et al. (2011) established that brachytherapy was a 
costlier treatment option for localized disease when compared with other PrCa 
treatments. Hence, current literature provided mixed findings on the survival advantage 
of brachytherapy treatment and ERBT among PrCa patients with low and intermediate 
stage disease. Additionally, the outcomes reported in the literature suggested that the 
effect of brachytherapy treatment for localized PrCa required further exploration 
particularly among African American males. 
In current publications, researchers documented favorable survival outcomes 
among PrCa patients who were diagnosed with low and intermediate risk disease and 
were managed without directive treatment (Bul et al., 2013; Odom et al., 2014; 
Selvadurai et al., 2013; Wilt et al., 2012). In three prospective studies, Bul et al. (2013), 
Klotz et al. (2010), and Selvadurai et al. (2013) reported low death rates among PrCa 
patients on active surveillance and observation. However, Klotz et al. recommended 
additional research, which include PrCa patients with the aggressive forms of the disease 
to verify their findings. Nepple et al. (2013) also suggested that observation should be 
added as a treatment option in studies, which examine the effects of ERBT and 
brachytherapy treatment in PrCa survival. 
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Additionally, findings of the review of the literature revealed that the 
sociodemographic characteristics of age, grade, and stage of the disease influenced the 
survival of PrCa patients, particularly the African American population (Antwi et al., 
2013; Fufaa, 2011; Lin et al., 2009). Scholars have also identified differences in survival 
of PrCa according to the sociodemographic characteristics and treatment status of men 
from varying geographic backgrounds, and indicated that these variables might be 
responsible for PrCa survival (Parris, 2013; Shafique et al., 2013; Xiao, Warrick, & 
Wang, 2009). Therefore, the sociodemographic indicators of age, marital, and health 
insurance status of a PrCa patient were examined in this study for their covariate effects. 
Finally, recent studies documented that smoking impacts the survival of PrCa 
patients (Kenfield et al., 2011; Warren et al., 2012; Watters et al., 2009). Smoking may 
be related to high death rates among PrCa patients, and the African American population 
is more likely to be affected (Kenfield et al., 2011; Warren et al., 2012; Watters et al., 
2009). Furthermore, data from the Jamaican Lifestyle Survey (453304) indicated that 
smoking was a common lifestyle factor among Jamaican males and a contributing factor 
to chronic diseases in that cohort (Wilks, Younger, Tulloch-Reid, Mcfarlane, & Francis, 
2008). Hence, smoking was a covariate in this study; but, data were not available for this 
research to examine its effects on PrCa survival. 
Chapter 2 includes the origins of the oxidative stress theoretical framework, its 
main propositions, and its role in the relationship between the independent and dependent 
variables. Chapter 2 also comprises the literature search strategy, the synthesized 
literature of the variables of the study, and the research questions. The main areas of the 
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literature review were prostate cancer survival, current trends in PrCa survival, 
differences in survival among ethnic groups, treatment for low and intermediate stage 
PrCa and survival, and the sociodemographic characteristics and PrCa survival.  
Literature Search Strategy 
I conducted the literature search using publications from the major databases of 
the Walden University Library. The primary library resources were ProQuest 
Dissertations and Theses at Walden University, Google Scholar, EBSCO Host, Academic 
Search Complete, Thoreau, and Science Direct. The Boolean search engines and phrases 
were the major search modes used to identify appropriate literature for this dissertation. 
The key search terms were prostate cancer, prostate cancer mortality and 
survival, prostate cancer and Jamaican males, prostate cancer in the White population of 
the United States, prostate cancer, and radiation treatment, prostate cancer in the 
Caribbean, and prostate cancer in the United States. Search terms also included, prostate 
cancer treatment for localized disease, active surveillance and prostate cancer, external 
beam radiation therapy (ERBT) and localized prostate cancer, and brachytherapy and 
localized prostate cancer, treatment of prostate cancer and 1973 to 2011. In addition, 
search terms included radiation and the oxidative stress theory, oxidative stress theory 
and prostate cancer, the mechanism of the oxidative stress theory, and radiation-induced 
apoptosis. Other terms used for the literature search were sociodemographic 
characteristics and prostate cancer treatment, smoking and prostate cancer survival, 
smoking among Jamaicans, and the SEER cancer registry. 
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 I also used the reference listings of current primary research articles to identify 
other relevant sources of the literature. Publications were sorted by relevance and 
currency, for those written in English, and included peer-reviewed primary sources. 
However, both peer-reviewed and non-peer-reviewed articles on the Jamaican population 
were included because of limited literature. I utilized the studies on the African American 
population to make deductions about Jamaicans where the data on the variables of 
interest and the research questions were inadequate. Articles older than five years were 
included where data were lacking on important variables, and for their relevance to the 
study. 
Theoretical Foundation 
  The free radical theory of ageing, currently known as the oxidative stress theory 
(Sowell et al., 2010) was utilized to conceptualize the relationship between treatment for 
localized PrCa, clinical characteristics of PrCa, and PrCa survival. Denham Harman 
developed this theory in 1956 (Sowell et al., 2010).  
Major Theoretical Propositions 
The oxidative stress theory proposed that oxidative stress is an outcome of 
increased and sustained metabolic processes of the body, which contributes to major age-
related chronic diseases, including cancers (Sowell et al., 2010, p. 341). The oxidative 
stress theory posits that accumulation of the production of free radicals and ROS, affects 
cellular functioning by impairing the DNA, lipid, and protein biomolecules of the cells of 
the body (Preedy, 2014; Sowell et al., 2010). Khandrika et al. (2009) linked the oxidative 
stress theory with programmed cell death, which occurs because of intracellular and 
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extracellular environmental conditions of the prostate gland. These intracellular and 
extracellular environmental conditions generate ROS during the metabolic activities of 
the cell, and ROS subsequently activate signaling pathways to react to the cellular states 
(Khandrika et al., 2009). According to Khandrika et al. radiation is one of the 
environmental conditions which induces oxidative stress in the prostate gland and 
consequently increases ROS production. Radiation also inhibits carcinogenesis by 
increasing ROS production (Khandrika et al., 2009). Increasing ROS production results 
in damage to the DNA of the cell and inhibits cell duplication and division (Khandrika et 
al., 2009). Subsequently, radiation-induced cell death occurs, and the damaged cells are 
removed from the body through apoptosis (Khandrika et al., 2009; Nakajima, 2008). The 
process of radiation-induced apoptosis impedes the progression of PrCa carcinogenesis 
(Nakajima, 2008). Thus, the assumptions of the oxidative stress theory are linked with the 
mechanism of radiation-induced programmed cell death in halting PrCa carcinogenesis. 
 Literature and Research-Based Analysis of Theory Application 
Findings from studies, which clarified the roles of the oxidative stress pathway in 
PrCa development, supported a relationship between oxidative stress and PrCa 
carcinogenesis (Barocas et al 2011, Freitas et al., 2012; Kumar et al., 2008). In the 
Nashville’s Men’s Health study Barocas et al. (2011) confirmed that oxidative stress 
played a role in PrCa development. Barocas et al. identified that F2-Isoprostane level, 
which is associated with oxidative stress in PrCa, was elevated in men with the disease. 
In another experimental study, which used the oxidative stress theory as its conceptual 
framework, Kumar et al. (2008) described the functions of oxidative stress in healthy 
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cells of the prostate gland and three different types of PrCa cells with varying degrees of 
aggressiveness. Kumar et al. confirmed that PrCa cells produced higher levels of ROS 
when compared with normal cells, and subsequently created functional abnormalities of 
the prostate cells. Freitas et al. (2012) also established that ROS was toxic to PrCa cells in 
the localized stage of PrCa. However, Freitas et al. indicated that the influence of ROS in 
low-grade PrCa was less marked when compared with metastatic disease. The finding of 
Freitas et al. suggested that small increments of ROS also create changes in the cells of 
the prostate gland.  
Experimental studies also supported the roles of the oxidative stress pathway in 
inhibiting PrCa carcinogenesis (Fang et al., 2012; You et al., 2015). Fang et al. (2012) 
and You et al. (2015) indicated that the oxidative stress pathway plays a key role in 
explaining the functions of ROS in stimulating signaling pathways in response to the 
cellular environment of the prostate gland. Fang et al. and You et al. demonstrated that 
radiation promotes apoptosis, and decreases cell proliferation in localized PrCa. The 
findings of these studies suggested that radiation promotes programmed cell death and 
subsequently inhibits carcinogenesis (Fang et al., 2012; You et al., 2015). The effects of 
radiation-induced programmed cell death in decreasing PrCa carcinogenesis may 
determine the length of time individuals who are treated with radiation live with the 
disease. Therefore, the oxidative stress theory was appropriate to explain the relationship 
between the primary variables of this dissertation because it clarified the mechanism of 




Relationship of the Theory to the Study and the Research Questions to the Theory 
The aim of this study and the research questions were to determine the survival 
intervals of ERBT and brachytherapy treated Jamaican PrCa patients with low and 
intermediate stages PrCa, and compare survival outcomes with White U.S.-born ERBT 
and brachytherapy treated PrCa patients. Experimental studies documented the role of the 
oxidative stress pathway in the development of PrCa, and paradoxically in halting PrCa 
carcinogenesis (Fang et al., 2012; Khandrika et al., 2009; You et al., 2015). According to 
the findings of these studies, radiation is an extracellular environmental factor which 
induces oxidative stress in the prostate gland and damages the cell’s DNA structure (Fang 
et al., 2012; Khandrika et al., 2009; You et al., 2015). Thus, the cell cycle is arrested, 
radiation-induced apoptosis occurs, and consequently, carcinogenesis of the prostate is 
halted (Fang et al., 2012; Khandrika et al., 2009; You et al., 2015). The outcome of this 
process may explain the length of time a PrCa patient lives with the disease. Therefore, 
this theory was appropriate to test the hypotheses of a relationship between the prime 
variables of this dissertation.  
Literature Review Related to Key Variables and Concepts 
In the literature review, I discussed the significant variables and covariates in the 
context of the study. I also highlighted how the key variables were measured in this 
dissertation, and the gaps addressed with the research questions.  
Prostate Cancer Survival 
Prostate cancer survival is the dependent variable in this dissertation and was 
investigated among Jamaican and White PrCa patients residing in the United States. In 
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defining PrCa survival, it was necessary to clarify the dates of initial diagnosis and the 
time of death from PrCa. Researchers who conducted investigations in PrCa survival 
defined survival as the date of initial diagnosis to the time of the first outcome (death or 
censoring) (Hu et al., 2014; Lin et al., 2009; Redaniel et al., 2013; Thompson et al., 
2013). According to Mills, (2011a) knowledge of the time of the event helps in 
determining whether continuous or discrete time methods should be used to complete 
survival analyses. Redaniel et al. (2013) examined PrCa survival with secondary data and 
used the definitions of the cancer registry that provided the data. Redaniel et al. defined 
the date of initial diagnosis of PrCa as the date of initial histological or cytological 
confirmation of the primary tumor. Mills and Redaniel et al. supported the relevance of 
establishing the parameters, which defined the survival intervals of the PrCa patients in 
this research.  
Another vital element of the definition of prostate cancer survival in this study 
was specifying the time of death. In survival data, the precise survival times for a variable 
may be difficult to determine, or data may not be available in the data set (Mills, 2011a). 
The survival time that is not known is usually accounted for as censoring in survival 
studies (Mills, 2011a). Hence, censoring was a critical component of the definition of 
survival in this research. An important consideration for the definition of censoring was 
variation in its meaning according to the source of data used for an investigation. In 
examining survival time, Lin et al. (2009) and Thompson et al. (2013) defined censoring 
of PrCa patients as the date that they were last reported as being alive in the study, based 
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on available follow-up data. In this dissertation, I used the definition for censored data 
that was available in the database. 
Additionally, an appropriate endpoint was a key aspect of the definition of 
prostate cancer survival. Prostate cancer-specific and cause-of-death mortality are two 
important endpoints which are used to estimate PrCa survival (NCI, 2011). However, the 
NCI (2011) reported that it is usually challenging to choose appropriate sources of 
information from which to confirm these endpoints for PrCa. Cause of death data is one 
source of information used for this purpose, but it is limited in providing the correct 
endpoint for verifying PrCa survival (NCI, 2011). Nonetheless, information from the NCI 
suggested that despite its limitations, cause-of-death data is useful to establish endpoints 
to estimate PrCa survival. The cause-of-death data represents the survival from PrCa in 
the absence of other causes of death and allows for censoring of individuals who die of 
causes that were not studied (NCI, 2011).  
Lin et al. (2009) and Thompson et al. (2013) used cause-specific and all-cause 
mortality data to measure PrCa survival and described the benefits and limitations of 
using both data sources. Thompson et al. indicated that there were limitations in using 
cause-specific data to determine PrCa survival; conversely, Lin et al. highlighted the 
advantage of using both cause-specific and all-cause mortality data to examine survival. 
In estimating survival in a treatment versus a placebo group using PrCa specific mortality 
data, Thompson et al. did not detect an effect in a placebo group because of inadequate 
information on cancer-specific deaths. On the other hand, Lin et al. identified a difference 
in overall survival (survival rate 2.1%, 95% [CI 1.38, 3.19]) and PrCa specific survival 
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(survival rate 0.71%, 95% [CI, 0.54, 0.92]), using cause-specific and all-cause mortality 
data from the SEER registry. Lin et al. examined PrCa survival in a 55 to 64 age group 
cohort diagnosed with all stages of PrCa. Although 38% of the data were reported 
missing in the study, this did not affect the study’s outcome (Lin et al., 2009). The 
studies’ results of Lin et al. and Thompson et al. implied that using both cause-specific 
and all-cause mortality data may be a better choice to estimate PrCa survival when 
compared with utilizing cause-specific data exclusively.  
Lin et al. (2009) relied on the information from death certificates to obtain cause 
of death data to base endpoints for PrCa survival; however, the NCI (2011) reported 
limitations in using death certificates for this purpose. According to the NCI, one of the 
drawbacks of using death certificates to determine death from PrCa is ensuring that the 
data accurately classify the cases. The precision of the endpoints from death certificates 
might vary according to the accuracy of the information of the death certificates; this 
could be problematic when classifying metastatic cases if the death certificates 
incorrectly list the cause of death (NCI, 2011). Although the NCI reported limitations in 
the use of death certificates, the organization advocates for its use to ascertain causes of 
death in population-based survival data obtained from cancer registries. In this 
dissertation, the definition of prostate cancer survival was developed based on the 
recommendations of the NCI, the findings of the literature, and the definitions of the 
cancer registries data description (SEER, 2014).  
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Differences in Prostate Cancer Survival Among the White U.S.-Born and Ethnic 
Groups  
Investigators who conducted studies on PrCa survival in the United States 
documented greater survival disadvantage of the U.S.-born ethnic groups when compared 
with the White population (Antwi et al., 2013; Meliker et al., 2009; Mutetwa et al., 2012; 
Ragin et al., 2011; Tyson & Castle, 2014). Antwi et al. (2013) explored differences in 
PrCa survival in a cohort of 18,200 (91.3% Whites, 8.7% African-American) men from 
the State of Kentucky cancer registry. The results of the enquiry demonstrated that the 
African American PrCa patients experienced higher mortality (10.9%) from the disease 
when compared with the Whites (7%), (p < .001) (Antwi et al., 2013). The African 
American men were also more likely to be diagnosed with distant stage PrCa (6.5%) 
when compared with the White population (4.3%) (Antwi et al., 2013). Additionally, a 
higher proportion of African American versus White PrCa patients received surgery as 
the primary treatment (29.6% versus 25.2%, p < .001) (Antwi et al., 2013). Additionally, 
the survival disparities of the White and African American cohorts remained at ten years 
of follow-up (Antwi et al., 2013). Antwi et al. recommended further exploration of 
survival differences of African Americans including socioeconomic status, treatment 
guidelines, underlying biological influences among the races, and comorbidities.  
Meliker et al. (2009) examined survival disparities in a sample of 120,615 PrCa 
patients from the State of Michigan cancer surveillance program and demonstrated mixed 
results. Using the Space-Time Intelligence System, Meliker et al. estimated racial 
disparities across Federal and State House Legislative Districts and community-defined 
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localities. The findings of the study revealed racial differences in PrCa survival in 47% of 
the Federal State House Legislative Districts (Meliker et al., 2009). However, the survival 
experience for the State House Legislative Districts and urban communities were mixed 
(Meliker et al., 2009). One of the high points of this study was the utilization of 
geographic information systems to quantify the survival outcomes of the PrCa patients 
(Meliker et al., 2009). On the other hand, Meliker et al. asserted that their study could not 
determine variations in PrCa survival according to the country of origins of 
subpopulations of Blacks and Whites.  
Tyson and Castle (2014) also documented disparities in PrCa survival among 
Blacks when compared with Hispanics, Asians, and Whites. Tyson and Castle utilized a 
cohort of 294,160 PrCa patients from the SEER cancer data registries who were 
diagnosed between January 1995 and December 2003. The findings of the study 
conducted by Tyson and Castle revealed that the Black PrCa patients had poorer survival 
when compared with the White U.S. cohort, HR 1.37, 95% [CI 1.33, 1.41], p < .001. 
Tyson and Castle alluded to the problems encountered in determining racial peculiarities 
due to the broad ethnic classification of the population-based data, and recommended 
future studies to explain the factors favoring differences in survival.  
Additionally, investigators demonstrated survival disparities among Caribbean-
born PrCa patients living in the United States and their country of birth (Mutetwa et al., 
2012; Ragin, 2011). Mutetwa et al. (2012) investigated the disparities of PrCa among 
Caribbean ethnic groups who resided in the United States and compared survival patterns 
with Caribbean men who lived in their native country. Mutetwa et al. utilized three 
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cancer registries databases in the United States, as well as Caribbean cancer registries 
data to estimate survival differences among the Afro-Caribbean males, and compare 
survival patterns with men living in the Caribbean. Mutetwa et al. recognized that males 
who were born in the Caribbean and resided in the United States had similar five-year 
survival patterns from PrCa as African Americans. The survival rate for Caribbean men 
living in their native countries was 78.1%, 95% [CI 70.9, 83.7] and 81.4% for African 
Americans males, 95% CI [69.5, 89.1] (p = 0.792) (Mutetwa et al., 2012).  
On the other hand, Mutetwa et al. (2012) reported that the survival rate for the 
Caribbean-born PrCa patients residing in the Caribbean was 41% when compared with 
81% for the men who resided in the United States. According to Mutetwa et al., the 
disparities in the survival rates of Caribbean-born PrCa patients who lived in their 
country of birth and the United States may be attributed to the methods of detection of the 
disease and genetic factors. One of the limitations reported by Mutetwa et al. was missing 
and incomplete data that defined the ethnic groups. On the other hand, a strong point of 
the researchers’ methodology was data triangulation with the Caribbean cancer registries 
and three United States cancer databases.  
Ragin et al. (2011) conducted further studies on the disparities in PrCa survival in 
a Brooklyn cohort of Caribbean-born males and PrCa patients living in the Caribbean to 
determine the underlying factors for their survival differences. Ragin et al. studied the 
survival differences among men who were currently diagnosed with stages 1 to 111 PrCa. 
The results of the study confirmed that the Caribbean-born PrCa patients who resided in 
their home country were three times more likely to die of PrCa, adjusted HR 3.6, 95%  
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[CI 2.8, 5.0] when compared with their Caribbean counterparts residing in the United 
States (Ragin et al., 2011). Ragin et al. also confirmed that there were significant 
differences in the treatments that the two cohorts received. The Caribbean-born males in 
the United States were managed surgically (35%); while, men residing in the Caribbean 
received hormone treatment (33%) (Ragin et al., 2011). Hence, the survival differences 
among PrCa patients in the Caribbean and the United States may be explained by 
treatment differences (Ragin et al., 2011). Ragin et al. recommended additional studies 
among Caribbean men to validate the results of their study.  
The findings of the current literature confirmed that the White U.S. PrCa patients 
had better survival probability from PrCa when compared with the Black population. 
Therefore, the White U.S. PrCa patients were suitable for the referent group for this 
research. The conclusions of studies on disparities in PrCa survival support the need for 
other research, which examine PrCa treatment outcomes in subpopulations of the African 
American and other ethnic communities in the United States. Additionally, researchers 
advocated for the inclusion of the socioeconomic status of PrCa patients in studies, which 
examine treatment effects in PrCa outcomes. Thus, it was necessary to study PrCa 
treatment outcomes in a minority population and include their socioeconomic 
characteristics. 
Trends in the Treatment of PrCa 1992 to 2011 
The treatment of PrCa evolved since the 1990s, and brachytherapy, ERBT, and 
active surveillance are widely used to treat localized disease (Cooperberg & Carroll, 
2015; Hager et al., 2014; Hamilton et al., 2010; Mahmood et al., 2014; Safdieh et al., 
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2016; Valdivieso et al., 2015, Weiner et al., 2015). Hamilton et al. (2010) examined 
trends in PrCa treatments for localized PrCa for the 1998 to 2002 interval using data from 
ten cancer registries in the United States. Hamilton et al. identified no significant changes 
in the number of PrCa patients who utilized radical prostatectomy or ERBT as 
monotherapy. Nevertheless, the proportion of patients who received brachytherapy 
treatment as monotherapy or combined with ERBT increased from 14.9% to 17.7% 
(Hamilton et al., 2010). Hamilton et al. also reported a decline in the number of PrCa 
patients who chose watchful waiting as an option for managing localized PrCa. Hamilton 
et al. recommended additional studies on recent trends in PrCa treatments for localized 
disease, and endorsed further studies which will delineate the subgroup of PrCa patients 
who would benefit from brachytherapy and ERBT. 
Hager et al. (2014) also reported a shift in treatment trends for localized PrCa for 
the period 2004 to 2011. Hager et al. compared current trends in PrCa treatments among 
cohorts of United States and German PrCa patients. The sample of U.S. PrCa patients 
was 132,506 PrCa patients whose data were abstracted from the SEER cancer registry. 
Hager et al. reported a decline in radical prostatectomy treatment (37.1% to 34.2%,  
p = .004), and radiotherapy (42.8% to 31.8%, p < .001) for the period 2004 to 2011. 
Hager et al. also identified that deferred and defensive treatments were the preferred 
choices for treating localized PrCa in the United States and there was a steady increase in 
the utilization of these treatment methods. However, Hager et al. alluded to the influence 
of physician’s preferences and the health care systems in the choice of treatment for men 
with localized PrCa. On the other hand, the PrCa patient’s preferences in treatment 
44 
 
options were not well documented (Hager et al., 2014). Additionally, Valdivieso et al. 
(2015) reported that brachytherapy was widely used among PrCa patients in the SEER 
Medicare-linked database for the 1992 to 2009 period. Forty percent of PrCa patients in 
the SEER Medicare-linked database used brachytherapy as monotherapy, 19% as a 
combination with ERBT, and 27% as a combination with Androgen Deprivation Therapy 
(ADT) (Valdivieso et al.,2015). Valdivieso et al. suggested that current investigations 
which extend beyond 2009 were needed to determine further shifts in PrCa treatment in 
the United States. 
On the other hand, Mahmood et al. (2014) and Safdieh et al. (2016) provided 
differing data on recent developments in PrCa treatments in the United States. Mahmood 
et al. investigated current trends in brachytherapy and ERBT utilization for treating 
localized PrCa for the period 2004 to 2009 using the SEER registry data. Mahmood et al. 
recognized a decline in brachytherapy treatment of 6.2% for the periods 2004 to 2009 and 
a similar increase of in ERBT uptake for that period. Brachytherapy utilization decreased 
according to the SEER geographic sites, race, age, marital status, health insurance status, 
and income, of the PrCa patients (Mahmood et al., 2014). Safdieh et al. studied a sample 
89,413 PrCa patients using the National Cancer Database for the period 2004 and 2012 
and reported a reduction in brachytherapy treatment from 62.9% in 2004 to 51.3%  
in 2012 (p < .001). Safdieh et al. indicated that the decrease in brachytherapy use was 
more evident among PrCa patients who lived furthest from treatment sites and purported 
that it could be attributed to physician’s preferences. Nonetheless, the study was limited 
by selection bias, coding errors, and incomplete data (Safdieh et al., 2016). Safdieh et al. 
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recommended further studies on the barriers to brachytherapy treatments. Based on the 
recommendations from researchers who investigated the current trends in PrCa 
treatments, this dissertation was necessary.  
Treatments for Low and Intermediate Stage PrCa and Survival 
In retrospective, observational, experimental, and prospective studies, researchers 
documented the survival benefits and limitations of ERBT and brachytherapy for treating 
PrCa patients in different settings (Alumini et al., 2015; Cendales et al., 2015; Goldner et 
al., 2012; Marshall et al. 2014; Nepple et al., 2013; Rodrigues et al., 2014; Smith et al., 
2015; Williams et al., 2011; Zuber et al., 2015). Among the benefits described in the 
literature, brachytherapy treatment provided fewer unpleasant side effects, and better 
biochemical control for PrCa patients with the localized disease when compared with 
other PrCa treatments (Alumini et al., 2015; Williams et al., 2011; Zuber et al., 2015). 
Alumini et al. (2015), Zuber et al. (2015), and Williams et al. (2011) established that 
brachytherapy is one of the safer methods to treat PrCa patients with early stage disease, 
and PrCa patients experienced fewer side effects with this treatment. The literature also 
highlighted that at higher doses, brachytherapy treatment was an equally effective 
treatment method for localized PrCa (Cendales et al., 2015; Rodrigues et al., 2014; 
Skowronek, 2013). Cendales et al. (2015), Rodrigues et al. (2014), and Skowronek 
(2013) confirmed that at high doses, brachytherapy treatment remained a safe and 
effective treatment for localized PrCa and toxicity among PrCa patients with localized 
disease was small. Additionally, the literature demonstrated that treatment outcomes for 
both low-dose and high-dose brachytherapy treatment were comparable (Rodrigues et al., 
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2014; Skowronek, 2013). Skowronek documented that at both Low-dose and high doses, 
brachytherapy treatment was equally cost effective for controlling localized PrCa. 
Similarly, Rodrigues et al. confirmed that brachytherapy at high and low doses was 
effective in reducing biochemical failure in both intermediate and low-risk PrCa patient. 
However, Rodrigues et al. reported that their study was limited by small sample size due 
to attrition of the study’s participants. 
On the other hand, researchers highlighted disadvantages with brachytherapy 
treatment in PrCa survival (Schreiber et al., 2013; Williams et al., 2011). The limitations 
of brachytherapy treatment included racial, socioeconomic, and age disparities; treatment 
side effects, and cost (Schreiber et al., 2013; Williams et al., 2011). Schreiber et al. 
(2013) reported racial and socioeconomic disparities in the use of brachytherapy among 
African Americans and Whites. Schreiber et al. documented that African American males 
of lower socioeconomic status were less likely to include brachytherapy in their PrCa 
treatment when compared with White males. Williams et al. (2011) asserted that 
brachytherapy is expensive, better accepted among men in the younger age group  
(p < .001), and resulted in bowel complications in PrCa treated patients. 
 Nonetheless, Schreiber et al. (2013), and Williams et al. (2011) cited limitations 
of their studies. Schreiber et al. acknowledged that misclassification, which occurred by 
arbitrarily assigning PrCa patients to socioeconomic groups was an important limitation 
of their study. Consequently, Schreiber et al. recommended further studies which 
examine racial and socioeconomic disparities in brachytherapy treatment. Schreiber et al. 
also indicated that lack of comorbidity data in the SEER cancer registry data was another 
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limitation, which influenced the results of the study. In addition, Williams et al. asserted 
that the quality of the clinical information used for their study was a prime limitation. 
Williams et al. noted that the data used for the study were lacking relevant clinical 
information about the PrCa patient because they were billing information. On the other 
hand, Aluwini et al. (2015), and Zuber et al. (2011) utilized prospective designs, reliable 
SEER coding, and documented that the high-quality Medicare data was one of the 
strengths of their study.   
Researchers have also compared the effectiveness of brachytherapy treatment 
with ERBT for the management of localized PrCa, and identified no statistically 
significant differences in overall survival of PrCa patients (Goldner et al., 2012; Nepple 
et al., 2013; Smith et al., 2015). In a Canadian cohort with low and intermediate stages 
PrCa, Smith et al. (2015) identified no significant differences in overall survival among 
men who were treated with brachytherapy versus ERBT. The hazard of death among low 
risk PrCa patients was, HR 1.41, (p = 0.500) and HR 1.27, (p = 0.687) for the 
intermediate risk cohort (Smith et al., 2015). Nepple et al. (2013) also detected no 
significant differences in prostate cancer mortality among a cohort of PrCa patients who 
were treated with ERBT and brachytherapy at the Cleveland Clinic in the United States, 
HR 1.83, 95% CI [0.88, 3.82]. Similarly, in a Dutch cohort, Goldner et al. (2012) 
confirmed that brachytherapy treatment might not provide a greater survival advantage to 
PrCa patients with intermediate risk PrCa when compared with ERBT. However, the 
studies were limited by small sample sizes and did not include an active surveillance 
group, as one of the treatment options for low-risk PrCa.  
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The findings of the literature on PrCa treatment outcomes may not generalize to 
Jamaican PrCa patients because of small samples of African American cohorts, and the 
study populations used to examine the relationship of the major variables. Additionally, I 
identified no studies on the outcomes of brachytherapy and ERBT in the Jamaican 
population. 
Survival of PrCa Patients Without Initial Treatment for Low and Intermediate 
Stage PrCa  
In recent publications investigators reported favorable survival outcomes among 
PrCa patients who were diagnosed with low and intermediate stage disease and were 
managed without directive treatment (Bul et al., 2013; Odom et al., 2014; Selvadurai et 
al., 2013; Wilt et al., 2012). Bul et al. (2013), Klotz et al. (2010) and Selvadurai et al. 
(2013) reported low death rates among PrCa patients who were managed with active 
surveillance and observation. However, Bul et al., Klotz et al., and Selvadurai et al. 
suggested that the findings of these studies might be inadequate to make safe assumptions 
about the impact of active surveillance on PrCa survival because they were limited by 
short follow-up periods. Klotz et al. recommended further studies on active surveillance 
for men with the more aggressive forms of the disease.  
Conversely, Wilt et al. (2012) identified favorable survival outcomes for PrCa 
patients who were managed with observation in a 12-year prospective study. Wilt et al. 
compared survival of PrCa patients managed with observation, versus PrCa patients who 
received prostatectomy treatment. The death rate for PrCa patients after prostatectomy 
treatment was 5.8% versus 8.4% for observation, HR 0.63, 95% CI [.36, 1.09], p = .09 
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(Wilt et al., 2012). One of the high points of the study conducted by Wilt et al. was its 
generalizability. Study participants had similar characteristics of age, health status, and 
PSA values (Wilt et al., 2012). The tumor risk characteristics were also similar for PrCa 
patients who were eligible to participate in the study but declined (Wilt et al., 2012). 
Based on the outcomes of this study, Wilt et al. recommended observation for men with 
localized PrCa.   
The findings of Bul et al. (2013), Klotz et al. (2010), Nepple et al. (2013), 
Selvadurai et al. (2013), and Wilt et al. (2012) indicated that the effects of observation or 
active surveillance on the survival of PrCa patients with low and intermediate stage 
disease should be examined in this dissertation. Bul et al., Klotz et al., Selvadurai et al., 
and Wilt et al. recommended further studies on the effects of observation in PrCa survival 
among men with the more aggressive forms of the disease. In addition, Nepple et al. 
suggested that observation is a treatment option, which should be explored in studies, 
which examine the effects of ERBT and brachytherapy treatment. However, due to data 
limitations, active surveillance was not measured in this research.  
Sociodemographic Characteristics and Prostate Cancer Survival 
The literature reviewed demonstrated that sociodemographic characteristics of 
PrCa patients played a key role in the survival of PrCa patients (Parris, 2013; Xiao et al., 
2009). Therefore, it was necessary to determine whether the sociodemographic indicators 
of age, marital status, and health insurance status were confounders in the treatment 
outcomes of the PrCa patients in this study. Parris (2013) identified that the 
sociodemographic indicators of age, racial background, and marital status of PrCa 
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patients were predictors of PrCa survival in a United States cohort, with localized 
disease. Likewise, Xiao et al. (2011) demonstrated that PrCa patients without health 
insurance had the conditions for poorer survival from PrCa because they were more 
likely to be diagnosed with the later stages of the disease.  
  Age of the PrCa patient and survival. Current studies have shown that the age 
of a PrCa patient influences the survival time; and that younger PrCa patients with 
advanced stage disease are experiencing similar mortality from PrCa as older men (Fufaa, 
2011; Lin et al., 2009). Antwi et al. (2013) reported higher mortality from PrCa among 
the younger African American PrCa patients in the state of Kentucky when compared 
with White males in that State (African American 10.9% and Whites 7%). Antwi et al. 
also documented that the African Americans were more likely to be diagnosed with PrCa 
at a younger age (63.9 years ± 10 years), when compared with the White PrCa patients 
(66.9 years ± 9.8 years, p < .001). This disparity of age in PrCa incidence and mortality 
among the racial groups of the State of Kentucky, which has a small proportion of 
African-Americans (8%) (Antwi et al., 2013), suggested that age is a key factor in the 
survival of PrCa patients. Fufaa (2011) demonstrated that older PrCa (age > 81years) and 
PrCa patients aged 31 to 40 years with the aggressive forms of the disease had shorter 
survival times when compared with patients in other age groups. Crawford (2013), Fufaa 
and Lin et al. (2009) also examined the effects of age and tumor grade in PrCa survival 
using cancer registry data and recommended additional research to clarify the outcomes 
of their research. Crawford (2013), documented that misclassification of tumor grade was 
a limitation of the investigation. Consequently, Crawford was unable to detect a 
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statistically significant difference in survival outcomes among U.S. Black and White 
PrCa patients. Fufaa and Lin et al. reported that misclassification of tumor grade and 
stage, and underreporting of the cancer registry data were limitations of their studies. 
Fufaa also reported limitations of using death certificates to obtain information about the 
PrCa patients’ characteristics. Antwi et al. documented their inability to measure 
comorbidities and generalize the findings to other populations. Based on the 
recommendations of Crawford, Fufaa, and Lin et al., it was important to clarify the 
influence of age on the treatment outcomes in this study. 
Health insurance status and PrCa survival. Current publications highlighted 
the effects of health insurance of PrCa patients in their survival (Abdalsattar, Hendren, & 
Wong, 2016; Mahal et al., 2014; Parris, 2013). Paris (2013) examined the effects of the 
socioeconomic status of a cohort of PrCa patients in the Florida Cancer Data System and 
identified that the health insurance status of these patients affected their survival. 
According to Paris, men without health insurance had higher odds of being managed with 
watchful waiting when compared with surgery, OR 2.04, 95% [CI 1.75, 2.38]. The PrCa 
patients who had no health insurance were also more likely to receive hormonal 
treatments, OR 1.43, 95% CI [1.22, 1.69] and radiation treatments, OR 2.32, 95%  
[CI 1.96, 2.7] when compared with PrCa patients who had privately funded health 
insurance (Parris, 2013).  
Abdalsattar et al. (2016) also identified that the health insurance status of PrCa 
patients affected their survival outcomes. Abdalsattar et al. studied the extent to which 
the health insurance status of cancer patients mitigated the social determinants of health 
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in cancer management. Abdalsattar et al. utilized the SEER data, a retrospective study 
design, and PrCa patients who were younger than 65 years. The PrCa patients were 
classified as living in communities that were either least or most disadvantaged 
(Abdalsattar et al., 2016). The findings of the study confirmed that having health 
insurance was associated with higher numbers of cancer-directed surgeries for low-risk 
patients and improved survival for all PrCa patients in both communities (Abdalsattar et 
al., 2016). 
 Similarly, Mahal et al. (2014) documented the benefits of health insurance in 
improving access to favorable PrCa treatments. Mahal et al. compared the odds of 
survival of U.S. White and African Americans who had localized PrCa and received 
definitive PrCa treatments according to their health insurance status. The PrCa cohort 
was taken from the SEER data and had Gleason scores 8 to10, or stage T3a PrCa (Mahal 
et al., 2014). The study’s result demonstrated that the odds of receiving life-saving 
definitive PrCa treatments were lower for the African American cohort when compared 
with the White patients, adjusted OR 0.60, 95% CI [0.56, 0.64], p < .001 (Mahal et al., 
2014). Health insurance status and race also interacted significantly (p < .001) indicating 
that having health insurance could reduce the differences identified in the treatment 
outcomes (Mahal et al., 2014).  
Paris (2013) alluded to a large sample size and a culturally diverse population as 
strengths of that study. However, Paris documented that the use all-cause mortality data 
to base decisions on survival of the PrCa patient was a limitation of the study. One of the 
strengths of the study conducted by Mahal et al. (2014) was the utilization of a 
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population-based cancer registry database. On the other hand, there were missing data on 
the stage and grade of the disease according to the patient’s health insurance status 
(Mahal et al., 2014). Abdalsattar et al. (2016) reported that the SEER data were limited in 
providing information on the timing of the patients’ enrolment in an insurance plan at 
initial diagnosis and treatment. Abdalsattar et al. also documented difficulties in 
interpreting the classification of the PrCa patients’ specific insurance because of the 
broad classification of the insurance information in the SEER data. Nonetheless, 
Abdalsattar et al., Mahal et al., and Parris illuminated the impact of having health 
insurance on the survival of PrCa patients. The findings of the studies on the effect of 
health insurance status on PrCa survival signified the relevance of including this 
covariate in this dissertation.  
Marital status and PrCa survival. The literature reviewed revealed a 
statistically significant relationship between the marital status of the PrCa patient and 
their likelihood of surviving the disease (Paris, 2013; Rand et al., 2014). Paris (2013) 
investigated the relationship between the marital status of PrCa patients and survival 
among PrCa patients in the Florida Cancer Data System who were diagnosed between 
2001 and 2009. The results of this study revealed that unmarried PrCa patients had 
increased odds of presenting with late stage disease, OR 1.24, 95% CI [1.18, 1.30] when 
compared with married PrCa patients (Parris, 2013). PrCa patients were followed for five 
years, and at the final year of observation, survival rates declined from 99% in the first 
year to 80% (p < .001) (Parris, 2013). The survival rates were more favorable for married 
54 
 
men (82%) when compared with the unmarried (74%), and the risk of dying was higher 
for the unmarried cohort, HR 1.34, 95% CI [1.27, 1.41] (Parris, 2013). 
Rand et al. (2014) also examined the demographic characteristics of a diverse 
population of PrCa patients and their tumor stage in PrCa mortality. The outcomes of the 
study showed that most of the PrCa patients (61.6%) were married; 24.3% of the men 
were single (Rand et al., 2014). The outcomes of the research also revealed that the 
probability of dying was significantly higher for PrCa patients who were single when 
compared with patients who were married, OR 1.99, 95% CI [1.06, 3.73], p = .032 (Rand 
et al., 2014). Rand et al. asserted that the findings of the study might be limited to the 
study’s cohort because it was conducted in a single population. Nonetheless, Rand et al. 
recommended future studies on patient demographics, treatment choices and health 
outcomes. Thus, it was relevant to include marital status as a covariate in this research. 
  Smoking and PrCa survival. The studies reviewed documented that smoking is 
related to higher death rates of PrCa patients (Kenfield et al., 2011; Warren et al., 2013; 
Watters, et al., 2009). Studies revealed higher mortality rates with current smokers when 
compared with PrCa patients who either were former smokers or had no history of 
smoking at the time of diagnosis (Kenfield et al., 2011; Warren et al., 2013; Watters, et 
al., 2009). Warren et al. (2013) identified hazards among smokers and PrCa patients with 
a history of current tobacco use, and this relationship was consistent in both overall and 
cancer-specific mortality. Additionally, Kenfield et al. (2011) confirmed a statistically 
significant relationship with smoking and PrCa mortality, and this relationship remained 
statistically significant after adjusting for the clinical stages and grades of the disease, HR 
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1.38, 95% CI [0.94, 2.03] and HR 1.41, 95% CI [0.80, 2.49]. The significant findings of 
the studies on smoking and PrCa indicate that PrCa patients with a history of current 
smoking at the time of diagnosis with the disease have a higher risk of dying from PrCa.  
In studies, which examine differences in smoking and PrCa survival across ethnic 
groups in the United States, researchers recognized disparities among Black and White 
PrCa patients (Antwi et al., 2013; Wong, Ettner, Boscardin, & Shapiro, 2009). Antwi et 
al. (2013) identified that Black males had poorer survival outcomes. In their study, Antwi 
et al. revealed that 44.7% of the PrCa patients who reported tobacco use were African 
Americans while 41.4% were White (p < .001). In this cohort, African Americans had 
53% higher risk of dying from PrCa when compared the White patients, HR = 1.53, 95% 
CI [1.31, 1.79]. Wong et al. (2009) also documented a difference of .05 years in survival 
from PrCa among White and African Americans in the United States, 95% CI [0.01, 
0.09] and indicated that this difference was attributed to tobacco use. Antwi et al. and 
Wong et al. reiterated that the Black population had similar biological characteristics that 
could provide reasonable explanations of the differences in survival among the racial 
groups due to their smoking exposure, and recommended further studies to clarify this 
supposition.  
Smoking is also a high-risk behavior among Jamaicans in their native country 
(Wilks et al., 2008). Approximately one-fifth of Jamaican males in their country of origin 
reported a history of smoking greater than 100 cigarettes over the life course, and 21% 
had a current and history of smoking (Wilks et al., 2008). The frequency of smoking is 
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also highest among Jamaican males who are in the high-risk age group for PrCa (Wilks et 
al., 2008).  
The results of these studies suggested that PrCa patients with a history of smoking 
may have differences in survival outcomes according to their racial background. Hence, it 
was important to control for effects of smoking in the relationship among the variables. 
However, the effects of smoking on the survival outcomes of the ERBT and 
brachytherapy treated cohorts were not evaluated in this dissertation because the SEER 
data does not report patient-level smoking data. Nevertheless, the influence of smoking 
on survival of the Jamaican PrCa patients should be measured in future studies on PrCa 
treatment outcomes. 
Summary and Transition 
The literature reviewed revealed that the African American population of the 
United States experienced a higher burden of PrCa and poorer survival of the disease in 
general when compared with other ethnic groups. Researchers also demonstrated that 
brachytherapy (with or without ERBT) was a widely used treatment option in the United 
States for PrCa patients with the low-grade disease, but its utilization is declining in 
recent years. Additionally, some researchers alluded to the survival advantages of 
brachytherapy in treating PrCa patients who were diagnosed with low and intermediate 
stage disease. Other investigators indicated that both ERBT and brachytherapy provided 
similar survival benefits. On the other hand, authors noted that brachytherapy is 
expensive; widely used in the younger cohort, and is less accessible to African-
Americans of lower socioeconomic status. Furthermore, the results in the literature 
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confirmed that PrCa patients who were diagnosed with low and intermediate stage 
disease, and were managed with observation or active surveillance for PrCa, 
demonstrated favorable survival prognosis. Finally, the findings of the literature reviewed 
demonstrated an association with the sociodemographic indicators age, marital status, and 
health insurance status, and PrCa survival. 
Among the literature reviewed, I identified no studies, which verified the 
relationship between brachytherapy and ERBT for the treatment of low and intermediate 
stage PrCa among the Jamaican cohort. Additionally, most studies reviewed were 
conducted primarily in the White populations of the United States and included small 
samples of African Americans. Likewise, studies on the relationship between treatment 
methods for early and intermediate stages PrCa were identified for the Canadian, 
German, and Dutch cohorts. However, the findings of these studies may not generalize to 
the Jamaican population because of differences in PrCa characteristics among populaces. 
Therefore, this study, which used a cohort of Jamaican-born males of the 18 participating 
SEER cancer registries, may provide new data, which are specific to the Jamaican PrCa 
patients. This research may also provide new insights on PrCa in the Jamaican cohort, 
particularly on the relationship between PrCa treatment and survival outcomes.  
In Chapter 3, I described the statistical measures used to examine the effects of 
brachytherapy and ERBT in the survival of PrCa patients and the covariates 
sociodemographic and smoking status of the PrCa patient. In addition, I provided a 
description of the study population, the sampling technique for the selecting the sample 
for this study, and ethical and validity issues of this dissertation. 
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Chapter 3: Research Method 
Introduction 
In this dissertation, I aimed to observe the effects of ERBT and brachytherapy 
treatment on the survival of Jamaican and White PrCa patients with low and intermediate 
stage disease. I also intended to examine the effects of sociodemographic characteristics 
of age, marital status, and health insurance status, in the survival outcomes of the PrCa 
patients. I utilized a retrospective cohort study design, secondary data, and survival 
models to examine the relationship between the independent and dependent variables.  
In Chapter 3, I explained and justified the retrospective study design for exploring 
the relationship between brachytherapy treatment and ERBT and the survival of 
Jamaicans and White U.S.-born PrCa patients. I also presented and rationalized the 
sampling techniques for selecting the study participants and the method employed to 
determine the sample size for this dissertation. A detailed data analysis plan describing 
the statistical measures applied to each of the research question was presented in Chapter 
3. In addition, I described the method for operationalization of each variable of the study 
in Tables 1 to 5. The procedures for data collection and possible validity and ethical 
issues of this research were also highlighted in Chapter 3.  
Research Design and Rationale 
This dissertation had two key independent variables. The primary independent 
variables of this study were PrCa treatments (brachytherapy, ERBT, and other radiation 
treatments), and PrCa patients (the Jamaican and White U.S.-born PrCa cohorts) of the 18 
participating SEER registries database, November 2013 submission. The dependent 
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variable was prostate cancer survival, which is the length of time a PrCa patient treated 
with ERBT, brachytherapy, and other radiation treatments lived with the disease. The 
covariates for this study were sociodemographic indicators age, marital status, and health 
insurance status.  
I utilized a retrospective cohort design to examine the relationship between past 
exposures (treatment for PrCa, and PrCa stage and grade) and the outcome (PrCa 
survival) (Ashengrau & Seage, 2008, p. 207). The retrospective cohort design was 
appropriate for the historic nature of this study (Ashengrau & Seage, 2008, p.156). 
Additionally, I chose the retrospective cohort design because it was cost efficient. The 
retrospective cohort study design generated large amounts of longitudinal data in a very 
short period with minimal expenses, and the data were already available. Besides, the 
retrospective cohort design facilitated the use of existing records on mortality occurrence 
linked to cancer registries (Szklo & Nieto, 2014, pp. 22-23). These design qualities were 
consistent with the methodology of this dissertation 
Methodology 
The Study’s Population  
I recruited the participants of this research from a population of Jamaican and 
White U.S.-born PrCa patients of the 18 participating SEER cancer registries database 
1973 to 2011, November 2013 submission (SEER, 2014). The total population of 
Jamaicans and White U.S.-born PrCa patients was 274,201 PrCa patients; this included 
273,447 White U.S.-born and 754 Jamaicans. 
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Sampling and Sampling Procedures 
I selected the Jamaican PrCa patients using purposive sampling. Purposive 
sampling reduced the possibility of eliminating from the study critical information about 
the research subjects and enhanced the representativeness of the sample (Battalgia, 2008). 
I chose purposive sampling method because the study required a cohort with specific 
characteristics (Battalgia, 2008; Polit & Beck, 2013, p. 312; Trochim, Donnelly, & Arora, 
2015, p. 87). I selected the comparison group from the White U.S.-born population of the 
18 participating SEER cancer registries using a random sampling approach (Trochim et 
al., 2015, p. 100). The random sampling method provided an equal chance to include the 
research subjects, and improve generalization of the findings (Trochim et al., 2015, 
p.100). 
A PrCa patient in this dissertation was selected for this study according to the 
ICD-O version 10, and the site-specific code (C60) (SEER, 2013). PrCa patients in each 
participating SEER registry with Jamaican birthplace and satisfied the selection criteria 
for a research participant, were purposively chosen from the SEER 18 registries data set 
using the birthplace variable. I selected the White U.S.-born PrCa patients from the 
population of the 18 participating SEER cancer registries using a random sampling 
technique.  
The study included all PrCa patients diagnosed with Gleason scores 6 and 7, and 
categorized according to the TNM stages T1 and T2, and SEER Historic Stage A 
classifications at the time of diagnosis. Included in this investigation were PrCa patients 
who received ERBT, brachytherapy and radiation sequenced with surgery for the period 
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of the observation. I excluded from the study PrCa patients, who were recommended for 
surgery only, refused surgery or had contraindications for surgery (SEER, 2013). I 
included the radiation sequenced with surgery variable in the study. The radiation 
sequenced with surgery variable comprised other types of radiation treatments that were 
not accounted for in the brachytherapy and ERBT definitions. Hence, it was important to 
determine whether radiation sequenced with surgery contributed significantly to the 
outcomes of the study.  
 In selecting this sample, I excluded from the sampling population three SEER 
districts, Hawaii, Iowa, and Alaska Native, which had no Jamaican PrCa patients. 
Subsequently, I reorganized in descending order the identification numbers of the 
research participants for the remaining 15 reporting SEER locations. I selected from each 
of the remaining 15 SEER reporting sites every 50th White U.S.-born PrCa patient who 
met the criteria for inclusion in the study. Finally, I purposively chose every Jamaican 
PrCa patient who met the selection criteria for inclusion in the study from the population 
of Jamaicans. Figure 1, presents the flow chart of the sampling process.  
The sample size determination for this study was derived from the criteria for 
survival analysis using the Log-Rank test (Stats Direct, 2013). The criteria for survival 
analysis using the Log-Rank test stated that there should be adequate power to detect a 
real effect, p-value estimates, and a median survival time for both experimental and 
comparison groups (Stats Direct, 2013). I chose an effect size of HR 1.6 based on 
estimates from previous studies on the association of radiation therapy and PrCa survival 
(Nepple et al., 2013; Smith et al., 2015; Rusthoven et al., 2015). Nepple et al. (2013) and 
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Rusthoven et al. (2015) demonstrated effect sizes ranging from HR 1. 31, 95% CI [1.22, 
1.41], p < .001, to HR 2.02, 95% CI [1.85, 3.15], p < .001 for ERBT treated PrCa patients 
with Gleason scores 6 and 7. Nepple et al. and Rusthoven et al. also provided hazard 
ratios ranging from HR 1.27 to HR 1.78, 95% CI [1.37, 2.3] p < .001, for overall survival 
of PrCa patients treated with brachytherapy. I used the hazard ratio estimates as a 
parameter in the sample size calculation because the results of this research were 
presented with hazard ratio estimates and accompanying 95% confidence intervals. I 
chose a median survival period of 7.2 years for the comparison group based on a priori 
findings (Smith et al., 2015). 
 Sample size was therefore calculated using the Log-Rank test statistic, two-sided 
alpha levels p < .05 (Za/2 = 1.96), 95% power (Zβ, = 1.645), and effect size (HR =1.6). 
The median survival time was 2.7 years for the PrCa patients with low and intermediate 
stages PrCa, and 7.2 years for the comparison group (the White U.S.-born PrCa patients). 
The ratio for the exposed and unexposed group was one Jamaican PrCa patient to four 
White U.S.-born PrCa patients. The sample size estimation was conducted using the PS: 
Power and sample size calculation (3.1.2) (Dupont & Plummer, 2014). Based on the 
sample size estimation, a total sample N = 1,335 was needed to reject the null hypothesis 
that the survival curves for PrCa patients in the exposure and the comparison groups were 
equal (Dupont & Plummer, 2014). The proposed sample included 267 Jamaican PrCa 
patients, and 1,068 White U.S.-born PrCa patients (Dupont & Plummer, 2014).  
However, due to the due to the sampling procedures used for the selection of the 
PrCa patients and the size of the dataset used for this investigation, the sample size of the 
63 
 
final study was expanded from N = 1,335 to N = 10,752 (8 times larger than the proposed 
sample). The dataset had 754 Jamaican PrCa patients; 719 met the criteria for selection 
and were chosen using purposive sampling. The sample of White U.S.-born PrCa patients 
was extended to 10,033, with the random sampling technique described in the research 
protocol. A final sample N = 10,752 Jamaican and White U.S.-born PrCa patients was 
used for the data analysis. 
Participant Recruitment 
I obtained the dataset for this research following an emailed request to the SEER 
Cancer Registry Data System for internet access to the November 2013 submission of the 
18 participating SEER registries database. I completed the application with the SEER 
Cancer Registry signed data use agreement form (see Appendix A). On receipt of the 
signed data use agreement, the SEER Cancer Registry granted approval for internet 
access to the SEER*Stat client-server system (see Appendix B). Subsequently, I prepared 
a smaller dataset of the 18 participating SEER Cancer Registry database for the study 
using a case listing of all the variables of the research. I exported the case listing to the 
IBM SPSS statistical software version 23 for data analysis.  
Operational Definitions of the Research Variables  
Dependent Variable 
The dependent variable of this dissertation was PrCa survival. PrCa survival was 
defined as the date of initial diagnosis to the time of the first outcome, death or censoring 
(Hu et al., 2014; Lin et al., 2009; Redaniel et al., 2013; Thompson et al., 2013). The time 
of diagnosis was the month and year of diagnosis documented in the SEER registry 
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database (SEER, 2013). The time of death was the time that the vital status of a case was 
recorded in the SEER cancer data (SEER, 2013). The definition of the vital status also 
included the SEER cause-specific mortality definition and confirmation of death using 
death certificate or autopsy information (SEER, 2013). Censored cases were PrCa 
patients who died of causes other than PrCa (NCI, 2017a). Additionally, the definition of 
PrCa survival included the active follow-up of each PrCa patient (SEER, 2013). I recoded 
and measured PrCa survival as a continuous variable on a monthly or yearly basis 
according to the research questions. 
Independent Variables 
The independent variables of the dissertation were the PrCa patients (Jamaican 
and White U.S.-born) and PrCa treatments (brachytherapy, ERBT, and other radiation 
treatments). I defined a PrCa patient according to the International Classification of 
Diseases for Oncology version 10 (ICD-O) code C60, and the SEER cause-specific death 
for sequence numbers 01 (NIH, 2017). PrCa patients were also classified according to 
Gleason grades G1, G2, and G3 (SEER, 2015, p. 96). Additionally, a PrCa patient had 
TNM stages T1 and T2 of the AJCC 6th Edition TNM, and the SEER Historic Stage A 
classifications (SEER, 2013; SEER, 2014; Young et al., 2000, p. 224). The localized 
stages T1a, T1b, and T1c PrCa were clinically in-apparent tumor (SEER, 2013; Young et 
al., 2000, p. 224). Stage T2a PrCa involved one lobe; and stage T2b more than one lobes 
of the prostate gland (Young et al., 2000, p.224). Stage T2NOS was assigned to each 
PrCa patient whose TNM stage was not specified (SEER, 2013). A prostate cancer 
patient in this research was also a confirmed case by histology, or cytology (SEER, 
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2013). I selected the Jamaican and White U.S.-born PrCa patients from the birthplace 
variable of the 18 SEER participating cancer registries (SEER, 2014) and measured as a 
categorical variable.  
Prostate cancer treatments were ERBT, brachytherapy and other radiation 
treatments. I combined radioactive implants, radioisotopes, and radioactive implants and 
radioisotopes, and recoded as brachytherapy treatment (SEER, 2013). ERBT was the 
recoded beam radiation variable of the SEER Research Data Record Description 1973 to 
2011 (SEER, 2013). The radiation sequenced with surgery variable was a combination of 
radiation before surgery, radiation after surgery, intraoperative radiation therapy, and 
radiation and surgery sequence unknown (SEER, 2013). The treatment variables were 
measured as categorical variables. 
Covariates 
Covariates for this study included the sociodemographic characteristics of the 
patient. The sociodemographic characteristics comprised the marital status, age, and 
health insurance status of the PrCa patient as reported at diagnosis and recorded in the 
SEER Research Data Description 1973 to 2011 (SEER, 2013). Marital status was the 
marital union communicated by the patient at the time of PrCa diagnosis (SEER, 2013). 
Health insurance status was the PrCa patient’s primary means of payment for health care 
and the health insurance coverage plan as recorded in the SEER data (SEER, 2013). Age 
was the actual age in years at diagnosis as recorded in the SEER registry database and 
covered all PrCa patients who were older than 35 years for the 1992 to 2011 SEER 
reporting period (SEER, 2013). I recoded and measured the variables representing the 
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sociodemographic characteristics of the PrCa patients in the SEER database as 
categorical and continuous variables. Tables 1 to 5 depict the operationalization of the 
research variables including the categories of each variable, coding of the variables, and 
the statistical analyses applied.  
Operationalization of the Variables  
Table 1 
 




Operational Concepts of the 
Variables 

















b) Vital Status. 
 




This is the length of time in 
months from the time of 
diagnosis to the time of the 
event (death or censored) 
(SEER, 2013). The survival 
period includes the complete 
dates of diagnosis and last 
contact with the PrCa patient 
(SEER, 2013). This period 
covered 21 years and 
indicated that a PrCa patient 
will die at any time on a 
continuum of zero to 21 
years. 
 
The cut-off date of the SEER 
data set was used for the last 
contact date if the PrCa 
patient’s recorded vital status 
was alive (SEER, 2013). 
Death was the confirmed 
time of death based on 
autopsy report or cause of 
death as recorded in the 
SEER registry (SEER, 2013).  
a) Coded according to the 
survival time in the SEER 
data as: 












b) Recoded as Alive = 1 
Dead = 2 
(SEER, 2013) 
Preliminary descriptive 
estimations of the hazard 
rates and cumulative 
survival probability of the 
PrCa patients with Kaplan 
Meier and Life Table 
estimates.  
 
Estimation of the median 
survival times of the PrCa 
cohorts. 
 
Comparison of the 
differences in the survival 
distributions of the 
Jamaican and White US-
born cohorts with Kaplan 
Meier survival curves, 
Log-rank, Tarone-Ware, 
and Breslow’s statistics.  
 
Comparison of the risk 
ratios of the Jamaican and 





Hypothesis tests of the 
Jamaican and White US-













for the Variables 























This was the time of 
initiation of the 
different types of 
treatment for each PrCa 
patient.  
1. No treatment was 
commenced. 
2. Time ERBT 
commenced to the 
time of death, or 
presumed alive 
(SEER, 2013). 
3. The time that 
brachytherapy 
commenced to the 
time of death or 
presumed alive 
(SEER, 2013). 




commenced to the 
time of death or 
presumed alive 
(SEER, 2013). 








surgery to the time 
of death (SEER, 
2013).  
 
Radioactive implants,  
radioisotopes,  
combination of 
radioactive implants, and 
radioisotopes (SEER, 
2013) recoded as: 
Brachytherapy = 1 
No brachytherapy = 0 
 
Beam radiation recoded 
as: 
ERBT = 1 
No ERBT = 0 
 
Intraoperative radiation, 
radiation after surgery, 
radiation prior to surgery, 
intraoperative radiation, 
radiation sequence 
unknown but both were 
given (SEER, 2013) was 
recoded as: 
Radiation sequenced with 
surgery = 1 
No radiation sequenced 
with surgery = 2 
 
Preliminary descriptive 
estimates of the frequencies 
of treatment utilization 
among the Jamaican and 
White U.S.-born PrCa 
patients. 
 
Estimation of the median 
survival times of the PrCa 
cohorts according to the 
treatments received. 
 
Comparison of the 
differences in the survival 
distributions of the Jamaican 
and White U.S.-born cohorts 
according to the treatments 
received using Kaplan Meier 
survival curves, Log-rank, 
Tarone-Ware, and Breslow’s 
statistics.  
 
Comparison of the risk ratios 
of the Jamaican and White 
PrCa patients according to 
treatments received  
using the Cox-proportional 
hazards analysis. 
Comparison of the 5-year 
survival outcomes of PrCa 
patients according to each 
treatment received. 
 
Hypothesis tests of the 
association of brachytherapy 
and ERBT in PrCa patients 













Operational Concepts for the 
Variables 
 
Variable Code Statistical 
Analyses 
 
Gleason grades 1 
and 11 PrCa at the 
time of diagnosis as 














2. Gleason grade 11 is 
moderately differentiated 
tumor, or intermediately 
differentiated tumor 
(SEER, 2013). 
3. Grade not specified NOS 
(SEER, 2013).  
 
Coded according to the 
SEER research data as: 
1 = Moderately 
differentiated, Grade 11 
2 = Poorly differentiated, 
Grade 111 






estimates of the 
frequencies of 
stages and grades 
of PrCa among 




PrCa stage is the 
early and 
intermediate stages 
of PrCa according 
to the Derived 
AJCC  6th Edition 






 (measured at the 









(measured at the 
categorical level of 
measurement) 
The stage of the disease is 
classified using the SEER 
AJCC 6th edition (2000) 
classification as: 
1. T1a, T1b, and T1c is 
clinically inapparent 
tumor (SEER, 2013). 
2. T1 NOS is clinically 
inapparent tumor not 
specified (SEER, 2013).  
3. T2a, T2b and T2c is 
tumor confined to the 
prostate (SEER, 2013). 
4. T2 NOS confinement to 
the prostate is not 
specified (SEER, 2013). 
5.  Unknown 
 
 
The variable description of 
the SEER dataset was 
Localized or regionalized 
prostate cancer (SEER, 2013) 
was used. 
Coded according to the first 
three of the stages of TNM 
stages 6th Ed of the SEER 
data as: 
a) T1a = 12 
b) T1b = 15 
c) T1c = 18 
d) T1NOS = 19 
e) T2a = 21 
f) T2b = 22 
g) T2c= 23 








Coded according to the 
SEER research data as: 
 
Blanks =1 
Distant = 2 
Localized/regionalized = 3 











for the Variables 
 
Variable Code  Statistical Analyses 
 
a) Jamaican born 
PrCa patient.  
 
(measured at the 
categorical and 




A Jamaican PrCa 
patient was one whose 
birthplace was 
recorded as Jamaica in 
the SEER research 
record description 
(SEER, 2013).  
 
The birthplace-
country variable of 
the SEER data 
(SEER, 2013) 
was recoded as: 
 
Jamaica = 1 




estimates of the frequencies of 
PrCa patients according to the 
different variables of the 
study.  
 
Estimation of the median 
survival times of the PrCa 
cohorts according to the 
treatments received. 
 
Comparison of the differences 
in the survival distributions of 
the Jamaican and White U.S.-
born cohorts per treatments 
received using Kaplan Meier 
survival curves, and the Log-
rank, Tarone-Ware, and 
Breslow’s statistics.  
 
Comparison of the risk ratios 
of the Jamaican and White 
PrCa patients according to 
treatments received  




treatment contingency tables 
for each 5-year interval and 
estimating the survival rates 
for each interval.  
 
Comparison of the 5-year 
survival outcomes of PrCa 
patients according to each 
treatment received. 
 
Hypothesis tests of the 
association of treatment 
effects and survival of the 
PrCa patients, using 
interaction analyses. 
 
b) The White U.S.-
born PrCa patient.  
  
(measured at the 
categorical and 




A White U.S.-born 
PrCa patient is a PrCa 
patient whose 
birthplace was 
recorded as Jamaica in 
the SEER research 
record description 
(SEER, 2013).  
 
The birthplace-
country variable of 
the SEER data 
(SEER, 2013) 
was recoded as: 
 
United States = 2 
















for the Variables 
Variable Code  Statistical Analyses 
For all Covariates 
a) Age at the 
time of 
diagnosis 








This is the age recode 
with < 1-year-old 
variable. This variable 
was recoded into 4-year 
age groups in the SEER 
(2013) and included all 
age groups. 
The original coding of the 
SEER (2013) was used. 
 
Ages 30-34 = 07 
Ages 35-39 = 08 
Ages 40-44 = 09 
Ages 45-49 = 10 
Ages 50-54 = 11 
Ages 55-59 = 12 
Ages 60-64 = 13 
Ages 65-69 = 14 
Ages 70-74 = 15 
Ages 75-79 = 16 
Ages 80 + 
 
Preliminary descriptive 
estimates of the 
frequencies of the age, 
marital status, and 
health insurance status 
of the PrCa patients. 
 
Crude estimations of 
the hazard ratios for age 
and health insurance 




Stratification of the 
birthplace variable 
(Jamaica and the United 
States), per ERBT and 
brachytherapy 
treatments with age, 
health insurance status, 
and estimations of 
adjusted hazard ratios. 
 
Estimations of the 
percent change of the 
crude and adjusted 
hazard ratios of the 







status at the 
time of 
diagnosis. 






Health insurance status 
as recorded in the 
SEER research record 
description (SEER 
2013). This was the 
primary payer for 
health care (SEER, 
2013) at the time of 
entering the study and 
included the recoded 
uninsured, any 
Medicaid, insured, and 
unknown health 
insurance status.  
Coded according to the 
SEER research data as: 
 
Uninsured = 1 
Any Medicaid = 2 
Insured = 3 
Insured/no specifics = 4 






Categorizing, Coding, and Measuring the Covariates of the Research  
 
Data Analysis Plan  
Data Cleaning 
The SPSS software version 23 was the statistical package for the analysis of the 
data. It was important to conduct data cleaning because secondary data were used to 
answer the research questions. The data cleaning process included an examination of the 
data distribution with skewness and kurtosis estimates and visual inspections of the data 





for the Variables 
Variable Code  Statistical Analyses 
c) Marital 










d) Marital status at the 
time of diagnosis as 
recorded in the SEER 
research record 
description. 










- status unknown 
(SEER, 2013) 
 
Coded according to the 
SEER research data as: 
 
Single/never married = 1 
Married including  
common-law = 2 
Separated = 3 
Divorced = 4 
Widowed = 5 
Unmarried/ 
domestic partner = 6 




estimates of the 
frequencies of marital 
status of the PrCa 
patients. 
 
Crude estimations of the 
hazard ratios for marital 




Stratification of the 
birthplace variable 
(Jamaica and the United 
States), per ERBT and 
brachytherapy and 
marital status and 
estimations of adjusted 
hazard ratios. 
 
Estimations of the 
percent change of the 
crude and adjusted 
hazard ratios of the 




2013b). I also checked the data for missing or incomplete information. It was necessary 
to identify missing or incomplete data because this may occur for justifiable reasons in 
the secondary database that was used (Osbourne, 2013c) and should be accounted for in 
the analysis. I analyzed the data with the following five research questions and their 
hypotheses. 
Research Question 1. Are there differences in the length of time Jamaican-born 
PrCa patients compared with U.S.-born White PrCa patients who were treated with 
brachytherapy for low and intermediate stages PrCa lived with the disease? 
H01: There are no differences in the length of time Jamaican-born and U.S.-born 
White PrCa patients treated with brachytherapy for low and intermediate stages PrCa 
lived with the disease. 
Ha1: There are differences in the length of time Jamaican-born PrCa patients 
versus U.S.-born White PrCa patients who were treated with brachytherapy for low and 
intermediate stages PrCa, lived with the disease. 
Research Question 2. Are there differences in the length of time Jamaican-born 
PrCa patients compared with U.S.-born White PrCa patients who were treated with 
ERBT for low and intermediate stages PrCa lived with the disease? 
H02: There are no differences in the length of time Jamaican-born PrCa patients 
and U.S.-born White PrCa patients treated with ERBT for low and intermediate stages 
PrCa lived with the disease. 
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Ha2: There are differences in the length of time Jamaican-born PrCa patients 
compared with U.S.-born White PrCa patients who were treated with ERBT for low and 
intermediate stages PrCa lived with the disease. 
Research Question 3. Are there differences in 5-year survival intervals of 
Jamaican-born PrCa patients compared with U.S.-born White PrCa patients according to 
treatment received for the period 1992 to 2011? 
H03: There are no differences in the 5-year survival intervals of Jamaican-born 
and U.S.-born White PrCa patients according to treatment received for the period 1992 to 
2011. 
Ha3: There are differences in the 5-year survival intervals of Jamaican-born PrCa 
patients compared with U.S.-born White PrCa patients according to treatment received 
for the period 1992 to 2011.  
Research Question 4. Are there differences in the length of time brachytherapy 
treated Jamaican-born PrCa patients and U.S.-born White PrCa patients with low and 
intermediate stages PrCa live with the disease, after controlling for sociodemographic 
characteristics?   
H04: There are no differences in the length of time brachytherapy treated 
Jamaican PrCa patients and U.S.-born White PrCa patients with low and intermediate 
stages PrCa, live with the disease, after controlling for sociodemographic characteristics. 
Ha4: There are differences in the length of time brachytherapy treated Jamaican 
PrCa patients, and U.S.-born White PrCa patients with low and intermediate stages PrCa 
live with the disease, after controlling for sociodemographic characteristics. 
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Research Question 5. Are there differences in the length of time ERBT treated 
Jamaican-born PrCa patients and U.S.-born White PrCa patients with low and 
intermediate stages PrCa live with the disease, after controlling for sociodemographic 
characteristics?   
H05: There are no differences in the length of time ERBT treated Jamaican PrCa 
patients and U.S.-born White PrCa patients with low and intermediate stages PrCa live 
with the disease, after controlling for sociodemographic characteristics. 
Ha5: There are differences in the length of time ERBT treated Jamaican PrCa 
patients and U.S.-born White PrCa patients with low and intermediate stages PrCa live 
with the disease, after controlling for sociodemographic characteristics. 
I conducted preliminary descriptive estimates of the different variables of the 
study to determine their frequency distributions in the data set. I calculated the survival 
distributions and cumulative survival probability of the PrCa patients with the Life Table 
estimators and Kaplan-Meier estimates (Forthofer, Lee, & Hernandez, 2007, p. 306). The 
Kaplan-Meier method determined the median survival times, and the differences in the 
cumulative survival curves of the PrCa cohorts. The Log-Rank, Tarone-Ware, and 
Breslow’s statistics confirmed the differences in the survival distributions of the 
Jamaican and White U.S. PrCa patients at varying periods of the observation 
(Balakrishnan, & Rao, 2004, p. 283). The Breslow’s statistics weighted the observations 
early in the follow-up, and the Tarone-Ware and Log-Rank statistics estimated the 
variances at the later intervals of the study (Balakrishnan, & Rao, 2004, p. 283). The Cox 
proportional hazard regression analyses estimated the differences in the hazard ratios of 
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the Jamaican and White U.S.-born cohorts (Forthofer et al, 2007, p. 412). Hypotheses 
tests of mediating effects in the association between brachytherapy and ERBT treatments 
and survival of the White U.S.-born and Jamaican-born PrCa patients were completed 
with interaction analyses (Szklo & Nieto, 2014, p.187). Finally, I determined whether the 
relationship between the treatment cohorts and PrCa survival was a result of the 
confounding effects of the covariates by stratifying these variables and evaluating the 
percent changes in the crude and adjusted hazard ratios (Szklo & Nieto, 2014, p.187). A 
description of the statistical analytical procedures for each research question follows.  
Data Analyses Plan for Research Questions 1 and 2 
Research Question1 and Research Question 2 focused on the estimation of the 
differences in the survival distributions of the brachytherapy and ERBT treated Jamaican 
and White U.S.-born cohorts. I conducted preliminary descriptive estimations of the 
crude and cumulative hazard rates, censoring intervals, probability density estimates, and 
the mean and median survival times of the PrCa patients for the 1992 to 2011 follow-up 
with Life-Table estimates and Kaplan-Meier estimators. The Kaplan-Meier estimator 
generated cumulative survival curves of the distributions of the brachytherapy and ERBT 
treated Jamaican and the White U.S.-born cohorts. The survival intervals of the PrCa 
patients were estimated on a month-by-month basis (SEER, 2015). Differences in the 
distributions of the survival curves were confirmed using the Log-Rank (Mantel-Cox), 
Breslow (Generalized Wilcoxon), and Tarone-Ware statistics. I conducted further 
comparisons of the survival experiences of the brachytherapy and ERBT treated 
Jamaican and White U.S.-born cohort with the multivariate Cox-proportional hazards 
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regression model. The Cox-proportional hazards model estimated the differences in the 
hazards ratios for the Jamaican and White U.S.-born PrCa patients based on the 
assumption that the hazards among the Jamaican and the White U.S.-cohort were 
constant throughout the follow-up (Forthofer et al., 2007, p. 412).  
I performed interaction analysis to determine whether there were modification 
effects in the association between brachytherapy and ERBT and survival among the 
Jamaican and White U.S.-born PrCa cohorts (Szklo & Nieto, 2014, p.187). The 
assumption for the hypothesis test was the relationship between brachytherapy and ERBT 
and the risk of death among Jamaican, and the White U.S.-born PrCa patients were of 
similar magnitude across subgroups of both cohorts. The alpha level for accepting a 
significant interaction was p < .05. A significant interaction indicates modification effect 
among the birthplace variable and PrCa treatment. A non-significant interaction effect 
confirmed that there were no modification effects in the association identified. 
Consequently, the first main effects of the differences in the hazard ratios were 
interpreted as the outcome of the analysis (Green & Salkind, 2011, pp. 205-206). I did 
further analysis of significant interaction effects with pairwise comparison of the second 
main effect (Green & Salkind, 2011, pp. 205-206). Two Cox proportional hazard 
regression models were created for the interaction analysis. The first model had the first 
main effect (birthplace) and the second main effect (PrCa treatments). The second model 
had the interaction terms (birthplace and PrCa treatments) with the interaction effect.  
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Data Analysis Plan for Research Question 3 
Research Question 3 focused on estimating the 5-year survival of PrCa patients 
who received brachytherapy, ERBT, and other radiation treatments (radiation sequenced 
with surgery). I developed cohort-treatment contingency tables for each 5-year interval 
and estimated the hazard rates and median survival times of the PrCa cohorts according 
to the treatments they received. I compared the differences in the survival distributions of 
the Jamaican and White U.S.-born cohorts per treatments received using the Log-Rank 
statistics. Further comparisons of the risk ratios of the Jamaican and White U.S.-born 
PrCa patients according to treatments received for each 5-year interval were estimated 
using the Cox-proportional hazards analysis.  
I performed interaction analyses for each 5-year interval to determine whether 
there were modification effects in the magnitude of the risk ratios of both cohorts (Szklo 
& Nieto, 2014, p.187). The assumption for the hypothesis test was the association 
between brachytherapy, ERBT, and other radiation treatments and the risk of death 
among Jamaican and the White U.S.-born PrCa patients were of similar magnitude in 
subpopulations of both cohorts. The alpha level for accepting a significant interaction 
was p < 0.05. A significant interaction indicated that there was modification effect among 
the birthplace variable and PrCa treatment. I conducted further analyses of all significant 
interaction effects with pairwise comparisons of the second main effects of each 
treatment group to determine where the differences were (Green & Salkind, 2011, pp. 
205-206). A non-significant interaction effect confirmed that there no modification 
effects in the association identified (Szklo & Nieto, 2014, p.187) and the first main 
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effects of the differences in the hazard ratios among the treatment groups were 
interpreted as the outcome of the analysis (Green & Salkind, 2011, pp. 205-206).  
Data Analyses Plan for Research Questions 4 and 5 
The data analysis for Research Question 4 and Research Question 5 focused on 
determining whether the association identified between brachytherapy treatment and 
ERBT were due to confounding effects of the covariates in the study. First, I estimated 
baseline hazard ratios of the birthplace variable, PrCa treatment variables, and the 
covariates with Cox regression analysis. Subsequently, I stratified the Jamaican and U.S.-
born White PrCa patients according to brachytherapy and ERBT treatment, marital status, 
health insurance status, and age and estimated the adjusted hazard ratios. Finally, I 
compared the crude hazard ratios of the brachytherapy and ERBT treated Jamaican, and 
White U.S.-born PrCa patients with the adjusted hazard ratios to determine percent 
changes in the magnitude of effects observed. I estimated the percent difference between 
the crude and adjusted hazard ratios of the birthplace main effects to determine the degree 
of confounding using the expression: Percent Excess Risk Explained = (Crude HR-
Adjusted HR)/Crude HR-1×100 (Szklo & Nieto 2014, p.161). Changes in the hazard 
ratios of less than 10% were interpreted as minimal confounding and the crude or 
adjusted hazard ratios accepted. The adjusted hazard ratios were interpreted where the 
excess risk was greater than 10%. Changes in the crude and adjusted hazard ratios that 
were close to one indicated that the confounder influenced the direction and magnitude of 
the effect observed, and there was no association with the PrCa treatments and survival 
(Szklo & Nieto 2014, p.171) 
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In this dissertation, I examined the covariate effects of the sociodemographic 
indicators age, marital status, and health insurance of the PrCa patients because studies 
have shown that these variables impacted the survival of PrCa patients (Parris, 2013; 
Xiao et al., 2009). Therefore, in examining the relationship between treatment outcomes 
and PrCa survival, it was important to evaluate whether these variables confounded the 
effects observed in this dissertation.  
Data Presentation and Interpretation 
The results of this study were presented using tables and graphs. I displayed 
descriptive analysis of baseline characteristics of the prostate cancer cases, cumulative 
hazard rates, censoring intervals, and probability density estimate in tables. I also used 
tables to present hazard ratios with accompanying 95% confidence intervals and alpha 
levels (p < 0.05). The cumulative incidence of prostate cancer-specific deaths was 
demonstrated with Kaplan-Meier survival curves (Kenfield et al., 2011). Statistical 
significance was interpreted using p-values (p < .05) and 95% confidence intervals (Rich, 
2011). Counts fewer than 10 for specific SEER location were suppressed and not 
presented in tables or graphs. 
Threats to Validity 
The internal validity of this dissertation may be influenced by the non-
randomization of the exposure group (Leighton, 2010c, p. 621). The Jamaican PrCa 
patients were purposively selected for this dissertation because the study required a 
cohort with specific characteristics for investigation, thus making it difficult to randomize 
the selection of this group (Trochim et al. 2015, p. 87). The threat of maturation of the 
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research participants was another consideration to the internal validity of the study 
(Leighton, 2010c, p. 620). The study spanned 20 years, and the research participants may 
experience developmental changes or comorbidities which influence their treatment 
outcomes (Leighton, 2010c, p. 620). Therefore, to enhance the internal validity of the 
study, I selected the participants based on similarities in their characteristics and the 
criteria specified for inclusion in this dissertation (Leighton, 2010c, p. 622). Another 
approach to improve the internal validity of the study was randomizing the comparison 
group to ensure that the characteristics of the research participants had the probability of 
being equally distributed among this group (Leighton, 2010c, p. 622).  
A potential threat to the external validity of the study was the likelihood of history 
and treatment interactions (Leighton, 2010b, p. 468). The observation spanned the 1992 
to 2011 interval, and it was important to determine whether trends in PrCa treatments and 
diagnosis impacted the treatment effects (Leighton, 2010b, p. 468). The data analysis 
included interaction analysis to detect interaction effects, which would indicate that the 
treatment effects varied with time (Leighton, 2010b, p. 468). 
Ethical Procedures  
The provisions of the Health Insurance Portability and Accountability Act 
(HIPAA) privacy rule (45 CFR 164.514 [e]), which established the conditions for the use 
of protected health of individuals using the limited data sets with a data use agreement, 
guided this research (US Department of Human Services [USDHS], 2003). I obtained 
approval for the conduct of this study from the Institutional Review Board (IRB) Walden 
University on April 16, 2016. The IRB approval number is 04-11-16-0179761. Approval 
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for access to the SEER program’s database was also granted prior to the conduct of the 
research (see Appendices A and B). The inclusion and exclusion criteria for the selection 
of the research participants were developed on the ethical principle that the harms and 
benefits of the research were distributed equally among all PrCa patients who are selected 
for the study (NIH, 2011).  
The research participants’ identifiable data were not used for this study, and no 
linkages were required to identify any of the research subjects during the investigation 
(NIH, 2011). In presenting the data, rates fewer than ten for PrCa patients of any of the 
SEER reporting locations were suppressed and not shown in figures and tables. This 
approach was taken to protect the research subjects from social harms.  
Confidentiality of the data was maintained by restricting its access to all 
individuals, except the members of my dissertation research committee (NIH, 2011). The 
data set was stored using a secured system (NIH, 2011) in zipped files on my personal 
computer. The use my personal computer and its log on information were not shared 
while accessing the SEER data set. The file name was disguised and file sharing options 
disabled. The data was used only for the purposes indicated in the dissertation proposal.  
I will share the research findings with the populations from which the sample was 
taken using journal publications for scholars and professionals, conferences for 
professional and special interest groups, the cancer societies for the cohorts, local 
organizations, public forums, and newsletters.  
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Summary and Transition 
Chapter 3 described the research methods for examining the relationship between 
the independent and dependent variables of this study. The research questions were 
answered using the SEER research data, a retrospective cohort design, Kaplan-Meier 
estimators, and the Cox proportional hazards regression model. The sample for this study 
was the Jamaican and White U.S.-born PrCa patients of the 18 U.S. participating SEER 
registries. A sample of N =10,572 research participants was selected from the SEER 18 
registries database 2013 submission, and this sample included all PrCa patients with and 
without a history of ERBT and brachytherapy treatment. The sample also comprised 
PrCa patients who were diagnosed with Gleason scores 6 and 7 PrCa, TNM stages T1 
and T2 PrCa, and SEER Historic Stage A classification. The variables were defined 
primarily with the definitions provided in the variable listing of the SEER Research Data 
Record 1973 to 2011 (SEER, 2013).  
IRB approval from the Walden University was obtained before the start of this 
study. I anticipated potential threats to the validity of this study according to the 
limitations of using secondary data. The validity threats were addressed using appropriate 
measures to reduce their effects in the findings of the research. The execution of the study 
was guided by the provisions of the HIPAA privacy rule (45 CFR 164.514 [e]) (USDHS 
2003), which established the conditions for the use of protected health of individuals 
using the limited data sets with a data use agreement. Appropriate data security measures 
were employed to protect the research participants. 
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In Chapter 4, I reported the results of the data analysis for the research questions 
and related hypotheses. I also provided descriptive statistics of the demographic 
characteristics of the study’s participants, and tests of the statistical assumptions of the 
Cox proportional hazard regression model. Additionally, in Chapter 4, I displayed the 
findings of univariate and bivariate analyses with tables of the hazard ratios and related 
95% confidence intervals and alpha levels for each variable. Furthermore, Chapter 4 
highlighted the results of hypothesis tests of the relationships between the dependent and 
independent variables and the tests for confounding effects. 
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Chapter 4: Results  
Introduction 
My primary goal of this quantitative dissertation was to examine survival patterns 
of brachytherapy, and ERBT treated Jamaican and White U.S.-born PrCa patients for the 
period 1992 to 2011. I also aimed to ascertain whether there were survival differences 
among brachytherapy and ERBT treated Jamaican and U.S.-born White PrCa patients 
who had a diagnosis of early and intermediate stage disease. Additionally, I intended to 
determine whether specific sociodemographic characteristics and a history of smoking in 
the ERBT and brachytherapy treated Jamaican and U.S.-born White PrCa patients 
affected their survival. I used a retrospective cohort study design, and analyses of 
secondary data with survival models to answer the research question. This study’s five 
research questions with their hypotheses are: 
Research Question 1. Are there differences in the length of time Jamaican-born 
PrCa patients compared with U.S.-born White PrCa patients who were treated with 
brachytherapy for low and intermediate stages PrCa, live with the disease? 
H01: There are no differences in the length of time Jamaican-born and U.S.-born 
White PrCa patients treated with brachytherapy for low and intermediate stages PrCa live 
with the disease. 
Ha1: There are differences in the length of time Jamaican-born PrCa patients 
versus U.S.-born White PrCa patients who were treated with brachytherapy for low and 
intermediate stages PrCa, live with the disease. 
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Research Question 2. Are there differences in the length of time Jamaican-born 
PrCa patients compared with U.S.-born White PrCa patients who were treated with 
ERBT for low and intermediate stages PrCa, live with the disease? 
H02: There are no differences in the length of time Jamaican-born PrCa patients 
and U.S.-born White PrCa patients treated with ERBT for low and intermediate stages 
PrCa, live with the disease. 
Ha2: There are differences in the length of time Jamaican-born PrCa patients 
compared with U.S.-born White PrCa patients who were treated with ERBT for low and 
intermediate stages PrCa, live with the disease. 
Research Question 3. Are there differences in 5-year survival intervals of 
Jamaican-born PrCa patients compared with U.S.-born White PrCa patients per treatment 
received for the period 1992 to 2011? 
H03: There are no differences in the 5-year survival intervals of Jamaican-born 
and U.S.-born White PrCa patients according to treatment received for the period 1992 to 
2011. 
Ha3: There are differences in the 5-year survival intervals of Jamaican-born PrCa 
patients compared with U.S.-born White PrCa patients according to treatment received 
for the period 1992 to 2011.  
Research Question 4. Are there differences in the length of time brachytherapy-
treated Jamaican-born PrCa patients and U.S.-born White PrCa patients with low and 




H04: There are no differences in the length of time brachytherapy-treated 
Jamaican PrCa patients and U.S.-born White PrCa patients with low and intermediate 
stages PrCa, live with the disease, after controlling for sociodemographic characteristics. 
Ha4: There are differences in the length of time brachytherapy-treated Jamaican 
PrCa patients and U.S.-born White PrCa patients with low and intermediate stages PrCa 
live with the disease, after controlling for sociodemographic characteristics. 
Research Question 5. Are there differences in the length of time ERBT treated 
Jamaican-born PrCa patients and U.S.-born White PrCa patients with low and 
intermediate stages PrCa live with the disease, after controlling for sociodemographic 
characteristics?  
H05: There are no differences in the length of time ERBT-treated Jamaican PrCa 
patients and U.S.-born White PrCa patients with low and intermediate stages PrCa live 
with the disease, after controlling for sociodemographic characteristics and history of 
smoking. 
Ha5: There are differences in the length of time ERBT-treated Jamaican PrCa 
patients and U.S.-born White PrCa patients with low and intermediate stages PrCa live 
with the disease, after controlling for sociodemographic characteristics. 
In Chapter 4, I provided descriptive statistics of the demographic characteristics 
of the study’s participants, and tests of the statistical assumptions of the Cox proportional 
hazard regression model. Subsequently, I presented a summary of the statistical analyses 
for each research question. The findings of univariate and bivariate analyses with tables 
of the hazard ratios and related 95% confidence intervals and p-values for each variable 
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are also described. Additionally, I displayed the Kaplan-Meier survival curves of the 
overall prostate cancer mortality for the Jamaican and White U.S.-born prostate cancer 
cohorts, and associated statistical tests of equality of survival of the two groups. Finally, 
the Chapter highlights the results of hypothesis tests of the relationships between the 
dependent and independent variables and the tests for confounding effects.  
Data Collection 
The 18 participating SEER registries of the United States (November 2013 
submission for the reporting years 1973 to 2011) was the secondary data used for data 
analysis. I chose the 1973 to 2011 version of the SEER cancer registries for data analysis 
because it had the Jamaican-born cohort for the study (SEER, 2013). I obtained the 
dataset with an emailed request to the SEER Cancer Registry Data System for internet 
access to the November 2013 submission of the 18 participating SEER registries 
database. The application was completed with the SEER cancer registry signed data use 
agreement form (see Appendix A). On receipt of the signed data use agreement, the 
support team of the SEER cancer registry granted approval for internet access to the 
SEER*Stat client-server system (see Appendix B). Subsequently, I prepared a smaller 
dataset of the 18 participating SEER cancer registries database for the study using a case 
listing of all the variables of the research. I exported the case listing into the IBM SPSS 
statistical software version 23 for data analysis.  
I modified the study’s protocol based on the limitations of the dataset. The cut-off 
age of the research participants was extended to include PrCa patients older than 65 
years. The proposed age-group for the data analysis was 30-64 years, and the cut-off age 
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age-group was 60-64 years. However, the dataset had fewer PrCa patients aged 30 to 64 
years when compared with the 65 and older age-group. The younger to older age-group 
comparisons were 48.1% versus 51.9% for the Jamaicans and 31.7% versus 68.2% for 
the U.S.-born Whites. Additionally, the highest proportion of Jamaican PrCa patients 
(292 or 39%) and U.S.-born Whites (4021 or 40.1%) were 65 to 74 years old. 
Consequently, the cut-off age was extended to include PrCa patients aged 65 years and 
older.  
The sample size of the research was expanded from N = 1,335 to N = 10,752 (8 
times larger) due to the sampling procedures used for the selection of the PrCa patients. 
The sample described in the research protocol included 267 Jamaicans and 1,068 White 
U.S.-born PrCa patients. However, the dataset had 754 Jamaican PrCa patients and 719 
met the criteria for selection; these PrCa patients were selected for the study using 
purposive sampling. The sample of White U.S.-born PrCa patients was extended to 
10,033, with the random sampling technique described in the research protocol. The 
samples of Jamaicans and White U.S.-born PrCa patients were taken from 15 of the l8 the 
SEER participating locations.  
Additionally, I excluded three of the SEER reporting sites from the dataset, the 
smoking variable was removed from the variable listing, and the SPSS version 23 
software package was used instead of the Pohar Perme and Ederer 11 for data analysis. 
The SEER reporting sites, Hawaii, Iowa, and Alaska Native were excluded from the data 
to balance the selection of research participants for the Jamaicans and White U.S.-born 
cohorts. The three excluded SEER locations had no Jamaican PrCa patients. The smoking 
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variable was removed from the list of variables because the SEER cancer registry does 
not report patient-level smoking data. The smoking data were available in the SEER 
registry dataset as County-level attributes, which were not applicable to the research 
questions. The Pohar-Perme and Ederer 11 statistical methods were not used for the data 
analysis because the sample of the study was expanded to include PrCa patients who 
were older than 65 years and these methods do not perform well in survival analyses 
involving the older age groups (Seppa et al., 2015). Furthermore, it was indicated in the 
SEER*Stat software, version 8.3.2 (SEER*Stat, 2016), that the Pohar-Perme survival 
method is still in development. Therefore, the IBM SPSS statistical software package 
(one of the alternative statistical software described in the research protocol) was used to 
analyze the data.  
The comparison group (U.S.-Born Whites) was selected with a simple random 
sampling technique to attain representativeness of the sample. In choosing this sample, 
the three SEER districts, Hawaii, Iowa, Alaska Native, which had no Jamaican PrCa 
patients were excluded from the sample frame. Subsequently, the identification numbers 
of the research participants for the remaining 15 reporting SEER locations were 
reorganized in descending order. Finally, every 50th White U.S.-born PrCa patient who 
met the selection criteria for inclusion in the study was selected from each of the 15 
SEER reporting sites. I selected every Jamaican PrCa patient who met the selection 



























Figure 1. Flow-chart of the sampling process for the prostate cancer patients. 
The White US-born PrCa 
patients were selected using 
a simple randomization 
process. 
The identification numbers 
of the White U.S.-born PrCa 
patients were reorganized in 
descending order. 
Every 50th White U.S.-born 
PrCa patients was selected 
from each of the 15 SEER 
reporting locations. 
n =10,033 White U.S.-born 
PrCa patients with the 
selection criteria were 
chosen for the sample. 
15 SEER reporting sites with 
Jamaican and White US-born 
PrCa patients remained. 
Total sample N = 10,752 Jamaican 
and White U.S.-Born PrCa patients 
who met the selection criteria for the 
study. 
The Jamaican-born 




PrCa patient was chosen 
according to the 
selection criteria. 
n =719 Jamaican-born 
PrCa patients were 
selected, 35 did not meet 
the criteria for selection. 
Hawaii, Iowa, and Alaska 
Native had no Jamaicans 
and were excluded 
The sampling population was 274,201 PrCa patients 
(273,447 White U.S.-born and 754 Jamaicans) from the 
18 SEER Reporting locations. 
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Additionally, proportions of PrCa patients in the sample were compared with 
proportions in the sampling population using the main variables of the study. The 
findings of the comparative analysis showed that the proportions of PrCa patients in the 
sample and sampling frame were similar (see Table 6). Furthermore, 95.4 % of the 
Jamaican PrCa patients (the exposure group) were included in the sample; a small 
percentage (4.6 %) of the Jamaican PrCa patients did not meet the criteria for inclusion. 
Therefore, the samples of Jamaican and White US-born PrCa patients were representative 
of their sampling populations. 
Table 6 
 
Comparison of the Proportions of the Sample and the Sampling Population of the 
Prostate Cancer Patients  
 US-Born Whites Jamaicans 





















ERBT 48,335 (22.9) 2,449 (24.4) 
 
185 (24.5) 185 (24.5) 
Gleason 
Grades 
Moderately Differentiated 119,712 (56.7) 6,149 (61.3) 419 (55.6) 415 (57.7) 
Well Differentiated 10,470 (5.0) 517 (5.2) 23 (3.1) 23 (3.1) 





11,3358 (53.7) 5,393 (53.7) 531 (70.4) 524 (72.9) 
Dead 
 
97,792 (46.3) 4,642 (46.3) 
 





59 (0.0) 3 (0.0) 2 (0.3) 2 (0.3) 
40-44 
 
676 (0.3) 31 (0.3) 5 (7%) 5 (7%) 
65-69 
 
41,319 (19.6) 2,037 (20.3) 173 (22.9) 165 (22.9) 













8,397 (83.7) 637 (84.5) 637 (84.5) 
Un-staged 5,574 (2.6) 251 (2.5) 11 (1.5) 11 (1.5) 
Note: * The comparison included the age-groups with the lowest and highest proportion 
of prostate cancer patients from the sample and sample frame. 
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Descriptive Statistics that Characterize the Sample 
The sample for this study comprised N = 10,752 PrCa patients selected from 15 of 
the 18 SEER reporting sites. The exposure sample consisted of 677 (94.2 %) Jamaican-
born Black and 42 (5.8 %) Jamaican-born White PrCa patients. The comparison group 
included 10,033 U.S.-born White PrCa patients. All PrCa cases were actively followed 
during the study period, at the end of 2011, 72.9 % of the Jamaican PrCa patients were 
censored, and 27.1 % died. Among the White U.S.-born PrCa patients in the study, 
53.8% were censored, and 46.2 % were deceased. The diagnosis for all PrCa cases was 




Baseline Characteristics of the Prostate Cancer Patients From 15 SEER Reporting 
Locations Reported for the Period 1992 to 2011  









Censored Deceased Histologically 
Confirmed 






719 719 100%) 524 (72.9%) 
 




10,033 10,033 (100%) 5,393 (53.8%) 4,640 (46.2%) 10,033 100% 
Total 10,752 10,752  5,917 (55.0%) 4,835 (45.0%) 10,752  
Note: N = 10,752 
  Among the 15 SEER reporting locations of the study, Greater California had the 
highest proportion of PrCa patients (16.3%) followed by Connecticut (15%) and Los 
Angeles (14.7%). The least number of PrCa patients were reported for the Greater and 
rural Georgia (3.0%) and Kentucky (3.1%) areas. Table 8 shows the frequency of the 
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Jamaican and White US-born PrCa patients of the 15 SEER reporting locations included 
in the study.  
Table 8 
 
Frequency of Prostate Cancer Patients for Each of the 15 SEER Reporting Locations for 
the Period 1992 to 2011 
SEER Registry  Frequency (n) % 
Atlanta (Metropolitan) 535 5.0 
California Excluding SF/SJ /LA 1,749 16.3 
Connecticut  1,614 15.0 
Detroit (Metropolitan) 557 5.2 
*Georgia (Rural and Greater) 328 3.0 
Kentucky 338 3.1 
Los Angeles 1,581 14.7 
Louisiana 342 3.2 
New Jersey 879 8.2 
New Mexico 393 3.7 
San Francisco-Oakland SMSA 600 5.6 
San Jose-Monterey 365 3.4 
Seattle (Puget Sound) 1,031 9.6 
Utah 440 4.0 
Total 10,752 100 
Note: N=10,752. *Georgia includes the research participants from rural and greater 
Georgia. 
 
  The frequency of PrCa patients for the 20-year period of observation ranged from 
367 (3.4 %) in 1994 to 822 (7.6%) cases in 2001. As shown in Table 9, higher numbers 
of PrCa patients were reported between 2000 and 2002, and in 2004. In the 1990s, except 
for 1992, the frequency of PrCa cases was lower than the number of PrCa cases reported 
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between 2000 and 2004. However, the rate of PrCa patients declined gradually for the 
reporting periods 2005 to 2011. In 2011, the number of PrCa patients was comparable 
with the low prevalence period 1995 to 1999. 
Table 9 
 
Frequency of Jamaican and White U.S.-Born Prostate Cancer Patients of the SEER 
Registry Database per Year for the Period 1992 to 2011 
Year Frequency (n) Percent (%) Cumulative (%) 
1992 664 6.2 6.2 
1993 425 4.0 10.1 
1994 367 3.4 13.5 
1995 402 3.7 17.3 
1996 381 3.5 20.8 
1997 410 3.8 24.6 
1998 414 3.9 28.5 
1999 398 3.7 32.2 
2000 720 6.7 38.9 
2001 822 7.6 46.5 
2002 776 7.2 53.7 
2003 575 5.3 59.1 
2004 720 6.7 65.8 
2005 583 5.4 71.2 
2006 619 5.8 77.0 
2007 577 5.4 82.3 
2008 514 4.8 87.1 
2009 496 4.6 91.7 
2010 490 4.6 96.3 
2011 399 3.7 100.0 
Total 10,752 100.0  
 Note: N = 10752 
 
  PrCa patients aged 55 to 79 years were well represented in the study’s sample. 
Fewer PrCa patients were 35 to 54 years, and the lowest number of PrCa patients (5%) 
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was in the 35 to 39 age group. The highest proportion of PrCa patients for both Jamaican 
and the White U.S.-born cohort was 65 to 69 years old; this included 165 (22.9%) 
Jamaican and 2027 (20.3%) White U.S.-born PrCa patients. A higher proportion of 
Jamaican PrCa patients were 55 to 69 years old when compared with the White U.S.-born 
(57.2% versus 45.2%), and fewer were in the 70 years and older age groups (29% versus 
47.9%) (see Table 10). 
Table 10 
 




















































3 31 162 490 981 1,519 2,037 1,984 1,579 845 402 
% 
 
0 0.3 1.6 4.9 9.8 15.1 20.3 19.8 15.7 8.4 4.0 
Total (n) 5 36 189 555 1,100 1,646 2,202 2,100 1,642 864 413 
Total % 0 0.3 1.9 5.2 10.2 15.3 20.5 19.5 15.3 8.0 3.8 
Note: N=10752.  
 
  Higher proportions of the PrCa patients were married (66.5% Jamaicans and 
72.4% White U.S.-born). However, the marital status of 15.2% of the PrCa patients was 
unknown. Lower proportions of PrCa patients were either widowed (11.2 %) or separated 
(2.7%) (see Table 11). 
  Higher numbers of Jamaican PrCa patients (56.9%) and White U.S.-born (80.5%) 
had health insurance. There were no specific details of the type of health insurance 
coverage for 19% of the Jamaican and 15.9% of the U.S.-born cohorts. The health 
96 
 
insurance status was unknown for 7.2% of the Jamaican PrCa patients and missing for 
6% of both cohorts (see Table 11).  
Table 11 
 
Marital and Health Insurance Status of the Jamaican and White U.S.-Born Prostate 
Cancer Patients 
 
 Jamaicans White U.S.-Born 
 




Married 478 66.5 7,267 72.4 
Divorced 49 6.8 642 6.4 
Separated 16 2.2 53 0.5 
Unmarried 86 12.0 691 6.9 
Widowed 32 4.5 671 6.7 
Unknown 58 8.1 709 7.1 
Total 719 100 10,033 100 
  
Health Insurance Status 
 
Insured 111 56.9 8,073 80.5 
Insured/No Specifics 
 
37 19.0 1,594 15.9 
Any Medicaid 20 10.3 222 
 
2.2 
Uninsured 13 6.7 14 
 
1.3 





195 100 9,903 100 
Note: * Data on the health insurance status for 654 (6.0%) of the PrCa patients were not 
available for the analysis. 
 
Thirty-eight percent of the sample was treated with one or more types of 
radiation; however, high numbers of PrCa patients (59.1%) received no radiation 
treatment, and the treatment status of 3% of PrCa patients was unknown. Among the 
White U.S.-born and Jamaican PrCa patients, ERBT was the most widely used PrCa 
treatment, and its use was reported for 2630 (24.5%) of the PrCa cohorts. Brachytherapy 
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was used among 1,435 (13.3%) of the PrCa patients. Table 12 describes the distribution 
of radiation treatment types among the PrCa patients. 
Table 12 
 
Distribution of Prostate Cancer Treatments Among the Jamaican and White U.S.-Born 
Prostate Cancer Patients  








Jamaica n 181 112 0 400 16 10 719 
% 
 
25.2 15.5 0 55.6 2.3 1.4 100 
USA n 2,449 1,323 20 5,951 201 89 10,033 
% 24.4 13.2 0.2 59.3 2.0 0.9 100 
Total (n) 2,630 1,435 20 6,351 217 99 10,752 
Note: N=10752. * The method of radiation is not specified. ERBT combined is 
combination of beam radiation with implants or isotopes.  
 
 High numbers of PrCa patients in the study were classified with Gleason grades 1 
and 11 PrCa, localized PrCa, and T1c and T2c PrCa. Higher proportions of the White 
US-born PrCa patients when compared with Jamaicans were classified with Gleason 
grade 1 PrCa (5.2% versus 3.2%) and Gleason grade 11 PrCa (61.3% versus 57.7%). On 
the other hand, a higher percentage of Jamaican PrCa patients had Gleason grade 111 
PrCa (39.1%) when compared with the White U.S.-born cohort (33.6%). The highest 
proportions of Jamaican (45.6%) and U.S.-born (38.6%) PrCa patients were categorized 
with T1c PrCa. There were no data for 23.7% of the PrCa patients of the SEER Historic 
Stage A classification. Table 13 describes the Gleason grades, SEER Historic Stage A 






Distribution of Jamaican and White US-Born Prostate Cancer Cases According to 





















Note: *The number of PrCa patients classified with the TNM Staging was reported for 
the period 2004 to 2011. 
 
An Evaluation of Statistical Assumptions Appropriate to the Study 
The assumption of proportionality of the Cox Regression model was evaluated 
with the graphical presentation of the Log Minus Log (LML) survival function versus the 
 Jamaicans White U.S.-Born 




Grade 1 23 3.2 517 5.2 
Grade 11 415 57.7 6,148 61.3 
Grade 111 281 39.1 3,368 33.6 
Total 719 100 10,033 100 
  
SEER Historic Stage A 
 
Localized 637 88.6 8,397 83.7 
Un-staged 11 1.5 251 2.5 
Blanks 71 9.9 1,385 
 
13.8 




SEER TNM Staging 
 
T1a 3 1.5 
 
225 2.2 
T1b 1 0.5 
 
121 1.2 
T1c 89 45.6 
 
3,871 38.6 
T1 NOS 0 0 
 
41 0.4 
T2a 17 8.7 
 
813 8.1 
T2b 5 2.6 
 
252 2.5 
T2c 55 28.2 
 
2,631 26.2 
T2 NOS 25 12.8 
 
2,069 20.6 





log of survival time; and statistical modelling with the time-dependent Cox model which 
introduced time as a linear variable. The assumption of proportionality of the Cox 
regression model was tested for each PrCa cohort per ERBT and brachytherapy prostate 
cancer treatments. The White U.S.-born PrCa cohort was the referent category because 
the research questions aimed at evaluating survival differences between the birthplace 
covariate and PrCa treatment. The cumulative hazard functions for each treatment group 
were plotted against time and the constancy of the ratios of the hazards determined 
(Forthofer et al., 2007). The assumption of proportionality of baseline hazards was 
accepted for each treatment cohort, on the basis that the cumulative survival curves for 
the Jamaican and White U.S.-born cohorts remained parallel for the period of 
observation. The results of the LML analysis demonstrated that the hazard of death for 
the brachytherapy treated Jamaican PrCa patient was significantly lower than the risk of 
death for the White U.S.-born brachytherapy treated PrCa patients, HR 0.63, 95% CI 
[0.55, 0.73], p < .001 (see Table 14). The graph of the LML survival curves for the 
Jamaican and White U.S.-born PrCa patients showed that both curves were parallel 
throughout the period of observation, and indicated that hazards for both cohorts were 
constant throughout the period of follow-up. The parallelism of the survival curves 
signified that the assumption of proportionality of the survival distributions for the 
Jamaican and White U.S.-born brachytherapy treated PrCa patients was met. Figure 2, 







Log Minus Log Analysis of the Proportionality of the Hazards of the Prostate Cancer 
Patients Treated With Brachytherapy 
 
Variables in the Equation 
 95% CI for 
 Exp (B) 
 
 Birthplace B SE Wald df Sig Exp 
(B) 
LL UL Covariate 
Mean 
χ2





           
Jamaica  
 
-0.46 0.07 39.39 1 .000 0.63 0.55 0.73 0.07 45.49 78,169.61 
 




Figure 2. Plot of Log Minus Log survival function for brachytherapy.  
 
The LML analysis of the hazard ratios for the ERBT Jamaican versus the ERBT 
U.S.-born PrCa patients showed that Jamaicans had a significantly lower hazard of death, 
HR 0.62, 95% CI [0.54, 0.72], p < .001 (see Table 15). The graph of the LML survival 
curves for the ERBT treated Jamaican, and White U.S.-born PrCa patients revealed that 
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both curves were divergent throughout the period of observation (see Figure 3). The 
parallelism of the survival curves indicated that the assumption of proportionality of the 
survival distributions for the ERBT treated Jamaican and White U.S.-born PrCa patients 
was met.  
Table 15 
 
Log Minus Log Analysis of the Proportionality of the Hazards of the Prostate Cancer 
Patients Treated With ERBT 
Variables in the Equation 






B SE Wald df Sig Exp 
(B) 
LL UL Covariate 
Mean 
χ2






           
Jamaica -0.46 0.07 40.28 1 .000 0.62 0.54 0.72 0.07 46.59 75,649.87 
 
Note: LL is lower limits and UL is upper limits. 
 
 




Cox regression analysis with time-dependent variable confirmed that the 
assumption of proportionality of the hazards was met for both brachytherapy and ERBT 
treated PrCa cohorts. At the inclusion of the time-dependent covariate with the country of 
birth and brachytherapy variables in the Cox regression model, the hazard ratio differed 
from the crude hazard ratio and was no longer statistically significant, HR 1.0,  
95% CI [0.99, 1.01], p = 0.93. The lack of statistical significance in the analysis indicated 
that time did not interact with covariates brachytherapy and country of birth. Hence the 
hazard ratios for brachytherapy were proportional with time. Table 16 demonstrates the 
interaction with time analysis for the brachytherapy treated PrCa patients 
Table 16 
 
Time-Dependent Analysis of the Proportionality of the Hazards of the Prostate Cancer 
Patients Treated With Brachytherapy 
Variables in the Equation 
 





































0.09 93.66 1 .000 0.40 0.33 .48 
 Birthplace* T_Cov_ -0.00 
 
 










0.00 0.00 0.00 1 0.927 1.00 0.99 1.01 
Note: * Indicates the interaction terms in the model. LL is lower limits UL is upper limits. 
 
The hazard ratio for the ERBT treated PrCa patients also differed from the crude 
hazard ratio and was no longer statistically significant with the introduction of the time-
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dependent covariate with the country of birth variable and ERBT to the model, HR 0.99, 
95% CI [0.99, 1.00], p = 0.84. The lack of statistical significance of the time-dependent 
covariate confirmed that time did not interact with covariates ERBT and country of birth. 
Hence the hazard ratios for ERBT were proportional with time. Table 17 shows the 
interaction with time analysis for the ERBT treated PrCa patients. 
Table 17 
 
Time-Dependent Analysis of the Proportionality of the Hazards of the Prostate Cancer 
Patients Treated With ERBT 
 
Variables in the Equation 
 
 95% CI for 
 Exp (B) 
 

























0.01 0.00 2.39 1 .122 1.01 1.00 1.01 
Birthplace*ERB
T* T_Cov_ 
0.00 0.00 0.04 1 0.839 1.00 0.99 1.00 
Note: * Indicates the interaction terms in the model. LL is lower limits, UL is upper 
limits. 
 
The LML estimate of the cumulative survival function versus the log of survival 
times of both brachytherapy and ERBT Jamaican and White U.S.-born PrCa patients 
confirmed that the survival curves were parallel. The time-dependent analyses verified 
that the hazards of both ERBT and brachytherapy treated Jamaican and White U.S.-born 
cohorts were constant throughout the period of observation. Therefore, the assumption of 
proportionality of the Cox proportional hazard regression model was met, and this model 
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was appropriate to examine survival differences of the brachytherapy and ERBT treated 
Jamaican and U.S.-born PrCa patients. 
Statistical Analyses for the Research Questions 
Research Question 1 Analysis 
Research Question 1: Are there differences in the length of time Jamaican-born 
PrCa patients compared with U.S.-born White PrCa patients who were treated with 
brachytherapy for low and intermediate stages PrCa, live with the disease? Ho1: There are 
no differences in the length of time Jamaican-born and U.S.-born White PrCa patients 
treated with brachytherapy for low and intermediate stages PrCa; live with the disease. 
Ha1: There are differences in the length of time Jamaican-born PrCa patients versus U.S.-
born White PrCa patients who were treated with brachytherapy for low and intermediate 
stages PrCa, live with the disease. 
Univariate analyses using the Life-Table estimates and Kaplan-Meier estimators 
provided preliminary descriptive statistics of the cumulative survival probability for the 
brachytherapy treated White U.S.-born and Jamaican PrCa patients. The Kaplan-Meier 
survival curves and the Log-Rank (Mantel-Cox), Breslow (Generalized Wilcoxon), and 
Tarone-Ware statistics were used to determine whether there were differences in the 
survival distributions of the brachytherapy treated Jamaican and the White U.S.-born 
cohorts. The Cox proportional hazards regression model was used to estimate the 
differences in the hazards ratios for the Jamaican and White U.S.-born PrCa patients 
based on the assumption that the hazards between both cohorts were constant throughout 
the follow-up. Hypothesis testing with interaction analysis was carried out to determine 
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modification effects in the magnitude of the risk ratios of the brachytherapy treated 
Jamaican and White U.S.-born cohorts. Tables 18 through 20, and Figure 4 present the 
statistical analyses for Research Question 1. 
Table 18, demonstrates the Life-Table estimates of the cumulative survival for the 
Jamaican and U.S.-born PrCa patients of the study. The death rates were stable for most 
of the period of observation but the number of Jamaican PrCa patients in the study 
declined markedly at 150 months and the White U.S.-born PrCa patients at 160 months. 
All Jamaican PrCa patients experienced the event at 190 months and the U.S.-Cohort at 
230 months of follow-up. 
Table 19 depicts the Kaplan-Meier comparison of the survival periods of the 
Jamaican and White U.S.-born PrCa patients and the overall comparisons of the survival 
distributions. The survival times for the Jamaican PrCa patients were similar (195 
months) for the first and second percentiles of the follow-up period. The median survival 
for the Jamaicans was undefined because more than 50 % of these PrCa patients survived 
beyond half the observation period. The median survival interval for the U.S.-born cohort 
was 142 months, SE 3, 95% CI [134.8, 147.1]. The Log-Rank, Breslow’s, and Tarone-
Ware comparisons of the survival distributions confirmed that the survival experiences 







Life-Table Estimates of Survival Times for the Jamaican and White U.S.-Born Prostate 
Cancer Patients Treated With Brachytherapy for the Period 1992 to 2011 
 
Note: N = 10,752= SE* is the standard error for the cumulative survival and SE**is the 
standard error for the hazard rate. PD is probability density of survival estimate; HR is the 















PD HR % SE** 
 
Jamaica 0 112 110 5 0 100 .00 .000 0 .00 
10 107 104 6 1 99 .01 .001 0 .00 
20 100 97 6 0 99 .01 .000 0 .00 
30 94 92 5 1 98 .01 .001 0 .00 
40 88 86 4 0 98 .01 .000 0 .00 
50 84 80 9 2 95 .02 .002 0 .00 
60 73 69 8 2 93 .03 .002 0 .00 
70 63 61 4 1 91 .03 .002 0 .00 
80 58 56 4 0 91 .03 .000 0 .00 
90 54 52 4 1 89 .04 .002 0 .00 
100 49 47 4 0 89 .04 .000 0 .00 
110 45 42 7 3 83 .05 .004 1 .00 
120 35 31 9 4 72 .07 .005 1 .01 
130 22 18 8 2 64 .08 .005 1 .01 
140 12 11 2 1 58 .09 .006 1 .01 
150 9 8 3 1 50 .11 .007 1 .01 
160 5 4 3 0 50 .11 .000 0 .00 
170 2 2 0 0 50 .11 .000 0 .00 
180 2 2 1 0 50 .11 .000 0 .00 
190 1 1 0 1 0 0 .011 2 .00 
           
United 
States 
0 1,323 1,314 19 4 100 .00 .000 0 .00 
10 1,300 1,285 30 19 98 .00 .001 0 .00 
20 1,251 1,234 34 36 95 .01 .003 0 .00 
30 1,181 1,156 50 26 93 .01 .002 0 .00 
40 1,105 1,081 47 41 90 .01 .004 0 .00 
50 1,017 988 58 38 86 .01 .003 0 .00 
60 921 885 72 38 83 .01 .004 0 .00 
70 811 782 58 35 79 .01 .004 0 .00 
80 718 686 65 37 75 .01 .004 1 .00 
90 616 580 73 34 70 .01 .004 1 .00 
100 509 484 51 29 66 .02 .004 1 .00 
110 429 394 70 31 61 .02 .005 1 .00 
120 328 292 72 24 56 .02 .005 1 .00 
130 232 205 55 20 50 .02 .005 1 .00 
140 157 144 26 18 44 .02 .006 1 .00 
150 113 103 20 7 41 .02 .003 1 .00 
160 86 74 24 7 37 .03 .004 1 .00 
170 55 47 17 5 33 .03 .004 1 .01 
180 33 30 7 2 31 .03 .002 1 .00 
190 24 21 7 0 31 .03 .000 0 .00 
200 17 15 5 1 29 .04 .002 1 .01 
210 11 11 1 2 23 .05 .005 2 .01 
220 8 7 2 2 17 .05 .007 3 .02 





Kaplan-Meier Comparison of the Survival Times for the Jamaican and White U.S.-Born 















25% 50% 75% χ2 Sig χ2 Sig χ2 Sig 
 
Est  SE Est SE Est SE LL UL 
 
 















219 15 142 3 89 3 134.8 147.1 
 
 
Overall 219 12 142 3 92 3 135.8 148.1 
Note: N = 10752. * No precision estimates were calculated for the median survival time 
for the Jamaicans because more than 50% of the patients survived beyond the 50th 
percentile of the observation period. Percentiles are the quartiles of the follow-up period 
in months. LL is lower limits, UL is upper limits. Est is estimate. Sig is the p-value. 
 
Figure 4 illustrates the Kaplan-Meier survival curves for the brachytherapy treated 
cohorts. The cumulative survival curves showed visible differences in the survival 
distributions of the Jamaican and White U.S.-born PrCa patients. The Kaplan-Meier 
survival curve for the brachytherapy treated Jamaican PrCa patients had higher survival 
probability overall when compared with the White U.S.-born PrCa patients. Both PrCa 
cohorts had similar survival probability at baseline, but at approximately 30 months of 
follow-up the survival curve for the Jamaican PrCa patients diverged from the U.S. 
cohort and assumed a parallel form throughout the rest of the study. Brachytherapy 
treatment demonstrated more favorable survival outcome for the Jamaican PrCa patients 
for the first 150 months of follow-up and the curve declined sharply at 190 months. The 
step-like appearance of the curve at 190 months of observation, indicated that fewer 
participants were in the study at that period. This shift in the survival curve correlated 
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with the descriptive statistics in Table 18. The small p-values (p < .001) of the 
comparative analysis shown in Table 19 confirmed that the cumulative survival curves 
were significantly different. 
 
 
Figure 4. Kaplan-Meier survival curves for the brachytherapy treated patients. 
 
I examined for differences in the hazards of the brachytherapy treated Jamaicans 
and White U.S.-born PrCa patients with Cox regression hazards analysis (see Table 20). I 
followed up with interaction analysis to determine whether the magnitude of the risk 
ratios of the Cox regression model were similar across subgroups of the Jamaican and 
White U.S.-born brachytherapy treated cohorts. The result of the interaction analysis is 
presented in Table 20. I created two Cox regression models to examine the independent 
and interaction effects of brachytherapy and birthplace in the survival outcomes of the 
PrCa patients. An interaction term was modelled with the birthplace variable and 
brachytherapy; the White U.S.-born cohort was the referent category. The hypothesis that 
109 
 
the association identified was of similar magnitude across subgroups of the 
brachytherapy treated Jamaican and White U.S.-born cohorts was accepted where there 
were no significant interaction effects and rejected where there were significant 
interaction effects in the model (Szklo & Nieto, 2014, p. 187). Alpha level (p < .05) was 
the basis for accepting or rejecting the null hypothesis. I accepted the main effect for the 
model with a non-significant interaction effect and a significant or non-significant 
birthplace main effect. Table 20 presents the two models with the hazard ratios of the 
main and interaction effects of brachytherapy and the birthplace variable. Model one 
depicts the analysis of the independent effects of the predictor variable brachytherapy on 
the outcome PrCa survival without interaction, and model two presents the analysis of the 
main and interaction effects.  
The result of the Cox regression analysis in model one showed a statistically 
significant difference with the birthplace variable, HR 0.63, 95% CI [0.55, 0.73], p < .001 
and brachytherapy, HR 0.69, 95% CI [0.63, 0.76], p < .001. At the introduction of the 
interaction covariate in model two, the main effects for birthplace, HR 0.65, 95% CI 
[0.56, 0.76], p < .001 and brachytherapy, HR 0.69, 95% CI [0.63, 0.77], p < .001 were 
statistically significant. However, the interaction effect of brachytherapy and the 
birthplace variable was not significant, HR 0.81, 95% CI [0.50, 1.23], p = .38. The main 
effect of the birthplace variable was accepted because of the non-significant interaction 
effect. The findings of the birthplace main effect indicate that brachytherapy reduced the 
risk of death by 37% for the Jamaican cohort when compared with the White U.S.-born 
PrCa patients, HR 0.63, 95% CI [0.55, 0.73], p < .001.  
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The focus of the study was to determine differences in the survival of the 
Jamaican versus the White U.S.-born PrCa patients who were treated with brachytherapy. 
The statistically significant main effect for the birthplace variable and non-significant 
interaction effect suggest that the coefficients were not modified by the interaction of 
brachytherapy and country of birth. The non-significant statistical interaction also 
indicates that brachytherapy treatment effects did not vary across subpopulations of the 
brachytherapy treated cohorts of the study (Leighton, 2010b, p. 468; Szklo & Nieto, 
2014). Hence, there is a significant difference in the survival times of the brachytherapy 
treated Jamaicans and White U.S.-born PrCa patients. 
Table 20 
 
Main and Interaction Effects of the Differences in the Hazard Ratios for Jamaican and 
White U.S.-Born Prostate Cancer Patients Treated With Brachytherapy 
 Variables in the Equation 
  95% CI for 
 Exp (B) 




Main Effects of Brachytherapy and Birthplace  
 
Model 1 Birthplace 
Reference = 
United States 
-0.45 0.07 38.97 1 .000 0.63 0.55 0.73 
Brachytherapy -0.37 0.04 59.39 1 .000 0.69 0.63 0.76 
 Main and Interaction Effects of Brachytherapy and Birthplace 
 















-0.21 0.02 0.77 1 .378 0.81 0.50 1.29 
 
Note: N = 10,752. * is the interaction covariate of brachytherapy and country of birth. LL 




The Life-Table estimates and Kaplan-Meier estimators of Research Question 1 
demonstrated that the Jamaican PrCa patients had a longer initial event-free period (100 
months) when compared with the White U.S.-born PrCa patients (60 months), but 
experienced the event earlier (190 months versus 230 months) (see Table 18 and Figure 
4). The median survival time for the U.S.-born PrCa patients was 142 months, SE 3, 
 95% CI [134.8, 147.1], p < .001, while more than 50% of the Jamaicans survived beyond 
half the period of follow-up (see Table 19). The Log-Rank, Breslow, and Tarone-Ware 
tests of equality of the survival distributions for the brachytherapy treated the White U.S.-
born, and Jamaican PrCa patients confirmed that the survival curves for both cohorts 
were significantly different (p < .001) (see Table 19).   
Cox regression analysis of the differences in the hazard ratios of the 
brachytherapy treated Jamaicans and White U.S.-born PrCa patients confirmed that there 
were significant differences in their survival times (see Table 20). The hypothesis of a 
modification effect in the magnitude of the risk ratios across subpopulations of the 
brachytherapy treated Jamaican and White U.S.-born cohorts showed a non-significant 
interaction effect. The brachytherapy treated Jamaicans were 0.63 times less likely to die 
from PrCa at any given time during the 1992 to 2011 period of observation when 
compared with the White U.S.-born PrCa patients, 95% CI [0.55, 0.73], p < .001. 
Therefore, the alternative hypothesis that there are differences in the length of time 
Jamaican-born PrCa patients versus U.S.-born White PrCa patients who were treated with 
brachytherapy for low and intermediate stages PrCa, live with the disease was accepted. 
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Research Question 2 Analysis 
Research Question 2: Are there differences in the length of time Jamaican-born 
PrCa patients compared with U.S.-born White PrCa patients who were treated with 
ERBT for low and intermediate stages PrCa, live with the disease? H02: There are no 
differences in the length of time Jamaican-born PrCa patients and U.S.-born White PrCa 
patients treated with ERBT for low and intermediate stages PrCa, live with the disease. 
Ha2: There are differences in the length of time Jamaican-born PrCa patients compared 
with U.S.-born White PrCa patients who were treated with ERBT for low and 
intermediate stages PrCa, live with the disease. 
I obtained preliminary descriptive statistics, and crude and cumulative estimates 
of the survival probability of the ERBT treated cohorts, using Life-Table estimates and 
Kaplan-Meier estimators. The Log-Rank, Tarone-Ware, and Breslow’s statistics were 
used to determine the equality of the survival distributions for the ERBT treated cohorts. 
The Cox proportional hazards model was used to estimate the differences in the hazards 
ratios for the ERBT treated Jamaican and White U.S.-born PrCa patients based on the 
assumption that the hazards of both cohorts were constant throughout the follow-up. 
Hypothesis testing with interaction analysis was carried out to determine modification 
effects in the association identified between ERBT treatment and survival of the PrCa 
patients. The findings of the statistical analyses for research question two are shown in 
Table 21 through Table 23, and Figure 5. 
Table 21 presents the Life-Table estimates of the ERBT treated PrCa cohorts. The 
cumulative hazard rates were stable at one percent for the first 180 months of follow-up 
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for the Jamaicans and 160 months for the White U.S.-born PrCa patients but increased to 
2% at 190 and 170 months respectively. At 190 months, the number of ERBT treated 
PrCa patients in the study declined significantly. All Jamaicans experienced the event at 





Life-Table Estimates of Survival Times for the Jamaican and White U.S.-Born Prostate 













PD HR % SE** 
 
Jamaica 0 181 173 16 2 99 .01 .001 0 .00 
10 163 159 8 4 96 .01 .002 0 .00 
20 151 146 10 2 95 .02 .001 0 .00 
30 139 135 8 2 94 .02 .001 0 .00 
40 129 124 11 4 91 .02 .003 0 .00 
50 114 110 9 4 87 .03 .003 0 .00 
60 101 98 6 4 84 .03 .004 0 .00 
70 91 88 6 5 79 .04 .005 1 .00 
80 80 77 7 6 73 .04 .006 1 .00 
90 67 64 6 4 68 .04 .005 1 .00 
100 57 54 5 1 67 .05 .001 0 .00 
110 51 49 5 5 60 .05 .007 1 .00 
120 41 37 9 1 58 .05 .002 0 .00 
130 31 29 5 3 52 .06 .006 1 .01 
140 23 21 4 0 52 .06 .000 0 .00 
150 19 19 1 1 49 .06 .003 1 .01 
160 17 16 3 2 43 .07 .006 1 .01 
170 12 11 3 1 39 .07 .004 1 .01 
180 8 8 0 0 39 .07 .000 0 .00 
190 8 7 3 1 33 .08 .006 2 .02 
200 4 4 1 1 24 .10 .009 3 .03 
210 2 2 0 2 00 .00. .024 0 .00 
           
United  
States 
0 2,449 2,413 72 21 99 .00 .001 0 .00 
10 2,356 2,323 67 76 96 .00 .003 0 .00 
20 2,213 2,167 92 85 92 .01 .004 0 .00 
30 2,036 2,008 57 90 88 .01 .004 0 .00 
40 1,889 1,857 64 99 83 .01 .005 1 .00 
50 1,726 1,692 68 91 79 .01 .004 1 .00 
60 1,567 1,533 69 73 75 .01 .004 0 .00 
70 1,425 1,389 72 101 70 .01 .005 1 .00 
80 1,252 1,214 77 103 64 .01 .006 1 .00 
90 1,072 1,039 69 72 59 .01 .004 1 .00 
100 931 900 62 85 54 .01 .006 1 .00 
110 784 743 83 78 48 .01 .006 1 .00 
120 623 589 69 60 43 .01 .005 1 .00 
130 494 465 58 54 38 .01 .005 1 .00 
140 382 360 45 40 34 .01 .004 1 .00 
150 297 283 29 33 30 .01 .004 1 .00 
160 235 224 22 31 26 .01 .004 1 .00 
170 182 169 26 26 22 .01 .004 2 .00 
180 130 122 17 19 18 .01 .003 2 .00 
190 94 85 18 14 15 .01 .003 2 .00 
200 62 60 4 5 14 .01 .001 1 .00 
210 53 47 12 8 12 .01 .002 2 .01 
220 33 27 12 5 10 .01 .002 2 .01 
230 16 9 14 2 7 .02 .002 3 .02 
Note: N = 10,752. SE* is the standard error for the cumulative survival and SE** is the 




  Table 22 shows the Kaplan-Meier comparison of the survival periods of the 
Jamaican and White U.S. cohorts. At the first percentile, Jamaicans survived the greater 
portion of the observation period (209 months). The median survival was 154 months for 
the Jamaicans, SE 14.6, 95% CI [125.2, 182.8] and 116 months for the White U.S.-born 
PrCa patients, SE 2.2, 95% CI [111.6, 120.4]. The Log-Rank, Breslow’s, and Tarone-
Ware tests of equality of the survival distributions confirmed that the survival 
experiences of the Jamaican and White U.S.-born PrCa patients were significantly 
different (p < .001). 
Table 22 
 
Kaplan-Meier Comparison of Survival Times for the Jamaican and White U.S.-Born 
















25% 50% 75% χ2 Sig χ2 Sig χ2 Sig 
 
Est  SE Est SE Est SE LL UL 
 
 















173 3 116 2 70 2 111.6 120.4 
 
 
Overall 175 3 117 2 71 2 112.5 121.5 
Note: N = 10,752. LL is lower limits, UL is upper limits. Est is estimate. Percentiles are 
the quartiles of the follow-up period in months. Est is estimate. Sig is the p-value. 
 
Figure 5 illustrates the cumulative survival probability for the ERBT treated 
Jamaican and White U.S.-born PrCa. The Kaplan-Meier curves demonstrated perceptible 
differences in the survival experiences of both cohorts. The curves shifted after 30 
months of follow-up and remained parallel throughout the observation. The cumulative 
survival curves showed that ERBT was more beneficial to the Jamaican PrCa patients 
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throughout the observation when compared with the White U.S.-born cohort. Fewer 
Jamaican and White U.S. PrCa patients were in the study between 160 and 200 months of 
follow-up. All Jamaican PrCa patients experienced the event earlier than the White U.S.-
born patients. The frequency of the ERBT treated Jamaicans presented Table 21 
corresponded with the shifts in the survival curves and confirmed that the number of 
PrCa patients declined at the latter months of the follow-up. The cumulative survival 
curve for the White U.S.-born cohort terminated at a later period (230 months) of follow-
up. The comparison analysis of the survival distributions demonstrated in Table 22 
verified that the survival curves for the Jamaicans and the White U.S. PrCa patients were 
significantly different.  
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The differences in the hazards of Jamaicans and White U.S.-born PrCa patients 
were examined further in Cox regression hazards analysis (see Table 23). The Cox-
proportional hazards model was used to estimate the differences in the hazards ratios for 
the ERBT treated Jamaican and White U.S.-born PrCa patients based on the assumption 
that the hazards among both cohorts were constant throughout the follow-up. I conducted 
hypothesis test with interaction analysis to determine modification effects in the 
magnitude of the association identified in the Cox regression analysis for the Jamaican 
and White U.S.-born ERBT treated cohorts. The differences in the hazard ratios of the 
main and interaction effects of ERBT and the birthplace variable were examined in two 
separate Cox regression models. An interaction term was modelled with the birthplace 
variable and ERBT; the White U.S.-born cohort was the referent category. The 
hypothesis that the association identified was of similar magnitude across subgroups of 
the ERBT treated Jamaican and White U.S.-born cohorts was accepted where there were 
no significant interaction effects and rejected where there were interaction effects in the 
model (Szklo & Nieto, 2014, p. 187). Alpha level (p < .05) was the basis for accepting or 
rejecting the null hypothesis. I accepted the main effect for the model with a non-
significant interaction effect and a significant or non-significant birthplace main effect. In 
Table 23, model one depicts the analysis of the independent effects of the predictor 
variable ERBT on PrCa survival without the interaction term, and model two presents the 
analysis of the main and interaction effects. 
The result of the Cox regression analysis in model one showed a statistically 
significant difference with the birthplace variable, HR 1.6, 95% CI [1.38, 1.84],  
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p < .001 and ERBT, HR 0.89, 95% CI [0.84, 0.95], p = .001. In model two, the Cox 
regression analysis showed a significant main effect for birthplace, HR 1.50, 95% CI 
[1.27, 1.78], p < .001 but ERBT did not, HR 1.14, 95% CI [0.61, 2.13], p = 0.69. The 
interaction effect of ERBT and the birthplace variable was also not significant  
HR 1.03, 95% CI [0.75, 1.41], p = 0.88. The birthplace main effect was accepted because 
of the non-significant interaction effect. The ERBT treated Jamaican PrCa patients were 
1.6 times more likely to die of PrCa when compared with the ERBT treated U.S.-born 
White PrCa patients, HR 1.6, 95% CI [1.38, 1.84], p < .001. 
The intent of the study was to determine differences in the survival of the 
Jamaican versus the White U.S.-born PrCa patients who were treated with ERBT. The 
birthplace main effect was statistically significant, and the interaction effect was not 
significant. The statistically significant main effect for the birthplace variable and non-
significant interaction effect confirmed that the coefficients were not modified by the 
interaction of ERBT and country of birth. The non-significant statistical interaction also 
indicates that ERBT treatment effects were similar in magnitude across subpopulations of 
the cohorts studied (Leighton, 2010b, p. 468; Szklo & Nieto, 2014, p. 187). Hence there 
is a significant difference in the survival of the ERBT treated Jamaicans and White U.S.-








Main and Interaction Effects of the Differences in the Hazard Ratios of the Jamaican and 
White U.S.-Born Prostate Cancer Patients Treated With ERBT 
  
Variables in the Equation 























Main Effects of ERBT and Birthplace 
 
 




0.46 0.07 40.62 1 .000 1.59 1.38 1.84 
ERBT 
 
0.11 0.03 11.73 1 .001 0.89 0.84 0.95 
 Main and Interaction Effects of ERBT and Birthplace 
 
 















0.02 0.16 0.02 1 .881 1.03 
 
0.75 1.41 
Note: N = 10,752. * is the interaction covariate of ERBT and Country of Birth. LL is 
lower limits and UL is upper limits. 
 
The analyses for Research Question 2 demonstrate that the Jamaican PrCa 
patients had a longer event-free period at the start of the follow-up when compared with 
the White U.S.-born PrCa patients (60 months versus 30 months). Both ERBT treated 
groups survived more than 200 months of follow-up (see Table 21). Kaplan-Meier 
statistics showed that the Jamaican ERBT treated PrCa patients had higher median 
survival time when compared with the White U.S.-born PrCa patients (154 months), SE 
15, 95% CI [125.2, 182.8], versus (116 months), SE 2, 95% CI [111.6, 120.4] The 
Kaplan-Meier cumulative survival curve showed that the ERBT treated Jamaican PrCa 
patients had higher survival probability when compared with the White U.S.-born cohort  
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(see Figure 5). The Log-Rank, Breslow’s, and Tarone-Ware tests of equality of the 
survival distributions for the ERBT treated White U.S.-born, and Jamaican PrCa patients 
confirmed that the survival curves were significantly different (p < .001) (see Table 22).  
Cox regression analysis of the differences in the hazard ratios of the Jamaican and 
White U.S.-born ERBT treated PrCa patients confirmed that the hazard ratios of both 
cohorts were significantly different (see Table 23). The hypothesis of a difference in the 
magnitude of the risk ratios across subgroups of the ERBT treated Jamaican and White 
U.S.-born cohorts demonstrated no interaction or modification effects. Hence, at any 
given time during the during the 1992 to 2011 period of observation the ERBT treated 
Jamaican PrCa patients were 1.6 times more likely to die of PrCa when compared with 
the White U.S.-born PrCa patients, 95% CI [1.38, 1.84], p < .000. Thus, the alternative 
hypothesis that there are differences in the length of time Jamaican-born PrCa patients 
versus U.S.-born White PrCa patients who were treated with ERBT for low and 
intermediate stages PrCa live with the disease was accepted. 
Research Question 3 Analysis  
Research Question 3: Are there differences in the 5-year survival intervals of 
Jamaican-born PrCa patients compared with U.S.-born White PrCa patients per treatment 
received for the period 1992 to 2011? H03: There are no differences in the 5-year survival 
intervals of Jamaican-born and U.S.-born White PrCa patients per treatment received for 
the period 1992 to 2011. Ha.3: There are differences in the 5-year survival intervals of 
Jamaican-born PrCa patients compared with U.S.-born White PrCa patients according to 
treatment received for the period 1992 to 2011. 
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 In analyzing Research Question 3, I developed cohort-treatment contingency 
tables for each 5-year interval and estimated the hazard rates and median survival times 
of the PrCa cohorts according to the treatments they received. I compared the differences 
in the survival distributions of the Jamaican and White U.S.-born cohorts per treatments 
received using the Log-Rank statistics. The findings of the Kaplan-Meier statistical 
analyses are presented in Tables, 24, 28, 32, and 36. I computed further analyses with the 
Cox proportional hazards regression model to test the differences in the survival 
experiences of the PrCa patients for each 5-year interval. Hypothesis testing with 
interaction analysis was conducted to determine interaction or modification in the 
magnitude of the risk ratios of the treatment cohorts. Each PrCa treatment 
(brachytherapy, ERBT, and radiation sequenced with surgery) was modelled separately 
with the birthplace variable and an interaction term which included birthplace and 
treatment type. The hypothesis that the magnitude of the risk ratios of the Cox regression 
model was comparable in subpopulations of the Jamaican and White U.S.-born cohorts 
was accepted for each model with a non-significant interaction outcome and a significant 
or non-significant birthplace main effect. In contrast, the hypothesis that the magnitude of 
the risk ratios was similar among subgroups of the cohorts was rejected for each model 
with a significant interaction effect. Alpha level (p < .05) was the basis for accepting or 
rejecting the null hypothesis. Follow-up tests using pairwise comparisons of the second 
main effects (the treatment groups and their corresponding non-treated groups) were 
completed for each model with a significant interaction effect. The main outcomes of the 
treatment and birthplace variables for each 5-year interval are presented in three separate 
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models in Tables 25, 29, 33, and 37. The interaction effects of the birthplace covariate 
and the PrCa treatments were modelled in Tables 26, 30, 34, 38. Tables 27, 31, 35, and 
39 present the results of the pairwise comparisons for the significant interaction effects. 
Survival interval 1992 to 1996. One thousand seven hundred and sixty-nine 
Jamaican and U.S.-born PrCa patients received brachytherapy, ERBT, and other radiation 
treatment for the 1992 to 1996 period of observation. Among the treatment groups, the 
brachytherapy treated Jamaican PrCa patients had the highest number of censored cases 
(55.2%) and higher median survival time (three years) when compared with the other 
treatments. Fifty percent of the Jamaican cohort survived two years of follow-up, and 
fewer received other types of radiation. Half of the U.S.-born PrCa patients who received 
all three treatments were alive at two years of follow-up. Table 24 demonstrates that the 
results of the Kaplan-Meier estimates of the 1992 to 1996 sample. 
Table 24 
 
Summary of Kaplan-Meier Estimates for the Sample of 1,769 Jamaican and U.S.-Born 
Prostate Cancer Patients per Treatment Received Between 1992 and 1996 
Birthplace Treatment Number 
at Risk 
(n) 






































19 10 9 (47.4) 2 1.01 2.98 8.68 .003 
United 
States 







1,080 837 243 (22.5) 2 1.91 2.08 
Other  220 159 61 (27.7) 2 1.80 2.19 8.68 .003 
Note: Median survival was estimated in years. LL is lower limits, UL is upper limits. 
Other is radiation sequenced with surgery.  χ2 is the Log-Rank comparison.  
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Table 25 describes the main effects of the birthplace covariate and brachytherapy, 
ERBT, and other radiation treatments for the period 1992 to 1996 period. The birthplace 
main effects were statistically significant for all treatments types. Model one focused on 
the difference between PrCa patients who were treated with brachytherapy, model two 
demonstrates the differences among the ERBT treated cohorts, and model three presented 
the differences among the PrCa patients who received other types of radiation. The 
Jamaican PrCa patients were 1.2 times more likely to die of PrCa when compared with 
the White U.S.-born (p < .001). Further analyses for the interaction or modification 
effects in the association of the treatments and PrCa survival were completed. 
Table 25 
 
Main Effects of the Differences in the Hazard Ratios for the Jamaicans and White U.S.-
Born Prostate Cancer Patients per Treatment Received Between 1992 and 1996 
Variables in the Equation 
 








Variables B SE Wald df Sig Exp (B) LL UL 
 




= United States 
 
0.18 0.08 4.40 1 .036 1.20 1.01 1.42 
Brachytherapy 
 
-0.18 0.07 7.20 1 .007 0.82 0.72 0.95 
ERBT Main Effects 
 
 
Model 2 Birthplace 
(Reference = United 
States) 
 
0.18 0.08 4.64 1 .031 1.20 1.02 1.43 
ERBT 
 
0.15 0.04 15.1 1 .000 1.16 1.08 1.26 
Other Radiation Treatment Main Effects 
 
 
Model 3 Birthplace 
(Reference = United 
States) 
0.19 0.08 4.85 1 .028 1.21 1.02 1.44 
Other -0.07 0.07 0.86 1 .354 0.92 0.79 1.09 




Table 26 shows the results of the interaction analyses for the PrCa patients who 
were treated with brachytherapy, ERBT, and other radiation for the period 1992 to 1996. 
In model one, which examined the effects of brachytherapy, the birthplace main effect, 
HR 1.19, 95% CI [0.99, 1.42], p = .063, brachytherapy main effect, HR 0.64, 95% CI 
[0.20, 2.03], p = 0.452 and the birthplace and brachytherapy interaction effect, HR 1.14, 
95% CI [0.63, 2.05], p = 0.664 were not statistically significant.  
In model two, which focused on treatment effects of ERBT, the birthplace main 
effect, HR 1.14, 95% CI [0.99, 1.40], p = .058 and the main effect for ERBT were not 
significant, HR 0.98, 95% CI [0.54, 1.78], p = 0.941. However, the interaction effect for 
ERBT and birthplace, HR 1.08, 95% CI [1.04, 1.13], p < .001 was statistically significant.  
In model three, which estimated the effects of other radiation treatment, the 
birthplace main effect, HR 1.31, 95% CI [1.04, 1.66], p = .021 and other radiation 
treatment main effect, HR 0.78, 95% CI [0.62, 0.98], p = .036 were significant. The 
interaction effect of birthplace and other radiation treatment was not statistically 
significant, HR 0.96, 95% CI [0.89, 1.04], p = .296.  
 The non-significant interaction effects for brachytherapy and other radiation 
treatment indicate that the third variable (the interaction term) did not modify the main 
effects observed. The brachytherapy treated Jamaicans and the Jamaican PrCa patients 
who were treated with other radiation had 1.2 times higher risk of dying of PrCa when 
compared with the White U.S.-born patients (p < .001). The main effect for ERBT was 
not interpreted for this analysis because of the significant interaction effects.  
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A follow-up, pairwise comparison of the hazard ratios of Jamaican and White 
U.S.-born PrCa patients who received and did not receive ERBT for 1992 to 1996 
interval was completed. The referent group was the PrCa patients who received no ERBT 
(see Table 27). The findings indicate that the hazard ratios were significant for the White 
U.S.-born PrCa patients but not for the Jamaicans. The risk of death for the ERBT treated 
Jamaican PrCa patient was 1.5 times greater than the risk for the non-ERBT treated 
patients, 95% CI [0.99, 2.20], p = .057. The risk of death for the White ERBT treated 
PrCa patients was 1.14 times higher than the non-ERBT treated White cohort, 95% CI 
[1.05, 1.25], p < .003. Hence, there was a significant difference among the ERBT treated 
versus the non-ERBT treated White U.S.-born PrCa patients. There were no significant 













Interaction Effects of the Differences in the Hazard Ratios of the Jamaican and White 
U.S.-Born Prostate Cancer Patients per Treatment Received Between 1992 and 1996 
Variables in the Equation 
 








Variables B SE Wald df Sig Exp (B) LL UL 
 




(Reference = United 
States) 
 
0.17 0.09 3.45 1 .063 1.19 0.99 1.42 
Brachytherapy 
 
-0.44 0.58 0.56 1 .452 0.64 0.20 2.03 
Brachytherapy 
*Birthplace 
0.13 0.30 0.18 1 .664 1.14 0.63 2.05 
ERBT with Interaction Variable 
 
 
Model 2 Birthplace 
(Reference = United 
States) 
 
0.16 0.08 3.60 1 .058 1.14 0.99 1.40 
ERBT 
 
-0.02 0.30 0.01 1 .941 0.98 0.54 1.78 
ERBT*Birthplace 
 
0.08 0.02 14.34 1 .000 1.08 1.04 1.13 
Other Radiation Treatment with Interaction Variable 
 
 
Model 3 Birthplace 
(Reference = United 
States) 
 
0.27 0.11 5.32 1 .021 1.31 1.04 1.66 
Other -0.25 0.11 4.38 1 .036 0.78 0.62 0.98 
Other*Birthplace -0.04 0.04 1.09 1 .296 0.96 0.89 1.04 
Note: N = 1,769. LL is lower limits, UL is upper limits. Other is radiation sequenced with 












Pairwise Comparison of the Hazard Ratios for the Jamaican and White U.S.-Born 
Prostate Cancer Patients Treated With ERBT for the 1992 to 1996 Period 
Variables in the Equation 
 95% CI for Exp 
(B) 
 





Reference = (No ERBT) 
ERBT 
 
0.39 0.20 3.63 1 .057 1.48. 0.99 2.20 
White U.S.-Born ERBT  0.13 0.04 8.86 1 .003 1.14 1.05 1.25 
Note: N = 1,769. LL is lower limits, UL is upper limits. 
 
Survival interval 1997 to 2001. Kaplan-Meier estimates of the cumulative 
survival of 1,271 Jamaican and U.S. PrCa treated cohort who were followed between 
1997 and 2001 demonstrated that the median survival was undefined for the 
brachytherapy and ERBT treated Jamaicans. However, an estimated 50% of the Jamaican 
and White U.S.-born PrCa patients who received other radiation were alive at three years 
of follow-up, 95% CI [2.18, 3.81] and [2.45, 3.54] respectively. Half of the U.S.-born 
PrCa patients who received brachytherapy also survived beyond three years of treatment, 
95% CI [2.79, 3.21], p = .010. On the other hand, 50% of the ERBT treated U.S.-born 
PrCa patients were alive at two years of treatment (p = .004). Table 28 demonstrates that 








Summary of Kaplan-Meier Estimates for the Sample of 1,271 Jamaican and White U.S.-
Born Cancer Patients per Treatment Received for the Period 1997 to 2001 
Birthplace Treatment Number 
at Risk 
(n) 
Died Censored (%) Median 
Survival 
95% CI for 
Median 
χ2 p-value 



























10 3 7 (70.0) 3 2.18 3.81 1.79 .005 
United 
States 







667 418 249 (37.3) 2 1.85 2.14 
Other  104 48 56 (53.8) 3 2.45 3.54 1.79 .005 
Note: Median survival was estimated in years. No median survival was estimated for 
Brachytherapy and ERBT treated Jamaicans because; more than 50% of the Jamaicans 
survived beyond the 50th percentile of the observation period. LL is lower limits, UL is 
upper limits. Other is radiation sequenced with surgery. χ2 is the Log-Rank comparison.  
 
Table 29 describes the main effects of the birthplace covariate and brachytherapy, 
ERBT, and other radiation treatments for the period 1997 to 2001 period. The birthplace 
main effects were statistically significant for all treatments types. Model one which 
focused on the difference between PrCa patients who were treated with brachytherapy 
confirmed that the Jamaican PrCa patients were 1.29 times more likely to die of PrCa 
when compared with the White U.S.-born, 95% CI [1.02, 1.66], p = .036. Model two 
which demonstrated the survival experience differences among the ERBT treated cohorts 
demonstrated that the hazard among the Jamaican PrCa patients was 1.33 times greater 
than the White U.S.-born, 95% CI [1.05, 1.71], p = .018. In model three which presented 
the differences among the PrCa patients who received other radiation treatments, the 
Jamaican PrCa patients had 1.32 times higher risk of dying of PrCa when compared with 
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the White U.S.-born, 95% CI [1.04, 1.70], p = .022. Further hypothesis testing was 
conducted with interaction analysis to determine modification effects in the survival 
outcomes observed in the 1997 to 2001 cohort (see Table 30).  
Table 29 
 
Main Effects of the Differences in the Hazard Ratios for the Jamaican and White U.S.-
Born Prostate Cancer Patients per Treatment Received Between 1997 and 2001 
Variables in the Equation 
 

















0.26 0.12 4.39 1 .036 1.29 1.02 1.66 
Brachytherapy 
 








0.29 0.12 5.55 1 .018 1.33 1.05 1.71 
ERBT 
 
0.14 0.05 6.30 1 .012 1.15 1.03 1.29 
Other Radiation Treatment 
 
 




0.28 0.12 5.25 1 .022 1.32 1.04 1.70 
Other 0.28 0.14 4.07 1 .043 1.33 1.01 1.76 
Note: N = 1,271. LL is lower limits, UL is upper limits. Other is other types of radiation 
treatments. 
 
Table 30 demonstrates the results of the interaction analysis for the PrCa patients 
who were treated with brachytherapy, ERBT, and other radiation for the period 1997 to 
2001. In model one, which shows the effects of brachytherapy, the birthplace main effect, 
HR 1.35, 95% CI [1.06, 1.72], p = .017 and interaction effect, HR 0.86, 95% CI [0.80, 
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0.92], p < .001 were significant. The main effect for brachytherapy was not statistically 
significant, HR 0.38, 95% CI [0.13, 1.08], p = .072.  
In model two, which focused on the effects of ERBT, the birthplace main effect 
HR 1.31, 95% CI [1.03, 1.67], p = .029 and interaction effect HR 1.08, 95% CI [1.02, 
1.14], p = .010 were statistically significant. However, the main effect for ERBT was not 
statistically significant, HR 0.50, 95% CI [0.19, 1.29], p = .149.  
In model three, which explains the effects of other radiation treatment the 
birthplace main effect, HR 1.00, 95% CI [0.69, 1.46], p = 0.982, other radiation treatment 
main effect, HR 0.93, 95% CI [0.66, 1.32], p = 0.687, and interaction effects, HR 1.16, 
95% CI [1.00, 1.33], p = .049 were not statistically significant.  
The main effect for other radiation treatment was accepted, HR 1.32, 95% CI 
[1.04,1.70], p =.022. The main effects of the birthplace covariate for brachytherapy and 
ERBT were not interpreted for this analysis because of the significant interaction effects 
in the two models. Further evaluations were conducted for brachytherapy, ERBT and 
their correspondent control groups to determine whether there were differences in the 
second main effects. The referent groups were PrCa patients who received no 
brachytherapy and no ERBT.  
Table 31 presents the pairwise comparisons of the hazard ratios of the different 
treatment groups. The findings demonstrated that the treatment effects were significant 
for the White U.S.-born PrCa patients but not for the Jamaicans. Among the White 
cohort, brachytherapy treated PrCa patients had 33% lower risk of death when compared 
with patients who did not receive brachytherapy, 95% CI [0.66, 0.90). The ERBT treated 
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patients were 1.14 times more likely to die of PrCa when compared with their control 
groups 95% CI [1.01, 1.28). The results showed that the White U.S.-born PrCa patients 
who were treated with brachytherapy, and ERBT between 1997 and 2001 had significant 
differences in their hazard ratios when compared with the groups that did not receive 
these treatments.  
Table 30 
 
Interaction Effects of the Differences in the Hazard Ratios of the Jamaican and White 
U.S.-Born Prostate Cancer Patients per Treatment Received Between 1997 and 2001 
Variables in the Equation 
 








Variables B SE Wald df Sig Exp (B) LL UL 
 







0.29 0.12 5.72 1 .017 1.35 1.06 1.72 
Brachytherapy 
 
-0.97 0.54 3.24 1 .072 0.38 0.13 1.08 
Brachytherapy 
*Birthplace 
-0.16 0.03 16.08 1 .000 0.86 0.80 0.92 
ERBT with Interaction Variable 
 
 




0.27 0.12 4.77 1 .029 1.31 1.03 1.67 
ERBT 
 
-0.70 0.48 2.07 1 .150 0.49 0.19 1.29 
ERBT*Birthplace 
 
0.07 0.02 6.60 1 .010 1.08 1.02 1.14 
Other Radiation Treatment with Interaction Variable 
 




0.00 0.19 0.00 1 .982 1.00 0.69 1.46 
Other -0.07 0.18 0.16 1 .687 0.93 0.66 1.32 
Other*Birthplace 0.14 0.07 3.88 1 .049 1.16 1.00 1.33 
Note: N = 1,271. LL is lower limits, UL is upper limits. Other is radiation sequenced with 







Pairwise Comparison of the Hazard Ratios for the Jamaican and White U.S.-Born 
Prostate Cancer Patients Treated With Brachytherapy, and ERBT, for the Period 1997 to 
2001 
Variables in the Equation 
 95% CI for Exp (B) 






Reference = (No brachytherapy, No ERBT,) 
 
Brachytherapy -0.41 0.32 1.69 1 .193 0.66 0.36 1.23 
ERBT 
 
-0.10 0.31 0.10 1 .743 0.90 0.49 1.66 
White 
U.S.-Born 
Brachytherapy -0.26 0.08 10.65 1 .001 0.77 0.66 0.90 
ERBT  0.13 0.06 4.50 1 .034 1.14 1.01 1.28 
Note: N = 1,271. LL is lower limits, UL is upper limits. Other is other types of radiation 
treatments. 
 
Survival interval 2002 to 2007. At the third 5-year interval of the study (2002 to 
2007), 1,461 Jamaican and U.S. PrCa patients were treated with ERBT, brachytherapy, 
and other radiation. More than 50% of the PrCa treatment groups, except the White U.S.-
born ERBT treated cohort, survived beyond half of the 2002 to 2007 period of 
observation (see Table 32). Cox regression analysis of the differences in the risk ratios 











Summary of Kaplan-Meier Estimates for the Sample of 1,461 Jamaican and White U.S.-
Born Prostate Cancer Patients per Treatment Received for the Period 2002 to 2007 
Birthplace 
 
Treatment At Risk 
(n) 
















48 9 39 (81.3) 
Other  
 





562 169 393 (70.0) 
ERBT 
 
701 272 42 (61.2) 
Other  112 41 71 (63.4) 
Note: The median survival times were undefined for the PrCa patients because more than 
50% survived beyond the 50th percentile of the observation period. Other is radiation 
sequenced with surgery.  
 
Table 33 demonstrates the main effects of the birthplace variables, brachytherapy, 
ERBT, and other radiation treatments for the 2002 to 2007 interval in three models. 
Model one focused on the difference between PrCa patients who were treated with 
brachytherapy, model two demonstrates the differences among the ERBT treated cohorts, 
and model three presented the differences among the PrCa patients who received 
radiation sequenced with surgery. The birthplace main effects were statistically 
significant for all treatments types. The Jamaican PrCa patients were treated with 
brachytherapy, ERBT, and other radiation treatments were 2.4 times more likely to die of 
PrCa when compared with the White U.S.-born (p < .001). Hypothesis testing with 
interaction analysis was completed to determine modification effects in the association 
between the three PrCa treatments and PrCa survival among the 2002 to 2007 cohort (see 






Main Effects of the Differences in the Hazard Ratios for the Jamaican and White U.S.-
Born Prostate Cancer Patients per Treatment Received Between 2002 and 2007 
Variables in the Equation 
 















(Reference = United 
States) 
 
0.89 0.17 26.17 1 .000 2.43 1.73 3.43 
Brachytherapy 
 




Model 2 Birthplace 
(Reference = United 
States) 
 
0.88 0.17 25.73 1 .000 2.41 1.72 3.40 
ERBT 
 
0.08 0.06 1.51 1 .218 1.08 0.95 1.24 
Other Radiation Treatment 
 
 
Model 3 Birthplace 
(Reference = United 
States) 
 
0.88 0.17 25.7 1 .000 2.42 1.72 3.40 
Other 0.04 0.16 0.07 1 .791 1.04 0.76 1.42 
Note: N = 1,461. LL is lower limits, UL is upper limits. Other is radiation sequenced with 
surgery. CI is confidence interval. 
 
Table 34 presents the results of the interaction analysis for the PrCa patients who 
were treated with brachytherapy, ERBT, and other radiation for the period 2002 to 2007. 
In model one, which examined the effects of brachytherapy and the birthplace main 
effect, HR 2.48, 95% CI [1.76, 3.48], p < .001, the main effect for brachytherapy, HR 
0.03, 95% CI [0.00, 0.52], p = .015, and the interaction effect of brachytherapy and 
birthplace, HR 0.88, 95% CI [0.81, 0.95], p = .002 were significant.  
In model two, which focused on the treatment effect of ERBT on PrCa survival, 
the birthplace main effect, HR 2.39, 95% CI [1.70, 3.37], p < .001 and ERBT main effect, 
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HR 0.23, 95% CI [0.06, 0.87], p = .030 were significant. The interaction effect of ERBT 
and birthplace was not significant, HR 01.04, 95% CI [0.97, 1.12], p = .230.  
Model three, which estimated other radiation treatment effects in PrCa survival, 
showed that the birthplace main effect, HR 2.33, 95% CI [1.48, 3.67], p < .001 and other 
radiation treatment main effect, HR 0.43, 95% CI [0.28, 0.68], p < .001 were statistically 
significant. The interaction effect of birthplace and other radiation was not statistically 
significant, HR 1.02, 95% CI [0.87, 1.19], p = 0.809.   
The non-significant interaction effects of ERBT and other radiation treatment in 
models two and three confirmed that the interaction terms did not mediate the birthplace 
main effects. The findings indicate that the ERBT treated Jamaican PrCa patients and 
those who received other radiation treatment had 2.41 and 2.42 times higher risk of death 
when compared with the White U.S.-born patients. Further evaluation of the significant 
interaction effects in model one was conducted using pairwise comparisons of the 
brachytherapy treated and non-brachytherapy treated PrCa patients.  
Table 35 presents the pairwise comparisons of the hazard ratios of brachytherapy-
treated and non-brachytherapy treated PrCa patients. The brachytherapy treated Jamaican 
PrCa patients had a 63% lower risk of dying from PrCa when compared with PrCa 
patients who did not receive brachytherapy, 95% CI [0.09, 1.55], p = .172. On the other 
hand, the brachytherapy treated White U.S.-born PrCa patients experienced 21% reduced 
risk when compared with the PrCa patients who did not receive brachytherapy, 95% CI 
[0.66, 0.93], p = .005. Although the brachytherapy treated cohorts experienced better 
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survival when compared with the non-brachytherapy treated group, the finding was not 
significant for the Jamaicans.  
Table 34 
 
Interaction Effects of the Differences in the Hazard Ratios of the Jamaican and White 
U.S.-Born Prostate Cancer Patients per Treatment Received Between 2002 and 2007 
Variables in the Equation 
 





Variables B SE Wald df Sig Exp (B) LL UL 
 




(Reference = United 
States) 
 
0.91 0.17 27.11 1 .000 2.48 1.76 3.48 
Brachytherapy 
 
-3.44 1.41 5.89 1 .015 0.03 0.00 0.52 
Brachytherapy 
*Birthplace 
-0.13 0.04 9.78 1 .002 0.88 0.81 0.95 
ERBT with Interaction Variable 
 
 
Model 2 Birthplace 
(Reference = United 
States) 
 
0.87 0.17 25.10 1 .000 2.39 1.70 3.37 
ERBT 
 
-1.46 0.67 4.71 1 .030 0.23 0.06 0.87 
ERBT*Birthplace 
 
0.04 0.03 1.43 1 .230 1.04 0.97 1.12 
Other Radiation Treatment with Interaction Variable 
 
 
Model 3 Birthplace 
(Reference = United 
States) 
 
0.85 0.23 13.22 1 .000 2.33 1.48 3.67 
Other -0.84 0.23 12.87 1 .000 0.43 0.28 0.68 
Other*Birthplace 0.02 0.08 0.05 1 .809 1.02 0.87 1.19 
Note: N = 1,461. LL is lower limits, UL is upper limits. Other is radiation sequenced with 










Pairwise Comparison of the Hazard Ratios for the Jamaican and White U.S.-Born 
Prostate Cancer Patients Treated With Brachytherapy for the Period 2002 to 2007 
Variables in the Equation 
 95% CI for Exp 
(B) 






Reference = (No brachytherapy) 
Brachytherapy -1.01 0.73 1.86 1 .172 0.37 0.09 1.55 
White U.S.-born Brachytherapy -0.24 0.08 7.98 1 .005 0.79 0.66 0.93 
Note: N = 1,461. LL is lower limits, UL is upper limits. 
 
Survival interval 2007 to 2011. Fewer White U.S.-born and Jamaican PrCa 
patients (899) were observed for survival outcomes for the 2007 to 2011 treatment period 
when compared with the other follow-up periods. All PrCa patients survived beyond 50% 
of the interval for the 2007 to 2011 period of observation. More than 80% of the U.S. 
cohort and all Jamaicans were censored. Table 36 demonstrates the results of the Kaplan-
Meier cumulative survival estimates for the 2007 to 2011 period of observation. Cox 
regression analysis confirmed the differences in the survival experiences for the 2002 to 











Summary of the Kaplan-Meier Estimates for the Sample of 899 Jamaican and White U.S.-
Born Prostate Cancer Patients per Treatment Received for the Period 2007 to 2011 
 
Note: The median survival times were undefined for the PrCa patients because more than 
50% survived beyond the 50th percentile of the observation period. Other is radiation 
sequenced with surgery.  
 
Table 37 describes the main effects of the birthplace covariate and brachytherapy, 
ERBT, and other radiation treatments for the period 2007 to 2011 period. The birthplace 
main effects were statistically significant for all treatments types. Model one focused on 
the differences in treatment effects for the PrCa patients who were treated with 
brachytherapy. The findings showed that the Jamaican PrCa patients were 3.72 times 
more likely to die of PrCa when compared with the White U.S.-born, 95% CI [1.84, 
7.51], p < .001. Model two which demonstrates the differences in treatment effects 
among the ERBT treated cohorts indicated that the Jamaican PrCa patients were 3.78 
times more likely to die of PrCa when compared with the White U.S.-born, 95% CI [1.88, 
7.64], p < .001. Model three which presented the differences in treatment outcomes 
among the PrCa patients who received other types of radiation showed that the Jamaican 
PrCa patients were 3.79 times more likely to die of PrCa when compared with the White 
Birthplace Treatment Number 
at Risk 
(n) 
Died Censored (%) 





0 34 (100) 
ERBT 
 
55 0 55 (100) 
Other 
 
7 0 7 (100) 
United 
States 
Brachytherapy 258 17 241 (93.4) 
ERBT 
 
480 60 420 (87.5) 
Other  65 7 58 (89.2) 
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U.S.-born, 95% CI [1.88, 7.67], p < .001. Further analyses with hypothesis tests were 
conducted to determine the interaction effects in the association between the three PrCa 
treatments and PrCa survival among the 2007 to 2011 cohort (see Table 38). 
Table 37 
 
Main Effects of the Differences in the Hazard Ratios of the Jamaican and White U.S.-
Born Prostate Cancer Patients per Treatment Received Between 2007 and 2011 
Variables in the Equation 
 

















1.31 0.35 13.45 1 .000 3.72 1.84 7.51 
Brachytherapy 
 








1.33 0.35 13.80 1 .000 3.78 1.88 7.64 
ERBT 
 
-0.12 0.14 0.79 1 .374. 0.88 0.66 1.17 
Other Radiation Treatment 
 
 




1.33 0.35 13.87 1 .000 3.79 1.88 7.67 
Other 0.27 0.38 0.51 1 .473 1.31 0.62 2.78 
Note: N = 899. LL is lower limits, UL is upper limits. Other is other types of radiation 
treatments. CI is confidence interval. 
 
Table 38 showed the findings of the interaction analysis for the PrCa patients who 
were treated with brachytherapy, ERBT, and other radiation for the period 2007 to 2011. 
Model one, which examined the treatment effects of brachytherapy, demonstrated that the 
birthplace main effect, HR 3.85, 95% CI [1.91, 7.76], p < .001, and interaction effect, HR 
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0.69, 95% CI [0.54, 0.89], p = .003 were statistically significant. Brachytherapy main 
effect, HR 0.00, 95% CI [0.00, 4.32], p = .776 was not significant.  
In model two, which estimated the treatment effect of ERBT, the birthplace main 
effect, HR 3.84, 95% CI [1.89, 7.74], p < .001 was significant but the ERBT main effect 
was not, HR 0.87, 95% CI [0.66, 1.16], p = .341. The interaction effect of birthplace and 
ERBT was also not significant, HR 0.95, 95% CI [0.82, 1.09], p = .445.  
 In model three, which presented the treatment outcomes for other radiation 
treatment the birthplace main effect, HR 2.93, 95% CI [1.05, 8.15], p = .040 was 
statistically significant. Other radiation treatment main effect, HR 0.36, 95% CI [0.13, 
0.99], p = .049 and interaction effect were not statistically significant, HR 1.14, 95% CI 
[0.78, 1.66], p = .493.   
The non-significant interaction effects for ERBT and other radiation treatment in 
models two and three confirmed that the interaction terms did not modify the main effects 
observed and demonstrated that there was a difference in the survival outcomes of the 
PrCa patients who received ERBT and other radiation treatments for the 2007 to 2011 
period. The risk of death was 3.8 times higher for the Jamaicans who received ERBT and 
other forms of radiation when compared with the White U.S.-born patients (p < .001). 
The main effect of brachytherapy and the birthplace covariate were not interpreted in this 
analysis because of the significant interaction effect. Further evaluation of the significant 
interaction effects for brachytherapy was conducted using pairwise comparisons of the 
brachytherapy treated and non-treated groups. Table 39 presents the pairwise 
comparisons of the hazard ratios of brachytherapy-treated PrCa patients. The results of 
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the comparison showed that brachytherapy reduced the risk of death for the Jamaicans 
and the White U.S.-born PrCa patients, but the findings were not significant for the 
Jamaicans. The brachytherapy treated Jamaican PrCa patient was 0.02 times less likely to 
die of PrCa patients when compared with patients who did not receive brachytherapy, 
95% CI [0.00, 285.5], p = .429. The White U.S.-born PrCa brachytherapy treated patients 
had 53% reduced risk of death when compared with the White cohort that did not receive 
brachytherapy, 95% CI [0.29, 0.78], p = .003. Therefore, the U.S.-born brachytherapy 



















Interaction Effects of the Differences in the Hazard Ratios of the Jamaican and White 
U.S.-Born Prostate Cancer Patients per Treatment Received Between 2007 and 2011 
Variables in the Equation 
 









Variables B SE Wald df Sig Exp (B) LL UL 
  







1.35 0.35 14.13 1 .000 3.85 1.91 7.76 
Brachytherapy 
 
-15.51 54.48 0.08 1 .776 0.00 0.00 4.32 
Brachytherapy 
*Birthplace 
-0.37 0.12 8.50 1 .003 0.69 0.54 0.89 
ERBT with Interaction Variable 
 




1.34 0.35 14.05 1 .000 3.84 1.89 7.74 
ERBT 
 
-0.14 0.14 0.90 1 .341 0.87 0.66 1.16 
ERBT*Birthplace 
 
-0.06 0.07 0.58 1 .445 0.95 0.82 1.09 
Other Radiation Treatment with Interaction Variable 
 




1.08 0.52 4.23 1 .040 2.93 1.05 8.15 
Other -1.04 0.52 3.89 1 .049 0.36 0.13 0.99 
Other*Birthplace 0.13 0.19 0.47 1 .493 1.14 0.78 1.66 
Note: N = 899. LL is lower limits, UL is upper limits. Other is radiation sequenced with 












Pairwise Comparison of the Hazard Ratios for the Jamaican and White U.S.-Born 
Prostate Cancer Patients Treated With Brachytherapy for the Period 2007 to 2011 
Variables in the Equation 
 95% CI for Exp (B) 
 






Reference = (No brachytherapy) 
 
Brachytherapy -3.820 4.83 0.62 1 .429 0.022 0.000 285.5 
White U.S.-born Brachytherapy -0.742 0.25 8.66 1 .003 0.476 0.291 0.781 
Note: N = 899. LL is lower limits, UL is upper limits. 
 
The analyses for research question three revealed statistically significant 
differences in the median survival for the Jamaican and U.S. PrCa patients who received 
brachytherapy, ERBT, and other radiation treatments for the 5-year periods 1992 to 1996 
and 1997 to 2001. At the first 5-year interval, the Jamaicans who were treated with 
brachytherapy had a median survival of three years, 95% CI, [2.43, 3.58], p = .005 and 
two years for ERBT and other treatments (p = .003). The median survival for the White 
U.S.-born cohort was two years for all treatment types (p < .001) (see Table 24).  
At the second 5-year period (1997 to 2001), 50% of the Jamaican brachytherapy 
and ERBT treated PrCa patients survived beyond half of the period of follow-up, and 
those who received other treatments were alive at three years of follow-up. The U.S. 
cohort had a median survival of three years (p = .010) after receiving brachytherapy and 
other radiation treatment and two years post ERBT treatment (p = .004) (see Table 28). 
At last two 5-year intervals, the survival time for 50% of all PrCa patients exceeded half 
of the observation periods (see Table 32 and Table 36).  
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The hypothesis tests of a modification effect in the differences in the hazard ratios 
of the Jamaican-born and White U.S.-born PrCa patients demonstrated interaction effects 
for ERBT (1992 to 1996), brachytherapy and ERBT (1997 to 2001), and brachytherapy 
(2002 to 2011). There were significant differences among the birthplaces for the 1992 to 
1996 brachytherapy and radiation sequenced with surgery cohorts. Between 2002 and 
2011, the birthplace cohorts differed significantly in treatment outcomes for ERBT and 
radiation sequenced with surgery, but not brachytherapy. Pairwise comparisons of the 
brachytherapy treated patients revealed significant differences among the White PrCa 
patients but not among the Jamaicans (see Tables 31, 35 and 39). Similarly, pairwise 
comparisons of the ERBT treated groups (see Tables 27 and 31) demonstrated significant 
differences among the White U.S.-born patients but not among the Jamaicans. There 
were no significant interaction effects for the cohorts that received other radiation 
treatment. Therefore, the hypothesis that there are differences in the 5-year survival 
intervals of Jamaican-born and U.S.-White PrCa patients according to treatment received 
for the period 1992 to 2011 was accepted. 
Research Question 4 Analysis 
Research Question 4: Are there differences in the length of time brachytherapy 
treated Jamaican-born PrCa patients and U.S.-born White PrCa patients with low and 
intermediate stages PrCa live with the disease, after controlling for sociodemographic 
characteristics?  
In determining the confounding effects of age, marital status, and health insurance 
status in the outcome of brachytherapy and PrCa survival, the baseline hazard ratios of 
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the birthplace variable, brachytherapy, and the covariates were first estimated with Cox 
regression analysis. Subsequently, the brachytherapy and ERBT treated Jamaican, and 
White U.S.-born White PrCa patients were stratified with the covariates marital status, 
health insurance status, and age, and the adjusted hazard ratios estimated. The results 
demonstrated that the crude hazard ratio for the birthplace variable was, HR .34, 95% CI 
[0.14, 0.82]. When the covariates were examined in separate models, the estimates for the 
adjusted hazard ratios for the birthplace variable for marital status, HR 0.26, 95% CI 
[0.11, 0.63] and health insurance status, HR 0.28, 95% CI [0.12, 0.68] reflected a 
decrease from the baseline. The adjusted hazard ratio for age increased minimally, HR 
0.37, 95% CI [0.15, 0.88]. Table 40, shows the Cox regression analysis of the birthplace 
covariate and brachytherapy treatment with all covariates; then separately with each 
covariate.  
In defining the degree of confounding effects of the covariates marital and health 
insurance status, I estimated the excess risk in the crude and adjusted hazard ratios of the 
birthplace main effects with the expression: Percent Excess Risk Explained = (Crude HR-
Adjusted HR)/Crude HR-1×100 (Szklo & Nieto 2014, p.161). Less than 10% change in 
the hazard ratios were interpreted as minimal confounding, and the crude or adjusted 
hazard ratio was accepted as the outcome. A change in the hazard ratio of the birthplace 
main effect that was greater than 10% was a confounding effect and the adjusted hazard 
ratios for the birthplace variable were interpreted in the results. Besides, a shift in the 
magnitude of the hazard ratios, which was close to one was interpreted as no association 
with the outcome of interest (Szklo & Nieto 2014, p.161).  
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The results of the analysis for confounding revealed that the excess risk for 
marital status was 12.8%, ([0.344-0.260]/ [0.344-1]), health insurance status was -9.6%, 
([0.344-0.260]/ [0.344-1]), and age was 3.3 % ([0.344-0.366]/ [0.344-1]). Furthermore, 
the magnitude and direction of the adjusted hazard ratios did not change greatly from the 
baseline estimates. Therefore, based on the percent change in the adjusted and crude 
hazard ratios, the association between brachytherapy treatment and PrCa survival was not 
explained by the patients’ marital status, health insurance status, and age. Thus, the 
alternate hypothesis that there are differences in the length of time brachytherapy treated 
Jamaican-born PrCa patients and U.S.-born White PrCa patients with low and 
intermediate stages PrCa live with the disease, after controlling for sociodemographic 















Cox Regression Analysis Adjusting for the Covariate Effects of Marital, Health 
Insurances Status, and Age of the Jamaican and White U.S.-Born Patients Treated With 
Brachytherapy 
 Model 1 Model 2 
 
Model 3 Model 4 
 
Covariates HR 95% CI HR 95% CI HR 95% CI HR 95% CI 








      
Brachytherapy 1.43 1.19, 1.73       
Marital Status 1.09 1.04, 1.16       
Health Insurance 
Status 
0.88 0.79, 0.99       





  0.26 0.11, 0.63     
Brachytherapy   1.51 1.25, 1.82     





    0.28 0.12, 0.68   
Brachytherapy     1.53 1.27, 1.84   
Health Insurance  
Status 





      0.37 0.15, 0.88 
Brachytherapy       1.45 1.20, 1.75 
Age at Diagnosis 
(Age Groups) 
 
      1.50 1.45, 1.55 
Note: N =10,752. HR is hazard ratio. CI is confidence interval. 
 
Research Question 5 Analysis 
Research Question 5: Are there differences in the length of time ERBT treated 
Jamaican-born PrCa patients and US-born White PrCa patients with low and intermediate 
stages PrCa live with the disease, after controlling for sociodemographic characteristics?   
In estimating the effects of age, marital status, and health insurance status in the 
association of ERBT and PrCa survival, the baseline hazard ratios of the birthplace 
variable, ERBT, and the covariates were first estimated with Cox regression analysis. The 
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ERBT treated Jamaican and U.S.-born White PrCa patients were then stratified with the 
covariates marital status, health insurance status, and age and the hazard ratios estimated. 
The findings revealed that crude hazard ratio for the birthplace variable was HR 0.34, 
95% CI [0.14, 0.82]. Estimation of the stratified covariates demonstrated a reduction in 
the adjusted hazard ratios of the birthplace covariates for the marital status, HR 0.26, 95% 
CI [0.11, 0.61], and health insurance status, HR 0.27, 95% CI [0.11, 0.66] of the PrCa 
cohorts. The adjusted hazard ratio for age showed a slight increase from the crude 
estimate, HR 0.36, 95% CI [0.15, 0.88]. Table 41, presents the Cox regression analysis of 
the birthplace covariate and ERBT treatment with all covariates; then separately with 
each covariate.  
Further analysis of the percent change in the crude and adjusted hazard ratios 
were carried out to determine the degree of confounding using the expression: Percent 
Excess Risk Explained = (Crude HR-Adjusted HR)/Crude HR-1×100 (Szklo & Nieto 
2014, p.161). An excess risk of greater than 10% in the hazard ratios was interpreted as 
confounding, and the adjusted hazard ratios were accepted. Less than 10% change in the 
birthplace variable was minimal confounding, and the crude or adjusted hazard ratios for 
the birthplace variable were interpreted in the results. Furthermore, changes in the 
magnitude of the hazard ratios which was close to one were measured as no association 
with the outcome of interest (Szklo & Nieto 2014, p.161). 
The findings showed that the percent change for marital status was 13.2%, 
([0.342-0.255]/ [0.342-1]), health insurance status was 10.3%, ([0.342-0.274]/ [0.342-1]), 
and age was 3.1 % ([0.342-0.366]/ [0.363-1]). Additionally, the magnitude and direction 
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of the adjusted hazard ratios did not change greatly from the crude estimates. The percent 
change in the adjusted and crude hazard ratios suggested that the covariates marital, 
health insurance status and age did not explain the association between brachytherapy 
treatment. Thus, the alternate hypothesis that there are differences in the length of time 
ERBT treated Jamaican-born PrCa patients and White U.S.-born PrCa patients with low 
and intermediate stages PrCa lived with the disease, after controlling for 
sociodemographic characteristics was accepted.  
Table 41 
 
Cox Regression Analysis Adjusting for the Covariate Effects of Marital, Health Insurance 
Status, and Age of the Jamaican and White U.S-Born Patients Treated With ERBT 
 Model 1 Model 2 Model 3 Model 4 
Covariates HR 95% CI HR 95% CI HR 95% CI HR 95% CI 








      
ERBT 1.19 1.03, 1.38       
Marital Status 1.10 1.04, 1.17       
Health Insurance 
Status 
0.88 0.78, 0.98       
Age at Diagnosis 
(Age Groups) 





  0.26 0.11, 0.61     
ERBT   0.96 0.83, 1.11     





    0.27 0.11, 0.66   
ERBT     0.93 0.80, 1.07   
Health Insurance 
Status 





      0.36 0.15, 0.88 
ERBT       1.19 1.03, 1.38 
Age at Diagnosis 
(Age Groups) 
 
      1.51 1.46, 1.57 
Note: N = 10752. HR is hazard ratio. CI is confidence interval. 
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Summary and Transition 
Chapter 4 presents the results of the statistical analyses related to the research 
questions and hypotheses. The Kaplan-Meier statistical methods and Cox regression 
hazard model estimated the survival differences of the Jamaican and White U.S.-born 
brachytherapy and ERBT treated PrCa patients.  
A sample of 10752 (719 Jamaicans and 10,033 White U.S.-born) PrCa patients 
was used to complete the data analysis. Preliminary descriptive statistics showed that 
higher proportions of the PrCa patients were reported from the SEER reporting locations 
of Connecticut (22%) and Seattle (15.1%), but there were no outliers for the Jamaican 
population. PrCa patients were more likely to be in the 55 to 79 age-group, married, and 
had health insurance. Higher numbers of the PrCa patients 415 (57.7%) were diagnosed 
with Gleason grade 11 PrCa. A greater proportion of the Jamaicans had Gleason grade 
111 PrCa (Jamaicans 39% versus U.S. Whites 34%). ERBT was the most widely used 
PrCa treatment among the Jamaicans and White U.S.-born PrCa patients.   
Univariate analyses revealed that brachytherapy and ERBT treated Jamaican PrCa 
patients had higher median survival when compared with the U.S. cohort. More than 50% 
of the brachytherapy treated Jamaican PrCa patients survived beyond the 50th percentile 
of the observation period. The median survival for the brachytherapy treated White U.S.-
born PrCa patients was 142 months, SE 3, 95% CI [134.8, 147.1], p < .001. The median 
survival for the ERBT treated Jamaican and White U.S.-born PrCa patient was 154 
months and 116 months respectively (p < .001).  
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Hypothesis test for interaction effects in the association of brachytherapy and 
ERBT in the survival of the PrCa patients showed no modification effects. Cox 
proportional hazards analyses confirmed that the Jamaican brachytherapy treated PrCa 
patients experienced lower hazard of death when compared with the brachytherapy 
treated White U.S.-born PrCa patients, HR 0.63, 95% CI [0. 55, 0.73], p < .001. On the 
other hand, the ERBT treated Jamaicans had a higher risk of death when compared with 
the ERBT treated White U.S.-born PrCa patients, HR 1.6, 95% CI [1.38, 1.84], p < .001.  
The Kaplan-Meier analyses for the 5-year survival intervals for brachytherapy, 
ERBT, and radiation sequenced with surgery showed significant differences in the 
survival times for the brachytherapy treated White U.S.-born and Jamaican PrCa patients. 
At the initiation of the observation period (1992 to 1996), brachytherapy treatment 
demonstrated higher survival probability for the Jamaicans (median survival three years) 
when compared the White U.S.-born and PrCa patients who received ERBT and radiation 
sequenced with surgery (median survival two years) (p < .001). As the follow up 
progressed into the second 5-year interval (1997 to 2001) the median survival for the 
brachytherapy treated White U.S.-born PrCa and all males who received other types of 
radiation increased to three years, (p < .001). The White U.S.-born PrCa patients 
experienced no change in their median survival for ERBT treatment (median survival two 
years) (p < .001). 
Cox regression analysis of the differences in 5-year survival of the Jamaican and 
White U.S. PrCa cohorts confirmed that brachytherapy, when compared with ERBT, was 
more beneficial to the survival of the Jamaican PrCa patients for the first 5-year interval 
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(1992 to 1996) and other types of radiation treatments at ten years of follow up. The risk 
was 1.2 times higher (p < .001) for the brachytherapy treated Jamaicans versus the White 
U.S.-born and those who received other types of radiation for the 1992 to 1996 interval. 
The hazard doubled for the Jamaicans for all treatments at ten years of follow-up and 
continued to increase for the subsequent 5-year intervals, HR 2.4 to HR 3.8, p < .001. The 
risk was 2.4 times greater for the Jamaicans who received ERBT and other radiation 
treatments between 2002 and 2007 and increased to HR 3.7 and HR 3.8 (p < .001) for 
2007 to 2011 follow-up. The White U.S.-born PrCa patients benefited from 
brachytherapy treatment for the 1997 to 2001 follow-up, HR 0.77, 95% CI [0.66, 0.90],  
p < .001. The White U.S.-born PrCa patients also had improved survival from 
brachytherapy during the last decade of therapy, HR 0.78, 95% CI [0.66, 0.93], p = .005 
and HR 0.48, 95% CI [0.29, 0.78], p = .003. Overall, the treatment effects waned with 
each 5-year interval. 
Cox regression analysis for confounding effects of the covariates demonstrated 
minimal confounding for marital status (brachytherapy 12% and ERBT 13%) and no 
confounding effects for age and health insurance status. The percent change in the crude 
and adjusted hazard ratios for age and health insurance status was less than 10%. The 
adjusted hazard ratios for the covariate main effect remained less than one, did not vary 
greatly from the crude estimates, and remained statistically significant (p < .001). The 
percent change in the crude and adjusted hazard ratios signified that there were no real 
deviations in the magnitude and direction of the effects identified.  
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The findings of all research questions satisfied the alternative hypotheses of the 
research questions that there are differences in survival outcomes of Jamaican and White 
U.S.-born PrCa patients. Hence, the alternative hypotheses were accepted for the five 
research questions. In Chapter 5, I corroborated the findings of Chapter 4 with the peer 
reviewed literature and discussed the results in the context of the theoretical framework 
of the study. Additionally, in Chapter 5, I provided the limitations of the dissertation, the 





Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
This dissertation was designed to examine the survival patterns of brachytherapy, 
and ERBT treated Jamaican PrCa patients in the SEER 18 registries database for the 
period 1992 to 2011. I also aimed to ascertain whether there were survival differences 
among brachytherapy and ERBT treated Jamaican and U.S.-born White PrCa patients 
who had a diagnosis of early and intermediate stages PrCa. Additionally, I intended to 
determine whether specific sociodemographic characteristics affected the survival 
outcomes of the ERBT and brachytherapy treated Jamaican and White U.S.-born PrCa 
patients. The research utilized quantitative methods, a retrospective cohort study design, 
and analyses of secondary data with survival models.  
The study was conducted to generalize findings on the outcomes of brachytherapy 
and ERBT to the Jamaican communities. Studies on the effectiveness of brachytherapy in 
other populations may not extrapolate to the Jamaican population because researchers 
documented that this cohort has a higher risk for PrCa due to genetic influences (Kidd et 
al., 2012). Additionally, Jamaicans are usually diagnosed with higher PSA levels, 
Gleason scores, and tumor stages when compared with other widely studied populations 
(Fedewa & Jemal, 2013; Rich et al., 2013). Furthermore, brachytherapy treatment has 
been acclaimed as an appropriate option for earlier stage PrCa among the White 
populations in the United States (Schreiber et al., 2013). However, brachytherapy is not 
well utilized among Jamaican PrCa patients (Morrison et al., 2014). There is also a lack 
of information on the efficacy of brachytherapy in PrCa patients who received the 
155 
 
treatment in Jamaica (Morrison et al., 2014). Additionally, ERBT is more widely used to 
treat PrCa patients in Jamaica when compared with brachytherapy (Morrison et al., 
2014). However, the treatment effect of brachytherapy and ERBT in the survival of the 
Jamaican PrCa patient is understudied. Hence, it was necessary to conduct this research. 
The study’s findings demonstrated that the Jamaican PrCa patients who received 
brachytherapy treatment and ERBT had a significantly higher cumulative survival 
probability when compared with the White U.S.-born PrCa patients (p < .001). Cox 
proportional hazards regression analyses confirmed that brachytherapy reduced the risk 
of death by 37% for the Jamaicans, HR 0.63, 95% CI [0. 55, 0.73], p < .001. On the other 
hand, the ERBT treated Jamaicans were 1.6 times more likely to die of PrCa when 
compared with the White PrCa patients 95% CI [1.38, 1.84], p < .001. Hypothesis testing 
for interaction effects in the survival outcomes of brachytherapy and ERBT among the 
Jamaican and White U.S.-born PrCa patients confirmed that there were no modification 
effects in the association identified.  
Significant differences in the hazard ratios of the Jamaican-born and White U.S.-
born PrCa patients at 5-year survival intervals were confirmed. For the period 1992 to 
1996, there were significant differences among the birthplace cohorts for brachytherapy 
and radiation sequenced with surgery. Between 1997 and 2011, brachytherapy treatment 
was effective for the White U.S. PrCa patients but not for the Jamaicans. Pairwise 
comparisons of the ERBT treated groups showed significant differences among the White 
U.S.-born patients but the effects were not significant for the Jamaicans. 
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Analyses for confounding effects of marital status, age, and health insurance 
status confirmed that age and health insurance status did not explain the effects observed 
(percent change less than 10%), and there was minimal confounding for marital status. 
The adjusted hazard ratios of the covariates did not vary significantly, indicating that 
there was no change in the direction of the association identified. Hence the alternative 
hypotheses that there are survival differences among the brachytherapy and ERBT treated 
Jamaican, and White U.S.-born PrCa patients were accepted for the five research 
questions. 
Interpretation of the Findings 
Descriptive Findings 
The study utilized a sample of 719 Jamaican and 10,033 White U.S.-born PrCa 
patients from a population of 274, 201 PrCa patients of the 18 SEER registries database 
2013 submission. The PrCa cohorts had positive microscopic confirmation of the disease, 
and they were actively followed for the 1992 to 2011 period of observation. The sample 
size was eight times larger than the proposed sample of the research due to the sampling 
technique used to select the research participants. The large sample size of this study was 
one of the strengths of the data analysis; it enabled the detection of the survival 
differences observed among the cohorts. The sampling technique also provided a sample 
in which the important characteristics of the White PrCa patients were represented 
proportionately and this facilitated ease of comparison with the Jamaican cohort. 
The sample of Jamaicans used in this study will be beneficial to infer findings of 
the analysis to the Jamaicans in their homeland because of its size and characteristics. 
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Anderson et al. (2012), Fedewa and Jemal (2013), and Kampel et al. (2011) asserted that 
despite their place of residence, Jamaicans in the SEER database demonstrated 
characteristics of PrCa that were homogeneous with PrCa patients in Jamaica. Fedewa 
and Jemal documented that Jamaicans were the largest non-U.S.-born Black population 
in the SEER databases. Fedewa and Jemal also cited that the Jamaican PrCa patients in 
the SEER databases had Gleason scores that were comparable with native Jamaicans. 
Anderson et al. and Kampel et al. established that a high proportion of Jamaicans in the 
SEER database (87.6%) had localized disease, and this is a current trend among 
Jamaicans in their country of birth and the United States. Additionally, the proportion of 
Jamaican PrCa patients in this study (719) was almost ten times larger than the number of 
Jamaican PrCa patients (75 PrCa patients) who were treated in Jamaica with 
brachytherapy since 2004 (Morrison et al. 2014). Morrison et al. (2014) documented their 
inability to make inferences about the effectiveness of brachytherapy treatment among 
native Jamaicans who received this treatment due to lack of information on treatment 
outcomes. Thus, the sample of Jamaicans in this study is a useful proxy for PrCa patients 
living in their native country to provide data on PrCa treatment outcomes.  
In this dissertation, I intended to measure both cause-specific and all-cause 
mortality according to the conclusions of Lin et al. (2009) and Thompson et al. (2013). 
However, the SEER cause-specific mortality was estimated as the appropriate endpoint in 
this study because of its comprehensive definition. The SEER cause-specific mortality 
was fitting for the analysis because the PrCa patients in this dissertation were selected 
using the SEER cause-specific definition of the ICD-O version10 site-specific code for 
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prostate cancer (C60) (NCI, 2017). The SEER program defined the PrCa patients who 
died of the disease as having the event, the PrCa patients who died of other causes were 
censored (NCI, 2017a). The SEER program also accounted for causes of death according 
to the tumor sequence, site, and other diseases associated with the site-specific disease, 
and used the ICD classification codes for specific cancer sites (NCI, 2017b). In this 
dissertation, the PrCa patients who died of the disease had the event of interest, and the 
censored cases were PrCa patients who died of other causes. The outcomes of this 
research demonstrated that higher proportions of Jamaican PrCa patients were censored 
when compared with the White U.S.-born PrCa patients (72% versus 53.8%). The 
Jamaican PrCa patients also had a lower death rate when compared with the White U.S.-
born PrCa patients (27.1%) versus (46.2%). Based on the definition of PrCa used in this 
study, the results established that higher numbers of Jamaican PrCa patients when 
compared with the White U.S.-born cohort died of causes other than PrCa.  
The differences in the death rates among the Jamaicans and U.S.-born White PrCa 
patients in this study contrasted with findings of studies in the Black population of the 
United States (Hernandez et al., 2010; Ragin et al., 2011; Tyson & Castle, 2014). 
Hernandez et al. (2010) documented that the incidence of PrCa among the U.S. Black and 
White male populations was higher for the Blacks (38.8% versus 26.4%). Ragin et al. 
(2011), and Tyson and Castle (2014) confirmed that among the different races in the 
United States, the White U.S. population had better survival rates for PrCa. The 
differences in the death rates of the Jamaicans and White U.S.-born PrCa patients in this 
study inferred that although Jamaicans are a subgroup of the African American 
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population in the United States the death rates for the general Black U.S. population of 
may not apply to them.  
Three of 18 SEER reporting sites (Hawaii, Iowa and Alaska Native) were 
excluded from the study because no Jamaican PrCa patients were identified in the SEER 
database for these locations. Iowa and Hawaii were two of eight SEER sites, which 
reported cancer cases to the SEER program since the inception of its data collection on 
cancer cases in January 1973 (NCI 2017c). Subsequently, the SEER program extended its 
coverage of Blacks and other minority groups between 1978 and 1992 and added ten 
predominantly Black rural counties (NCI 2017c). Thus, the lack of information on 
Jamaicans for Hawaii, Iowa, and Alaska suggests that these three geographic areas may 
not report data on these PrCa patients for the period of observation. Therefore, the three 
reporting sites, which had no Jamaican PrCa patients were removed from the study to 
balance the selection of PrCa patients for the comparison group.  
Higher proportions of PrCa patients were reported from the SEER locations of 
Greater California (16.3%), Connecticut (15%), and Los Angeles (14.7%). The Greater 
California and Los Angeles areas had the highest total populations reported by the U.S. 
Bureau of Census (2010) and accounted for 20,585,610 and 9,818,605 residents 
respectively (NCI 2017d). Hence, the rate of the disease in Greater California and Los 
Angeles may be a result of the populace of these two areas. The frequency of PrCa cases 
reported for Connecticut could be attributed to its duration in the SEER program because 
its total population 3,574,097 (NCI 2017d) was lower than many of the SEER reporting 
locations. The State of Connecticut participated in the SEER program since the initiation 
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of its data collection for cancer patients in 1973 and remained in the program throughout 
the years (NCI 2017c). However, none of the SEER locations, which reported higher 
numbers of PrCa patients were outliers for the Jamaican population. 
Higher numbers of PrCa patients were reported for the 2001 and 2002, reporting 
periods but the incidence of PrCa declined in 2011. The increase in the occurrence of 
PrCa patients between 2001 and 2002 was concurrent with the expansion of the SEER 
program at that period. In 2001, the SEER program added four reporting sites including 
Greater California, which had a high number of PrCa patients (NCI 2017c). Thus, the 
extended coverage in 2001 may have contributed to the increase in the frequency of PrCa 
cases reported between 2001 and 2002. In 2011, the reduction in the rate of the PrCa 
patients coexisted with a decrease in the use of radical prostatectomy combined with 
ERBT to treat PrCa in the United States (Hager et al., 2014), and an increase in the 
utilization of active surveillance (Cooperberg & Carroll, 2015). Additionally, in 2011 and 
2012 brachytherapy utilization declined significantly and the usage of ERBT increased 
(Safdieh et al., 2016). Thus, the population size of the SEER reporting locations, 
changing trends in the SEER program and PrCa treatments, were interrelated with the 
shifts in the PrCa reporting patterns of the SEER registries for the observation period. 
The results of this research indicated that the Jamaican PrCa patients were more 
likely to be diagnosed with earlier stage PrCa. Sixty percent of Jamaican PrCa patients 
were diagnosed with Gleason grade 11 PrCa, and 88.6% had localized PrCa. The results 
of this study supported the conclusions of Anderson et al. (2012) and Kampel et al. 
(2011) which, purported that increasing numbers of Jamaicans are currently diagnosed 
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with earlier stages PrCa. Although a high proportion of Jamaicans had localized PrCa and 
Gleason grades 1 and 11 in this research, the proportion of Jamaican PrCa patients with 
Gleason grade 111, T1c and T2c PrCa was higher than the percentage of the White US-
born cohort. Fifty-two-point one percent of the Jamaican PrCa patients had T1c PrCa, 
and 39.2% was diagnosed with T2c. On the other hand, 41.4% of the White US PrCa had 
T1c PrCa, and 36.8% had the T2c stage of the disease. The proportions of Jamaican and 
White U.S.-born PrCa patients with Gleason grade 111 were 39.1% and 33.6% 
respectively. The results indicate that while Jamaicans were diagnosed with earlier stage 
PrCa, they had higher Gleason scores and TNM stage when compared with the White 
U.S.-born patients. Fedewa and Jemal (2013) and Rich et al. (2013) documented similar 
findings in their studies. According to Fedewa and Jemal and Rich et al., the frequency of 
Gleason grades and tumor stage among the Jamaicans and the White population was 
higher for the Jamaicans  
The Research Questions 
Research Questions 1 and 2 compared the differences in the survival of the 
brachytherapy treated Jamaicans and the White U.S.-born PrCa patients. The alternate 
hypotheses that there are differences in the survival of the brachytherapy treated and 
ERBT treated Jamaicans versus the U.S.-born White PrCa patients were accepted. A 
higher proportion of the Jamaican PrCa patients (15.5%), when compared with the White 
U.S.-born PrCa patients (13.2%) utilized brachytherapy treatment. The Jamaican PrCa 
patients also had higher survival probability. The median survival time for the White 
U.S.-born brachytherapy treated PrCa patients was 142 months, SE 3, 95% CI [134.8, 
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147.1], p < .001; while more than 50% of the Jamaicans survived beyond half the period 
of follow-up (p < .001). The socioeconomic indicators age, marital status, and health 
insurance status, of the Jamaicans in this dissertation, may explain the higher uptake of 
brachytherapy treatment in this cohort. In this study, among the Jamaicans and White 
U.S.-born PrCa patients, a higher proportion of the Jamaicans was younger than 69 years 
old (71% versus 52%). Additionally, the highest proportions of Jamaican PrCa patients in 
this research were married (66.5%) and had health insurance (80.5%). The results were 
consistent with the findings of Williams et al. (2011), Schreiber et al. (2013), and 
Morrison et al. (2014).  
Williams et al. (2011) established that PrCa patients in the younger age group 
were more likely to be treated with brachytherapy. Schreiber et al. (2013), cited that PrCa 
patients of lower socioeconomic status in the United States had poorer utilization of 
brachytherapy treatment. Morrison et al. (2014) indicated that in Jamaica, PrCa patients 
who had health insurance had greater access to brachytherapy treatment. Despite the 
limitations of small samples, misclassification, and the quality of the secondary data used 
for their studies, the patterns of brachytherapy use among PrCa patients identified by 
Morrison et al., Schreiber et al., and Williams et al. compared with the results of this 
study.  
The study’s findings also demonstrated that brachytherapy treated Jamaican PrCa 
patients had a lower risk of death from PrCa when compared with the brachytherapy 
treated White US-born PrCa patients, HR 0.63, 95% CI [0.55, 0.73], p < .001. The 
treatment effects of brachytherapy in this study corroborated with the findings of Aluwini 
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et al. (2015), Cendales et al. (2015), Rodrigues et al. (2014), Skowronek (2013), Williams 
et al. (2011), and Zuber et al. (2015). Aluwini et al. (2015), Williams et al. (2011), and 
Zuber et al. (2015) documented that brachytherapy treatment was beneficial for 
maintaining biochemical control in PrCa patients with the earlier stage disease. Cendales 
et al., Rodrigues et al., and Skowronek, established that brachytherapy was equally 
effective at both high and low doses for treating localized PrCa. The effects of 
brachytherapy treatment in this research, as well as other prospective and retrospective 
studies, which used reliable SEER coding and high-quality Medicare data were similar 
(Aluwini et al., 2015; Zuber et al., 2011).  
ERBT was prevalent among the PrCa patients in this study when compared with 
brachytherapy treatment (49.6% versus 28.7%). The difference in ERBT utilization 
among the Jamaicans and White U.S. born PrCa was marginal (25.2% versus 24.4%). 
The trend in ERBT uptake in this dissertation differed with recent findings of Valdivieso 
et al. (2015) and Safdieh et al. (2016). In observational studies, Valdivieso et al. and 
Safdieh et al. identified that ERBT as a monotherapy was less popularly used to treat 
low-risk PrCa when compared with brachytherapy. Valdivieso et al. reported that 40% of 
PrCa patients in a sample of 2701 PrCa patients in the 1992 to 2009 SEER Medicare-
Linked database used brachytherapy as monotherapy for low-risk disease; 33% used 
ERBT in combination with other PrCa treatments. In a sample of 89413 PrCa patients 
taken from the National Cancer Database, Safdieh et al. established that 58.4% of the 
patients used brachytherapy and 41.6% received ERBT as monotherapy. On the other 
hand, Mahmood et al. (2014) cited a 6.2% increase in ERBT usage and a similar decrease 
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in brachytherapy between 2004 and 2009. Despite the decline in brachytherapy use 
reported by Mahmood et al., Safdieh et al. indicated that the utilization of ERBT for 
treating localized PrCa is less prevalent in recent years.  
In this research, the ERBT treated Jamaican PrCa patients had a higher a median 
survival time when compared with the White U.S.-born PrCa patients (154 months versus 
116 months, p < .001). However, Cox regression analysis revealed that the risk of dying 
from PrCa among the ERBT treated Jamaican and White U.S. cohort was 1.6 times 
higher for the Jamaican PrCa patients, 95% CI [1.38, 1.84], p < .001. Current studies on 
the outcomes of ERBT focused on the effects of ERBT with surgery and other types of 
radiation in the survival of PrCa patients (Nepple et al., 2014; Hoffman et al., 2013). 
There were limited recent peer-reviewed literature on the effects of ERBT as 
monotherapy to validate findings with the results of this dissertation. Hence, I 
corroborated the ERBT outcomes of this research with studies which compared the 
effects of ERBT with surgery, and brachytherapy. Nepple et al. (2014) and Hoffman et al. 
(2013) showed that ERBT was associated with increased risk of death from PrCa. Nepple 
et al. compared the hazard of death among PrCa patients who were treated with ERBT, 
surgery, and brachytherapy. The findings of Nepple et al. showed that the ERBT cohorts 
versus patients who received surgery (radical prostatectomy) had a higher risk of death, 
HR 1.66, 95% CI [1.05, 2.63]. However, the difference in the risk for the brachytherapy 
and the surgery cohort was not significant, HR 1.83, 95% CI [0.88, 3.82]. In another 
study which examined the survival differences of a surgery and ERBT treated cohort, 
Hoffman et al. observed that higher numbers of ERBT treated PrCa patients died (ERBT 
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464, surgery 104), HR 0.35, 95% CI [0.26, 0.49], p < .001. The conclusions of Nepple et 
al. and Hoffman et al. confirmed that ERBT might be associated with higher risk of death 
when compared with the hazard associated with surgery and brachytherapy. The findings 
also demonstrated that ERBT may not be as effective as other forms of PrCa treatments. 
The Jamaican PrCa patients also demonstrated greater survival benefits from 
brachytherapy treatment versus ERBT. Brachytherapy reduced the risk of death for the 
Jamaicans by 37% (p < .001). On the other hand, the hazard for ERBT treated Jamaicans 
was 1.6 times higher when compared with the White U.S. ERBT treated patients  
(p < .001). The brachytherapy treatment outcomes for the Jamaican and White U.S. PrCa 
patients were not consistent with the effects observed in a Canadian cohort (Smith et al. 
2015), the Cleveland Clinic PrCa cohort (Nepple et al., 2013), and a Dutch cohort 
(Goldner et al., 2012). Smith et al. (2015), Nepple et al. (2013), and Goldner et al. (2012) 
identified no significant differences in the treatment effects of brachytherapy versus 
ERBT treatments among the United States, Canadian, and Dutch PrCa patients with 
localized disease (p > .05). However, the findings of Smith et al., Nepple et al., and 
Goldner et al. may not apply to Jamaicans because of the small samples of African 
American PrCa patients in their studies.  
The differences in treatment outcomes of brachytherapy and ERBT identified 
among the Jamaican PrCa patients in this study varied with finding in other populations 
(Goldner et al., 2012; Smith et al., 2015; Nepple et al., 2013), and suggest that the results 
may be unique to the Jamaicans. However, the findings on the treatment outcomes 
require further explorations among Jamaicans in their homeland because differences in 
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the delivery of treatments to PrCa patients in the United States and the Caribbean may 
create survival advantages for Jamaicans residing in the United States. Example, in the 
United States, radiotherapy is widely utilized to treat PrCa, and there are advancements in 
other treatment methods for PrCa (Hager et al., 2015). Furthermore, integrated prostate 
cancer centers are being implemented in the United States, and the expansion of deferred 
and defensive treatment strategies for PrCa patients in this country is well documented 
(Hager et al., 2015).  
On the other hand, while Jamaicans residing in the United States are in an 
environment where the management of PrCa is constantly evolving, they may be less 
likely to receive appropriate treatments. Moses, Orom, Brasel, Gaddy, and Underwood 
(2017) alluded to disparities in access to PrCa treatments for African Americans and 
other minority groups. Jamaicans comprise the African American and minority 
populations of the United States and may experience similar disparities in treatment 
access. Although the findings of the study may not extrapolate to Jamaicans in their 
homeland because of differences in the settings in which the study was conducted, 
considerations should be given to similarities in the characteristics of Jamaicans living in 
Jamaica and the United States. Furthermore, data on the Jamaican population were 
collected from a wide cross section of SEER reporting locations (15 SEER sites) 
improving the representativeness of the sample. Thus, the findings of this study indicate 
that there are treatment effects of brachytherapy and ERBT, which require follow-up 
studies among Jamaicans in their homeland. 
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Research Question 3 focused on the 5-year survival probability of the Jamaican 
versus the White U.S.-born PrCa patients who were treated with brachytherapy, ERBT, 
and radiation sequenced with surgery (other radiation). The study’s outcome 
demonstrated that brachytherapy was more active in the survival of the Jamaican PrCa 
patients at five years of follow-up when compared with ERBT and radiation sequenced 
with surgery (median survival three years versus two years, p < .001). At ten years of 
observation, radiation sequenced with surgery demonstrated greater survival probability 
for the Jamaicans and the White U.S. PrCa cohorts (median survival three years,  
p < .001). Additionally, at the 10-year follow-up brachytherapy improved the median 
survival time for the White U.S.-born patients. ERBT provided no tangible changes in the 
median survival times for the White U.S.-born cohorts for both 5-year and 10-year 
intervals.  
Cox regression analysis confirmed that brachytherapy was more beneficial to the 
Jamaicans for the first 5-year interval (1992 to 1996) and radiation sequenced with 
surgery at ten years of follow-up. The White U.S.-born brachytherapy treated PrCa 
patients had enhanced survival for the 1997 to 2001 follow-up and at the last decade of 
the study. The hazard doubled for all treatment groups at ten years of follow-up and 
continued to increase for the subsequent 5-year intervals, HR 2.4 to HR 3.8, p < .001. 
The survival outcomes for brachytherapy identified among the PrCa patients in 
this study contrasted with the findings of Valdivieso et al. (2015). In a sample of 2701 
low-risk U.S. PrCa patients of the SEER-Medicare-linked database, Valdivieso et al. 
reported that fewer than 50% of the brachytherapy-treated PrCa patients survived ten 
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years of follow-up. The conclusions of this dissertation may differ with Valdivieso et al 
who used the SEER Medicare data exclusively for their study. In this study, the sample 
included PrCa patients from varying health insurance providers in the United States. On 
the other hand, in a 5-year prospective study (2002 and 2007) Dickinson et al. (2014) 
cited favorable survival outcomes among three U.K. PrCa cohorts with localized PrCa 
who were treated with brachytherapy. Dickinson et al. identified 94.2% biochemical 
relapse-free survival (p = .033) for the 5-year observation period. Similarly, in a follow-
up study on low-risk PrCa patients, Parekh et al. (2016) confirmed that brachytherapy as 
a monotherapy provided good 5-year and 8-year survival advantage for PrCa patients 
with localized disease (96.6% PSA failure-free survival). Although the endpoints for 
PrCa survival were different in the studies conducted by Dickinson et al., Parekh et al., 
and this dissertation, the findings established that brachytherapy is advantageous for 
treating localized PrCa at 5-year and 10-year intervals. Hence, the 5-year and 10-year 
survival advantage among the brachytherapy treated Jamaicans in this study may infer to 
Jamaicans.  
The 5-year survival outcomes of the ERBT treated patients in this dissertation 
were lower than the effects observed for those who received brachytherapy, and men who 
were treated with radiation sequenced with surgery. The findings differed with Kibel et 
al. (2017) but related with the results of Vassil (2010). Vassil compared the 5-year 
survival rates for PrCa patients who received ERBT, permanent seed implants, and 
surgery and identified lower survival rates for patients who received ERBT (85.7%) 
versus permanent seed implant (89.5%). Conversely, Kibel et al. demonstrated no 
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significant differences in the survival rates of the ERBT versus brachytherapy treated 
PrCa patients (82.6% versus 81.7%) at 10 years of follow-up. The survival rates of ERBT 
identified by Kibel et al. did not differ markedly and suggested that ERBT may not be 
more efficient at five years and ten years of treatment. Kibel et al reported limitations of 
small samples in their study. In this study, the pairwise comparisons showed survival 
differences among the ERBT treated and non-ERBT treated White patients for ten years 
of follow-up, but not the Jamaicans. The treatment effects identified among the White 
cohort may be due to their consistently larger sample sizes for each 5-year interval. 
Hence, the survival differences reported in the interaction effects of the 5-year and 10-
year survival outcomes among the ERBT treated cohorts in this dissertation require 
follow-up with larger samples of Jamaicans in future studies on 5-year treatment effects 
among Jamaicans. 
Research Question 4 and Research Question 5 evaluated for confounding effects 
of the sociodemographic indicators of the Jamaican and White U.S.-born PrCa patients. 
The findings showed minimal percent changes in the crude and adjusted hazard ratios for 
health insurance status (brachytherapy -9.6%, ERBT 10.3%) and age of the PrCa patients 
(brachytherapy 3.3%, ERBT 3.1%). The excess risk for marital status was greater than 
10% (brachytherapy 12.8%, ERBT 13.2%). However, the hazard ratios for the main 
effects of all covariates remained less than one and did not vary considerably after 
adjustment (p < .001), indicating that there was an effect and there were no changes in the 
direction of the effects observed (Szklo & Nieto, 2014, p.171).  
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The covariate effects of age in this investigation contrasted with the relationship 
of age and PrCa survival in studies conducted by researchers Antwi et al. (2013), Fufaa 
(2011), and Lin et al. (2009). In a predominantly White U.S. community, Antwi et al. 
reported higher mortality from PrCa among a cohort of young African American PrCa 
patients. Antwi et al. also documented that African American PrCa patients were more 
likely to be diagnosed at younger ages. Fufaa demonstrated that older PrCa  
(age > 81years) and PrCa patients aged 31 to 40 years had shorter survival intervals when 
compared with patients in other age groups. Lin et al. reported that younger PrCa patients 
with advanced disease had higher probability of dying of PrCa. However, the study 
conducted by Fufaa was limited by underreporting and the use of death certificates to 
provide data on patient’s characteristics. Additionally, the investigation carried out by 
Antwi et al. applied to the population of a predominantly White U.S. PrCa cohort. 
Besides, Lin et al. cited misclassification of tumor grade and stage. Furthermore, Antwi 
et al. and Lin et al. documented that their inability to measure comorbid conditions 
affected the findings of their studies. The differing conclusion of this research with the 
studies conducted by Antwi et al., Fufaa, and Lin et al. could be attributed to the large 
sample size of this study. Moreover, in the design of this dissertation, all age-groups of 
the participants were included.  
The covariate effects of marital status and health insurance status in this study 
also demonstrated minimal confounding and may not explain the association between 
brachytherapy, ERBT, and PrCa survival among the Jamaicans and White U.S-born 
cohorts. The results also contrasted with the relationships documented in studies 
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conducted by Abdelsattar et al. (2017), Mahal et al. (2014), Mahmood et al. (2014), 
Parris (2013), Rand et al. (2014), and Xiao et al. (2011). Paris identified that the health 
insurance of a cohort of the Florida Cancer Data System was a determining factor in the 
choice of PrCa treatments, which improved survival from the disease Likewise, 
Abdelsattar et al. revealed that having health insurance reduced survival disparities of 
PrCa patients living in communities with differing socioeconomic conditions. Similarly, 
Mahal et al. alluded to the advantages of health insurance in improving access to 
favorable PrCa treatments among African American PrCa patients. Furthermore, Xiao et 
al. documented that White U.S. PrCa patients who had no health insurance progressed to 
the later stages of PrCa (p < .001). Mahmood et al. confirmed that age and marital status 
were significant predictors of PrCa survival in a U.S. cohort with localized disease  
(p < .001). Additionally, Paris and Rand et al. documented a statistically significant 
relationship between the marital status of the PrCa patient and their likelihood of 
surviving the disease.  
Although peer-reviewed literature established that the health insurance and 
marital status are linked to survival outcomes of PrCa patients, the investigators alluded 
to limitations, which may explain the results of their studies (Abdelsattar et al. 2017; 
Mahal et al. 2014; Parris, 2013). According to Mahal et al. (2014), data were missing on 
important characteristics such as the grade and stage of the PrCa patients and their health 
insurance status. Abdelsattar et al. (2017) utilized the SEER registry dataset and 
documented that data on health insurance of the PrCa patients were classified broadly and 
increased the likelihood of misclassification in their study. Paris (2013) used data on all-
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cause mortality to determine differences in PrCa survival and marital and health 
insurance status because cancer-specific data were not available in the dataset used for 
that study. The findings of this dissertation may contrast with Abdelsattar et al., Mahal et 
al., and Parris, because missing information was minimal (six percent for health 
insurance). However, the health insurance variable did not explain the association 
identified in this dissertation. Furthermore, the definition of PrCa in this research 
included both cause-specific and all-cause mortality. Additionally, the characteristics of 
the PrCa patients were distributed among the study’s participants reducing the risk of 
misclassification.  
Theoretical Framework 
The oxidative stress theory was chosen for this dissertation because of its 
assumptions that oxidative stress contributes to age-related cancers such as PrCa and 
promotes radiation-induced programmed cell death in the prostate gland (Khandrika et 
al., 2009; Nakajima, 2008). The treatment effects of this study relate to the assumptions 
of this theory because the alternative hypotheses of the research questions were accepted 
and in this dissertation, and the incidence of PrCa increased as men aged. The mechanism 
of radiation-induced cell death of the oxidative theory explains the effects of 
brachytherapy, ERBT, and radiation sequenced with surgery in the survival outcomes of 
the Jamaican and White U.S.-born PrCa patients. Khandrika et al. (2009), posited that 
radiation induces oxidative stress in the prostate gland and causes an increase in ROS 
production in the gland. Continuous increases in ROS production damage the cell’s DNA 
of the prostate and inhibit duplication and cell division (Khandrika et al., 2009). 
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Subsequently, programmed cell death occurs and stops the progression of carcinogenesis 
(Khandrika et al., 2009; Nakajima, 2008).  
The results of this study demonstrated that brachytherapy reduced the risk of 
death for the Jamaican PrCa patients and ERBT improved the survival outcomes of the 
White U.S. cohort. The radiation treatments were also effective at varying 5-year 
intervals for the 20-year observation. Brachytherapy was effective in the survival of 
Jamaicans and the White PrCa patients. ERBT and radiation sequenced with surgery 
were effective for the first ten years of follow-up. Additionally, the treatment differences 
in treatment effects observed among the Jamaicans and White U.S.-born PrCa patients 
remained significant after controlling for the sociodemographic characteristics of the 
PrCa patients. Hence, the alternative hypotheses for the research questions were accepted.  
The relationship among the variables of this study confirmed the mechanism of 
radiation-induced PrCa cell death in halting carcinogenesis and subsequently improving 
the survival times of the PrCa patients. The treatment effects observed among the PrCa 
patients of this study correlated with findings in experimental studies conducted by Fang 
et al. (2012), You et al. (2015) and Khandrika et al. (2009) on the functions of the 
oxidative stress pathway in interrupting PrCa carcinogenesis. Fang et al., You et al., and 
Khandrika et al. established that radiation is an extracellular environmental factor, which 
induces increased oxidative stress in the prostate gland and damage the cell’s DNA 
structure. Fang et al. and You et al. confirmed that radiation promotes apoptosis, and 
decreases cell proliferation in localized PrCa. Thus, the assumption of the oxidative 
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theory that radiation-induced programmed cell death halts carcinogenesis in the prostate 
gland was accepted for this study. 
The oxidative stress theory also links the role of ageing in the development of 
PrCa. The oxidative stress theory proposed that oxidative stress contributes to significant 
age-related chronic diseases, including cancers (Sowell et al., 2010, p. 341). Ageing 
causes cellular dysfunction of the prostate gland, which results in abnormal signaling, 
genotoxic alterations, and subsequently cancer of the prostate gland (Khandrika et al., 
2009). In this dissertation, fewer PrCa patients were in the younger age-group (30 to 64 
years) when compared with the 65 and older age-group. The highest proportion of 
Jamaican PrCa patients (73.3%) and the White U.S.-born PrCa patients (60.7 %) were 
older than 55 years. The frequency of PrCa patients who were in the older age-group in 
this dissertation indicates that age may have contributed to the disease. Thus, the 
assumption of the oxidative theory that increasing age plays a role in PrCa development 
is a consideration for the PrCa patients in this dissertation.  
Limitations and Strengths of the Study 
  This dissertation utilized secondary data, which had its limitations. Due to the 
data limitations, the smoking variable was not measured in this study because the SEER 
registry reports the smoking data at the County level. I recommended that follow-up 
studies in the Jamaican population should examine the covariate effects of smoking. 
Additionally, the definition for the covariate age was expanded to include men who were 
30 years and older. Fewer PrCa patients in the data set were in the age group (30 to 64 
years) which was proposed for data analysis. Hence, I changed the focus of the study 
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from the younger cohort. Due to the expansion of the age group of the PrCa patients, the 
Pohar-Perme and Ederer 11 statistical methods were not used for the data analysis 
because these methods do not perform well in survival analyses involving the older age 
groups (Seppa, et al., 2015). However, the alternative statistical software, SPSS version 
23, that was indicated in the research protocol was used for data analysis. 
  Another limitation of the dataset was the broad classification of the PrCa patients 
in the SEER dataset according to their health insurance status. PrCa patients who were 
classified as uninsured, having private insurance or had unknown health insurance status 
were also Medicare eligible; the PrCa patients who were diagnosed before 65 years old 
were not. Therefore, the likelihood of misclassifying the PrCa patients who were older 
than 65 years according to their health insurance status at the time of diagnosis was a 
consideration for this study. However, I stratified the PrCa patients in age groups greater 
and younger than 65 years and conducted statistical adjustments to examine for 
intervening effects of age. Age was not a confounder in this study. 
  The research was also limited by unavailable patient-level data on the PrCa 
patient’s primary means of payment for health care and the health insurance coverage 
plan at the time of diagnosis (SEER, 2013). Similarly, if the PrCa patient’s health 
insurance plan was different between the time of diagnosis and treatment initiation, 
information on the health insurance coverage at the time that the PrCa patient started 
treatment was not available (SEER, 2013). Additionally, the SEER program began 
reporting data on the health insurance status of the PrCa patients in 2007 (Abdelsattar et 
al., 2017; Mahal et al., 2014); hence, data for prior years in this study were not available 
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for the analysis. These limitations were reported by other researchers as well (Abdelsattar 
et al., 2017; Mahal et al., 2014) and should be considered in the interpretation of the 
findings and included in follow-up investigations. 
  It was difficult to determine the patients who had the lowest grade disease from 
the SEER Historic Stage A classification. The PrCa patients with the lower grade PrCa 
were categorized with localized or regionalized PrCa, and this classification was not 
disaggregated. Thus, the Gleason grades 1, 11, and 111 categorizations for PrCa were 
used in combination with the SEER Historic Stage A, and the AJCC’s 6th edition of the 
TNM staging to make conclusions about the effects of stage and grade of the disease.  
  The study used the 1973 to 2011 version of the SEER 18 SEER registries to 
examine the relationship between the variables. The SEER program released its most 
recent version of the 18 SEER registries database in 2016. However, the later version of 
the SEER 18 registries research data did not include the Jamaican cohort which was 
needed for this study. Subsequently, the SEER 18 registries Research data, November 
2013 submission was used for the data analysis instead of the current version of the 
SEER dataset. Hence, I could not make deductions on the current trends of PrCa 
treatments.  
  There were limited current peer-reviewed sources on the relationship between 
radiation treatment sequenced with surgery and the use of ERBT as a monotherapy in 
PrCa survival in the Jamaican cohort. Consequently, it was difficult to corroborate the 
findings of other studies with the results of the relationships identified for this variable in 
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this dissertation. Hence, I used current studies that compared treatment effects of ERBT, 
with brachytherapy and surgery for validation where data were lacking. 
  I was unable to measure comorbidities in this research. In this study, PrCa 
patients may change their vital status with time, irrespective of the treatment they receive, 
because of comorbidities. The SEER research data did not include comorbidities; hence 
this could not be measured in the data analysis. However, this may not impact the results 
greatly because the SEER program includes other diseases that are associated with the 
site-specific disease in their definition of PrCa. 
  The findings of this dissertation may be limited for extrapolation to the Jamaicans 
living in their homeland due to differences in the delivery of PrCa treatments among 
Jamaicans residing in the United States and the Caribbean. Ragin et al. (2011) 
documented that there are differences in access to and utilization of PrCa treatments 
among Caribbean-born males residing in their country when compared with PrCa patients 
living in the United States. The differences in access to treatments influence the survival 
outcomes of the Caribbean-born males residing in their homeland (Ragin, 2011). 
Mutetwa et al. (2012) also reported differences in PrCa survival among the Caribbean-
born males in the United States and asserted that the disparities may be due to differences 
in screening interventions between countries. Although the findings of the study may be 
limited to generalize to Jamaicans in their homeland because of differences in the setting 
in which the study was conducted, there are some important inferences of the results. The 
Jamaican population of this study has similar characteristics as Jamaicans living in 
Jamaica and the United States. Additionally, the data on the Jamaican population of this 
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study were collected from a wide cross section of SEER reporting locations (15 SEER 
sites) improving the representativeness of the sample of Jamaicans. Thus, the findings of 
this study have clinical and practical significance for treatment decisions for Jamaican 
PrCa patients and may function as a baseline for follow-up investigations in that cohort.  
  One of the strengths of this research was the representativeness of the sample 
used. The study used the SEER registries database, which is a comprehensive national 
database that covered approximately 27.8% of the U.S. population (NCI, 2017e). The 
SEER 18 registries database comprised different ethnicities and expanded its inclusion of 
many minority groups over the years (NCI, 2017c). Thus, the SEER 18 registries 
coverage of PrCa cases in the United States may be representative of the general United 
States population. Additionally, the characteristics of the sample and the sampling frame 
were similar (see Table 6). The proportions of the PrCa patients in the sample 
corresponded with the sampling frame. The proportionality of the sample enhanced its 
representativeness and facilitated comparisons of both cohorts. Additionally, although I 
selected the Jamaicans using purposive sampling, a large percentage (93. 4%) of these 
patients met the criteria for inclusion. Thus, the sample of the study was appropriate for 
generalization to Jamaican and White US-born communities.  
  Another high point of this study was the statistical methods applied to determine 
whether the association identified was explained by mediating and confounding factors. 
First, I tested the differences in the survival experiences among the Jamaican and White 
U.S.-born PrCa patients that were observed in the Kaplan-Meier analysis with the Cox 
Proportional hazard regression analysis. The Cox regression model satisfied the 
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proportional hazards assumption that the hazards were constant for the period of 
observation. Subsequently, I conducted hypothesis testing with interaction analysis to 
identify interaction or mediating effects in the association of brachytherapy and ERBT 
treatments in the survival outcomes of the PrCa patients. There were fewer significant 
interactions in the analysis when compared with non-significant interactions. The non-
significant interactions were important for generalizing the findings among subgroups of 
the cohorts studied and over the period of observation. Finally, I adjusted for 
confounding effects of covariates of this dissertation which were defined a priori 
and determined the excess risk between the crude and adjusted hazard ratios. The 
statistical analyses revealed that the association identified in this investigation was not 
influenced by mediating or confounding factors. 
Recommendations 
Findings of this dissertation provide the foundation for additional studies in PrCa 
treatments for the Jamaican males. Future research should be conducted on the effects of 
radiation treatment among Jamaicans using prospective designs and covering a current 
period. This research spanned the 1992 to 2011 reporting periods of the SEER 18 
research registries due to the limitations of the dataset used for the study. PrCa treatment 
trends, incidence patterns, and diagnostic approaches are changing (Cooperberg & 
Carroll, 2015; Hager et al., 2014; Safdieh, et al. 2016) and current data are needed for 




Further research on the effects of ERBT and brachytherapy treatments among the 
Jamaican males should include PrCa patients who are managed with active surveillance. 
Klotz et al. (2010) recommended future studies on the effects of active surveillance on 
PrCa patients with the aggressive forms of the disease. Additionally, Nepple et al. (2013) 
suggested that active surveillance should be included in studies that examine the effects 
of ERBT and brachytherapy. Active surveillance was not measured in this dissertation 
because the variables that comprise the specific criteria for this variable were not 
available in the data set. Comparison of active surveillance, brachytherapy, and ERBT 
treatment effects among the Jamaicans could provide substantial evidence to generalize 
findings to this population, because Jamaicans demonstrate similar characteristics of 
PrCa staging irrespective of their geographic locations. 
 Future studies on the effects of ERBT and brachytherapy in PrCa survival should 
include the smoking variable. The smoking variable was not measured in this dissertation 
because smoking data were reported at the County level in the SEER registries databases. 
Studies have shown that smoking may be associated with high death rates among PrCa 
patients particularly among the African American population (Antwi et al., 2013; Wong 
et al., 2009). Smoking is a prevalent lifestyle factor among Jamaicans in their homeland 
and contributed to chronic diseases in the country (Wilks et al., 2008). Thus, it is 
important to determine its influence on PrCa treatment outcomes. 
Additional research on the effects of ERBT and brachytherapy in PrCa survival 
should compare the treatment effects in PrCa patients who are younger and older than 65 
years. Fufaa (2011) and Lin et al. (2009) documented that the age of the PrCa patient may 
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affect survival outcomes. In this dissertation, all PrCa patients older than 30 years were 
included in the analysis due to limitations of the data set.  
Implications 
Positive Social Change 
This dissertation has important social change implications for the Jamaican 
population. Studies have shown that the Jamaicans have a high rate of PrCa, and 
experience disparities in access to PrCa treatment and preventive care (Aiken & 
Eldemire-Shearer, 2012; Gibson et al., 2013; Morrison et al., 2014; Rich et al., 2012). In 
Jamaica, the population without health insurance experiences challenges in utilizing 
brachytherapy and there is a need for improving access to ERBT (Morrison et al., 2014). 
This study may create social change by revealing opportunities for expanding PrCa 
treatments and reducing mortality from prostate cancer among Jamaicans. Currently, the 
Jamaican Government is seeking to advance the services offered to cancer patients in 
Jamaica and is promoting research activities in prostate cancer in the country (Ministry of 
Health, 2013; Reynolds-Baker, 2013). Therefore, this investigation is timely, and its 
objectives align with the government’s goals to address cancer epidemiology among 
Jamaicans.  
Clinicians in Jamaica are also challenged with providing PrCa treatments which 
are accessible and affordable to Jamaicans, and they need data on treatment outcomes to 
make informed decisions (Morrison et al., 2014). The results of this study will enlighten 
health care providers in Jamaica about the effectiveness of brachytherapy and ERBT in 
treating a Jamaican PrCa cohort. Additionally, health care planners may use the data for 
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cost-benefit analysis for policy decisions aimed at increasing access to brachytherapy and 
ERBT treatments to Jamaicans. Improving access to affordable PrCa treatments is likely 
to reduce morbidity and deaths from the disease, reduce the years of potential life lost 
(YPLL) from PrCa, and enhance the life expectancy (LE) of the country.  
I anticipate that this dissertation will provide important contributions to public 
health practice and policies through patient education, advocacy, and policy 
development. Based on the results of this research, I recommend that there should be a 
greater focus on educating Jamaican PrCa patients with localized disease and their 
families about the benefits of brachytherapy as an option for managing localized disease. 
I also propose that greater prominence should be given to collaborative efforts of the 
privately funded health care facilities, government-funded hospitals, the Radiation 
Oncology Center of Jamaica and the Jamaica Cancer Society to increase access to 
brachytherapy and ERBT use among the Jamaican PrCa patients. Additionally, I suggest 
that cost-benefit evaluations on brachytherapy and ERBT use among the Jamaican PrCa 
patients should be conducted to inform policy making decisions in the redirection of 
resources to improve access to these PrCa treatments. I anticipate that the findings of this 
study will be useful for cost-benefit determinations aimed at increasing access to 
brachytherapy and ERBT for the Jamaican cohort. 
 The findings of this dissertation will add new information to the existing body of 
knowledge on the treatment outcomes of ERBT and brachytherapy treatment in PrCa 
survival specifically in the Jamaican population. Extensive studies of PrCa treatment 
effects were carried out among the White populations and in the general population of 
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African Americans (Alumini et al., 2015; Cendales et al., 2015; Marshall et al. 2014; 
Nepple et al., 2013; Rodrigues et al., 2014; Williams et al., 2011). Currently, I have not 
identified publications which examined the effects of brachytherapy and ERBT in the 
survival of a subgroup of the African American population or the Jamaican PrCa patients. 
Hence, I anticipate that the findings of this study will be vital to the scholar practitioners 
who are engaged in PrCa studies on PrCa treatment effects, particularly in the Jamaican 
population. 
Conclusion 
The management of PrCa is a prime challenge for Jamaican clinicians, and the 
disease pattern among Jamaicans is a public health concern in the country. The efforts of 
clinicians to provide effective treatment interventions for PrCa patients in Jamaica are 
constrained by a lack of the physical infrastructure that will enable access to PrCa 
treatment. Clinicians are also limited in accessing current empirical data on treatment 
effectiveness in the Jamaican society and are consequently challenged to make informed 
decisions for treatment. This study confirms that brachytherapy is efficacious for 
managing PrCa in the Jamaican communities and this treatment option should be given 
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Appendix B: The SEER Data Request Approval 
 
Information in this e-mail may be confidential. It is intended only for the addressee(s) identified above. If you are 
not the addressee(s), or an employee or agent of the addressee(s), please note that any dissemination, 
distribution, or copying of this communication is strictly prohibited. If you have received this e-mail in error, 
please notify the sender of the error. 
 
 
From: Seertrack <seertrack@imsweb.com> 
Date: Wed, 12 Aug 2015 12:04:16 +0000 
 
Subject: SEER Data Request Approved 
 
Thank you for your interest in the SEER Research Data. Your signed Research Data Agreement 
is on file at SEER. Your username and password have been generated for Internet access. 
These will allow you to utilize the SEER*Stat client-server system and/or download the files 





You can change your password once you log into SEER*Stat from the "Client Server User 
Information" option located under the Profile menu. 
 
A recent preliminary evaluation of SEER data uncovered problems with the quality of the PSA 
value and PSA interpretation variables. As data quality is our primary concern, PSA values 
have not been included in the current data file (November 2014 submission) on the SEER 
website and in the SEER*Stat software while a more complete evaluation of these data is 
underway to explore the full magnitude of the problem.  While this problem also exists in prior 
submissions of the SEER data, we have not removed the fields from earlier submissions at this 
time and will reevaluate this decision when we have a better understanding of the magnitude of 
the problem.  However, we do not recommend using these fields for analyses.  For more 
information, see http://seer.cancer.gov/data/psa-values.html. 
 
Send questions or comments to: 
  - seertrack@imsweb.com -- regarding access to SEER Research Data 
  - seerstat@imsweb.com -- for SEER*Stat technical support 
  - seerweb@imsweb.com -- general questions regarding SEER or SEER data 
 
Thank you, 
SEER*Stat Technical Support 
IMS, Inc. 
 
